,SYMBOL,COMPANY NAME,SUBJECT,DETAILS,BROADCAST DATE/TIME,RECEIPT,DISSEMINATION,DIFFERENCE,ATTACHMENT,Date,Open,High,Low,Close,Adj Close,Volume,Dividends,Stock Splits,Next_Date,Sentiment
0,DRREDDY,Dr. Reddy's Laboratories Limited,shareholders meeting,"dr. reddy's laboratories limited has submitted the exchange a copy srutinizers report of  postal ballot. further, the company has informed the exchange regarding voting results.",14-Feb-2024 19:47:57,2024-02-14 19:47:57,14-Feb-2024 19:48:02,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_14022024194757_StockExchangeintimation_resultsofPB_14022024.pdf,14-02-2024,6330.0498046875,6339.9501953125,6170.10009765625,6258.35009765625,6258.35009765625,344869,0.0,0.0,21-02-2024,0
1,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'intimation under regulation 30 of the sebi (listing obligations and disclosure requirements) regulations, 2015   update on the usfda inspection at the company s r&d centre (integrated product development organisation or ipdo) in bachupally, hyderabad'.",12-Feb-2024 14:58:38,2024-02-12 14:58:38,12-Feb-2024 14:58:43,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_12022024145838_SE_intimationdated12022024.pdf,12-02-2024,6234.2998046875,6388.4501953125,6230.0,6333.5,6333.5,859292,0.0,0.0,19-02-2024,0
2,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'initmation on filing of form 6k for the quarter ended december 31, 2023'.",31-Jan-2024 17:39:58,2024-01-31 17:39:58,31-Jan-2024 17:40:09,00:00:11,https://nsearchives.nseindia.com/corporate/DRREDDY_31012024173958_SEIntimation_6Kfiling.pdf,31-01-2024,5825.0498046875,6137.5,5807.0498046875,6121.14990234375,6121.14990234375,1571485,0.0,0.0,07-02-2024,0
3,DRREDDY,Dr. Reddy's Laboratories Limited,outcome of board meeting," regarding outcome of board meeting   unaudited financial results for the quarter and nine months ended december 31, 2023",30-Jan-2024 16:08:48,2024-01-30 16:08:48,30-Jan-2024 16:08:54,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_30012024160848_SEintimation_30012024.pdf,30-01-2024,5898.9501953125,5949.0,5831.0,5840.9501953125,5840.9501953125,315317,0.0,0.0,06-02-2024,1
4,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'intimation under regulation 30 of the sebi (listing obligations and disclosure requirements) regulations, 2015'.",30-Jan-2024 16:06:06,2024-01-30 16:06:06,30-Jan-2024 16:06:12,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_30012024160606_SE_intimation_Reg30.pdf,30-01-2024,5898.9501953125,5949.0,5831.0,5840.9501953125,5840.9501953125,315317,0.0,0.0,06-02-2024,1
5,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended december 31, 2023.",30-Jan-2024 15:58:53,2024-01-30 15:58:53,30-Jan-2024 15:58:57,00:00:04,https://nsearchives.nseindia.com/corporate/SEintimation_30012024_30012024155853.pdf,30-01-2024,5898.9501953125,5949.0,5831.0,5840.9501953125,5840.9501953125,315317,0.0,0.0,06-02-2024,1
6,DRREDDY,Dr. Reddy's Laboratories Limited,updates, regarding 'grant of stock options to the eligible employee(s) under the employees stock option schemes of the company'.,29-Jan-2024 15:55:39,2024-01-29 15:55:39,29-Jan-2024 15:55:48,00:00:09,https://nsearchives.nseindia.com/corporate/DRREDDY_29012024155539_SEintimation_ESOPgrants_29012024.pdf,29-01-2024,5800.0,5892.60009765625,5740.2001953125,5843.7001953125,5843.7001953125,301914,0.0,0.0,05-02-2024,0
7,DRREDDY,Dr. Reddy's Laboratories Limited,news verification,the exchange has sought clarification from dr. reddy's laboratories limited with respect to recent news item captioned dr reddy s laboratories eyes mega brand in uk - the financial express.  the response from the company is attached.,18-Jan-2024 18:47:01,2024-01-18 18:47:01,18-Jan-2024 18:47:08,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_18012024184701_NSE_Clarification_News_Item_18012024_final.pdf,18-01-2024,5647.4501953125,5668.2998046875,5520.64990234375,5649.9501953125,5649.9501953125,345527,0.0,0.0,29-01-2024,0
8,DRREDDY,Dr. Reddy's Laboratories Limited,copy of newspaper publication, about copy of newspaper publication regarding postal ballot notice - advertisement,17-Jan-2024 17:07:02,2024-01-17 17:07:02,17-Jan-2024 17:07:08,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_17012024170702_StockExchangeIntimation_newspaperadvertisement.pdf,17-01-2024,5740.0,5740.0,5627.0,5649.9501953125,5649.9501953125,355792,0.0,0.0,25-01-2024,0
9,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding ''disclosure under regulation 30 of sebi (listing obligations & disclosure requirements) regulations, 2015",16-Jan-2024 18:57:07,2024-01-16 18:57:07,16-Jan-2024 18:57:11,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_16012024185707_SE_intimation_GST_Penalty.pdf,16-01-2024,5790.0,5790.0,5706.0498046875,5758.14990234375,5758.14990234375,228429,0.0,0.0,24-01-2024,0
10,DRREDDY,Dr. Reddy's Laboratories Limited,change in directors/ key managerial personnel/ auditor/ compliance officer/ share transfer agent, about change in directors/ key managerial personnel/ auditor/ compliance officer/ share transfer agent,11-Jan-2024 10:44:25,2024-01-11 10:44:25,11-Jan-2024 10:44:31,00:00:06,https://nsearchives.nseindia.com/corporate/xbrl/DRREDDY_11012024104425_CIM_16139_1015347_11012024104424_WEB.xml,11-01-2024,5778.0,5778.0,5645.10009765625,5692.4501953125,5692.4501953125,592985,0.0,0.0,18-01-2024,0
11,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'disclosure under regulation 30 of the sebi (listing obligations and disclosure requirements) regulations, 2015'.",05-Jan-2024 19:42:39,2024-01-05 19:42:39,05-Jan-2024 19:42:45,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_05012024194239_SE_intimation_GST_Penalty.pdf,05-01-2024,5870.0,5874.5498046875,5806.5,5835.64990234375,5835.64990234375,207451,0.0,0.0,12-01-2024,0
12,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 03, 2024, titled ""ￂﾬￂﾬdr. reddy's announces the acquisition of menolabsￂﾮ, a leading women s health and dietary supplements portfolio of brands"".",03-Jan-2024 14:22:41,2024-01-03 14:22:41,03-Jan-2024 14:22:46,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_03012024142241_PressRelease03012024.pdf,03-01-2024,5926.7998046875,5970.0,5888.2001953125,5931.89990234375,5931.89990234375,282407,0.0,0.0,10-01-2024,0
13,DRREDDY,Dr. Reddy's Laboratories Limited,change in directors/ key managerial personnel/ auditor/ compliance officer/ share transfer agent, about change in directors/ key managerial personnel/ auditor/ compliance officer/ share transfer agent,29-Dec-2023 17:48:52,2023-12-29 17:48:52,29-Dec-2023 17:48:58,00:00:06,https://nsearchives.nseindia.com/corporate/xbrl/DRREDDY_29122023174852_CIM_15569_1004944_29122023054852_WEB.xml,29-12-2023,5830.10009765625,5844.5,5761.0,5797.89990234375,5797.89990234375,290523,0.0,0.0,05-01-2024,0
14,DRREDDY,Dr. Reddy's Laboratories Limited,board meeting intimation, about board meeting to be held on 30-jan-2024 to inter-alia consider and approve the unaudited financial results of the company for the quarterly ended december 2023 .,21-Dec-2023 16:18:44,2023-12-21 16:18:44,21-Dec-2023 16:18:56,00:00:12,https://nsearchives.nseindia.com/corporate/xbrl/DRREDDY_21122023161844_PRIOR_INTIMATION_15329_999931_21122023041843_WEB.xml,21-12-2023,5540.0,5594.0,5471.2001953125,5554.5,5554.5,336380,0.0,0.0,29-12-2023,0
15,DRREDDY,Dr. Reddy's Laboratories Limited,trading window," regarding the trading window closure pursuant to sebi (prohibition of insider trading) regulations, 2015",21-Dec-2023 11:22:33,2023-12-21 11:22:33,21-Dec-2023 11:22:41,00:00:08,https://nsearchives.nseindia.com/corporate/DRREDDY_21122023112234_BoardMeetingNoticeIntimation_21122023.pdf,21-12-2023,5540.0,5594.0,5471.2001953125,5554.5,5554.5,336380,0.0,0.0,29-12-2023,0
16,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 14, 2023, titled ""dr. reddy s becomes first indian pharma company to debut on the dow jones sustainability world index"".",14-Dec-2023 15:51:43,2023-12-14 15:51:43,14-Dec-2023 15:51:50,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_14122023155143_SEintimation14122023.pdf,14-12-2023,5611.85009765625,5626.60009765625,5567.89990234375,5573.35009765625,5573.35009765625,632912,0.0,0.0,21-12-2023,0
17,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 06, 2023, titled ""press release"".",06-Dec-2023 17:35:35,2023-12-06 17:35:35,06-Dec-2023 17:35:42,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_06122023173535_Intimation06122023.pdf,06-12-2023,5796.0,5820.0,5708.0498046875,5730.35009765625,5730.35009765625,531941,0.0,0.0,13-12-2023,0
18,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," regarding allotment of 3362 securities pursuant to esop/esps at its meeting held on november 21, 2023",21-Nov-2023 16:40:39,2023-11-21 16:40:39,21-Nov-2023 16:40:46,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_21112023164039_SEintimation_ESOP_final_21112023.pdf,21-11-2023,5610.0,5678.9501953125,5605.5,5646.4501953125,5646.4501953125,380693,0.0,0.0,29-11-2023,0
19,DRREDDY,Dr. Reddy's Laboratories Limited,shareholders meeting,"dr. reddy's laboratories limited has submitted the exchange a copy srutinizers report of  postal ballot. further, the company has informed the exchange regarding voting results.",16-Nov-2023 15:56:53,2023-11-16 15:56:53,16-Nov-2023 15:57:01,00:00:08,https://nsearchives.nseindia.com/corporate/DRREDDY_16112023155653_StockExchangeintimationresultsofPB16112023.pdf,16-11-2023,5425.0,5575.0,5420.85009765625,5544.25,5544.25,339012,0.0,0.0,23-11-2023,0
20,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 16, 2023, titled ""press release/media release"".",16-Nov-2023 14:00:13,2023-11-16 14:00:13,16-Nov-2023 14:00:55,00:00:42,https://nsearchives.nseindia.com/corporate/DRREDDY_16112023140013_PressRelease16112023.pdf,16-11-2023,5425.0,5575.0,5420.85009765625,5544.25,5544.25,339012,0.0,0.0,23-11-2023,0
21,DRREDDY,Dr. Reddy's Laboratories Limited,acquisition, about acquisition of securities of o2 renewable energy ix private limited,10-Nov-2023 19:02:49,2023-11-10 19:02:49,10-Nov-2023 19:02:57,00:00:08,https://nsearchives.nseindia.com/corporate/DRREDDY_10112023190249_SEIntimation10112023.pdf,10-11-2023,5439.9501953125,5450.7001953125,5372.0,5424.89990234375,5424.89990234375,228984,0.0,0.0,20-11-2023,0
22,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'intimation under regulation 30 of the sebi (listing obligations and disclosure requirements) regulations, 2015 '.",09-Nov-2023 19:41:22,2023-11-09 19:41:22,09-Nov-2023 19:41:29,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_09112023194122_SEIntimationunderReg3009112023.pdf,09-11-2023,5478.89990234375,5498.9501953125,5440.0,5457.9501953125,5457.9501953125,328532,0.0,0.0,17-11-2023,0
23,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," regarding allotment of 12090 securities pursuant to esop/esps at its meeting held on november 06, 2023",07-Nov-2023 10:43:21,2023-11-07 10:43:21,07-Nov-2023 10:43:27,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_07112023104321_StockExchangeintimation07112023.pdf,07-11-2023,5374.0,5473.0498046875,5319.7998046875,5404.35009765625,5404.35009765625,699747,0.0,0.0,15-11-2023,0
24,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'intimation on intimation on filing of form 6-k for the quarter ended september 30, 2023'.",02-Nov-2023 17:20:13,2023-11-02 17:20:13,02-Nov-2023 17:20:23,00:00:10,https://nsearchives.nseindia.com/corporate/DRREDDY_02112023172013_SEIntimation6Kfiling02112023.pdf,02-11-2023,5380.0,5415.0,5323.39990234375,5338.5,5338.5,473167,0.0,0.0,09-11-2023,0
25,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 27, 2023, titled ""press release"".",27-Oct-2023 15:33:39,2023-10-27 15:33:39,27-Oct-2023 15:33:45,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_27102023153339_OutcomeofBM27102023.pdf,27-10-2023,5421.89990234375,5453.9501953125,5351.0,5397.2998046875,5397.2998046875,431945,0.0,0.0,03-11-2023,0
26,DRREDDY,Dr. Reddy's Laboratories Limited,outcome of board meeting," regarding  outcome of board meeting   unaudited financial results for the quarter and half-year ended september 30, 2023",27-Oct-2023 15:26:38,2023-10-27 15:26:38,27-Oct-2023 15:27:31,00:00:53,https://nsearchives.nseindia.com/corporate/DRREDDY_27102023152638_OutcomeofBM27102023.pdf,27-10-2023,5421.89990234375,5453.9501953125,5351.0,5397.2998046875,5397.2998046875,431945,0.0,0.0,03-11-2023,0
27,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended september 30, 2023.",27-Oct-2023 15:24:07,2023-10-27 15:24:07,27-Oct-2023 15:24:14,00:00:07,https://nsearchives.nseindia.com/corporate/OutcomeofBM27102023_27102023152407.pdf,27-10-2023,5421.89990234375,5453.9501953125,5351.0,5397.2998046875,5397.2998046875,431945,0.0,0.0,03-11-2023,0
28,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'intimation under regulation 30 of the sebi (listing obligations and disclosure requirements) regulations, 2015 '.",12-Oct-2023 18:46:25,2023-10-12 18:46:25,12-Oct-2023 18:46:31,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_12102023184625_Intimation12102023.pdf,12-10-2023,5567.60009765625,5584.0498046875,5515.0,5530.2001953125,5530.2001953125,339049,0.0,0.0,19-10-2023,0
29,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'intimation under regulation 30 of the sebi (listing obligations and disclosure requirements) regulations, 2015 '.",09-Oct-2023 19:55:28,2023-10-09 19:55:28,09-Oct-2023 19:55:33,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_09102023195528_Intimation09102023.pdf,09-10-2023,5410.0498046875,5527.35009765625,5400.14990234375,5494.85009765625,5494.85009765625,473622,0.0,0.0,16-10-2023,0
30,DRREDDY,Dr. Reddy's Laboratories Limited,board meeting intimation, about board meeting to be held on 27-oct-2023 to inter-alia consider and approve the unaudited financial results of the company for the half yearly ended september 2023 .,22-Sep-2023 19:34:28,2023-09-22 19:34:28,22-Sep-2023 19:34:36,00:00:08,https://nsearchives.nseindia.com/corporate/xbrl/DRREDDY_22092023193428_PRIOR_INTIMATION_10673_933433_22092023073427_WEB.xml,22-09-2023,5668.5,5693.89990234375,5502.0,5517.0498046875,5517.0498046875,489557,0.0,0.0,29-09-2023,0
31,DRREDDY,Dr. Reddy's Laboratories Limited,change in directors/ key managerial personnel/ auditor/ compliance officer/ share transfer agent, about change in directors/ key managerial personnel/ auditor/ compliance officer/ share transfer agent,20-Sep-2023 16:16:20,2023-09-20 16:16:20,20-Sep-2023 16:16:24,00:00:04,https://nsearchives.nseindia.com/corporate/xbrl/DRREDDY_20092023161620_CIM_10579_932369_20092023041620_WEB.xml,20-09-2023,5721.85009765625,5721.85009765625,5602.0,5615.0498046875,5615.0498046875,453281,0.0,0.0,27-09-2023,0
32,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," regarding allotment of 13283 securities pursuant to esop/esps at its meeting held on september 05, 2023",05-Sep-2023 22:26:56,2023-09-05 22:26:56,05-Sep-2023 22:27:02,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_05092023222656_SE_intimation_ESOP_allotment_05092023.pdf,05-09-2023,5640.0,5640.0,5560.5498046875,5578.89990234375,5578.89990234375,393694,0.0,0.0,12-09-2023,0
33,DRREDDY,Dr. Reddy's Laboratories Limited,updates, regarding 'cancellation of certificate of registration( cor ) by reserve bank of india of m/s imperial credit private limited ( wholly owned subsidiary )'.,29-Aug-2023 15:26:20,2023-08-29 15:26:20,29-Aug-2023 15:26:25,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_29082023152620_SEIntimationSurrenderofCoR29082023.pdf,29-08-2023,5770.0,5786.5,5715.0,5723.7998046875,5723.7998046875,651617,0.0,0.0,05-09-2023,0
34,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," regarding allotment of 12322 securities pursuant to esop/esps at its meeting held on august 24, 2023",24-Aug-2023 18:29:15,2023-08-24 18:29:15,24-Aug-2023 18:29:18,00:00:03,https://nsearchives.nseindia.com/corporate/DRREDDY_24082023182915_SEintimationESOPfinal.pdf,24-08-2023,5980.0,5989.7001953125,5891.2001953125,5907.14990234375,5907.14990234375,824946,0.0,0.0,31-08-2023,-1
35,DRREDDY,Dr. Reddy's Laboratories Limited,updates, regarding 'disclosure pursuant to regulation 30 of the sebi lodr 2015'.,14-Aug-2023 22:24:55,2023-08-14 22:24:55,14-Aug-2023 22:25:29,00:00:34,https://nsearchives.nseindia.com/corporate/DRREDDY_14082023222455_DRL_Reguation30_14082023.pdf,14-08-2023,5829.9501953125,5879.0,5800.0,5823.35009765625,5823.35009765625,433519,0.0,0.0,22-08-2023,0
36,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 10, 2023, titled ""dr. reddy's laboratories announces its launch of saxagliptin and metformin hydrochloride extended-release tablets in the u.s"".",10-Aug-2023 12:52:12,2023-08-10 12:52:12,10-Aug-2023 12:52:22,00:00:10,https://nsearchives.nseindia.com/corporate/DRREDDY_10082023125212_PressRelease10082023.pdf,10-08-2023,5880.10009765625,5916.64990234375,5806.0,5851.14990234375,5851.14990234375,552662,0.0,0.0,18-08-2023,0
37,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," regarding allotment of 201234 securities pursuant to esop/esps at its meeting held on august 03, 2023",03-Aug-2023 22:34:12,2023-08-03 22:34:12,03-Aug-2023 22:34:28,00:00:16,https://nsearchives.nseindia.com/corporate/DRREDDY_03082023223412_SEintimationESOPfinal.pdf,03-08-2023,5645.0,5734.0,5621.5,5659.5,5659.5,514104,0.0,0.0,10-08-2023,0
38,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'disclosure under regulation 30 of the sebi (listing obligations & disclosure requirements) regulations, 2015 '.",02-Aug-2023 16:35:32,2023-08-02 16:35:32,02-Aug-2023 16:35:45,00:00:13,https://nsearchives.nseindia.com/corporate/DRREDDY_02082023163532_AnnuncementunderReg3002082023.pdf,02-08-2023,5667.10009765625,5695.85009765625,5634.4501953125,5660.4501953125,5660.4501953125,358359,0.0,0.0,09-08-2023,0
39,DRREDDY,Dr. Reddy's Laboratories Limited,shareholders meeting," regarding proceedings of annual general meeting held on july 27, 2023. further, the company has informed the exchange regarding voting results along with copy of scrutinizers report .",28-Jul-2023 18:44:37,2023-07-28 18:44:37,28-Jul-2023 18:44:54,00:00:17,https://nsearchives.nseindia.com/corporate/DRREDDY_28072023184437_Outcome39thAGM.pdf,28-07-2023,5512.0,5618.0,5512.0,5583.0,5583.0,636108,0.0,0.0,04-08-2023,0
40,DRREDDY,Dr. Reddy's Laboratories Limited,change in directors/ key managerial personnel/ auditor/ compliance officer/ share transfer agent, about change in directors/ key managerial personnel/ auditor/ compliance officer/ share transfer agent,27-Jul-2023 13:07:22,2023-07-27 13:07:22,27-Jul-2023 13:07:46,00:00:24,https://nsearchives.nseindia.com/corporate/xbrl/DRREDDY_27072023130722_CIM_7799_901287_27072023010721_WEB.xml,27-07-2023,5530.0,5614.0,5420.0498046875,5507.0,5507.0,1507811,0.0,0.0,03-08-2023,0
41,DRREDDY,Dr. Reddy's Laboratories Limited,retirement," about retirement of mr. sridar iyengar (din:00278512), independent director of the company",26-Jul-2023 16:06:41,2023-07-26 16:06:41,26-Jul-2023 16:06:49,00:00:08,https://nsearchives.nseindia.com/corporate/DRREDDY_26072023160641_Reg30announcement26072023.pdf,26-07-2023,5440.0,5490.0,5401.0498046875,5475.64990234375,5475.64990234375,340212,0.0,0.0,02-08-2023,0
42,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 26, 2023, titled ""results-press release"".",26-Jul-2023 16:04:10,2023-07-26 16:04:10,26-Jul-2023 16:04:25,00:00:15,https://nsearchives.nseindia.com/corporate/DRREDDY_26072023160410_Resultoutcom26072023.pdf,26-07-2023,5440.0,5490.0,5401.0498046875,5475.64990234375,5475.64990234375,340212,0.0,0.0,02-08-2023,0
43,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended june 30, 2023.",26-Jul-2023 16:02:19,2023-07-26 16:02:19,26-Jul-2023 16:02:24,00:00:05,https://nsearchives.nseindia.com/corporate/Resultoutcom26072023_26072023160219.pdf,26-07-2023,5440.0,5490.0,5401.0498046875,5475.64990234375,5475.64990234375,340212,0.0,0.0,02-08-2023,0
44,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'disclosure under regulation 30 of the sebi (listing obligations and disclosure requirements) regulations, 2015 (sebi listing regulations)'.",26-Jul-2023 15:59:34,2023-07-26 15:59:34,26-Jul-2023 15:59:44,00:00:10,https://nsearchives.nseindia.com/corporate/DRREDDY_26072023155934_Reg30announcement26072023.pdf,26-07-2023,5440.0,5490.0,5401.0498046875,5475.64990234375,5475.64990234375,340212,0.0,0.0,02-08-2023,0
45,DRREDDY,Dr. Reddy's Laboratories Limited,outcome of board meeting," regarding  outcome of board meeting unaudited financial results for the quarter ended june 30, 2023",26-Jul-2023 15:55:54,2023-07-26 15:55:54,26-Jul-2023 15:56:09,00:00:15,https://nsearchives.nseindia.com/corporate/DRREDDY_26072023155554_Resultoutcom26072023.pdf,26-07-2023,5440.0,5490.0,5401.0498046875,5475.64990234375,5475.64990234375,340212,0.0,0.0,02-08-2023,0
46,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," regarding allotment of 2424 securities pursuant to esop/esps at its meeting held on july 25, 2023",25-Jul-2023 18:09:20,2023-07-25 18:09:20,25-Jul-2023 18:09:35,00:00:15,https://nsearchives.nseindia.com/corporate/DRREDDY_25072023180920_SEESOPintimation.pdf,25-07-2023,5420.0,5479.9501953125,5391.85009765625,5425.39990234375,5425.39990234375,432431,0.0,0.0,01-08-2023,0
47,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 12, 2023, titled ""dr. reddy s proposed rituximab biosimilar application accepted for review by usfda, ema and mhra"".",12-Jul-2023 18:32:36,2023-07-12 18:32:36,12-Jul-2023 18:32:45,00:00:09,https://nsearchives.nseindia.com/corporate/DRREDDY_12072023183236_PressRelease12072023.pdf,12-07-2023,5150.0,5198.9501953125,5130.0,5189.0,5189.0,240718,0.0,0.0,19-07-2023,0
48,DRREDDY,Dr. Reddy's Laboratories Limited,copy of newspaper publication, about copy of newspaper publication for notice of agm and e-voting instructions,05-Jul-2023 17:48:57,2023-07-05 17:48:57,05-Jul-2023 17:49:03,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_05072023174857_SEintimationnewspaperad.pdf,05-07-2023,5185.0,5201.7998046875,5137.0,5178.35009765625,5138.16845703125,282054,0.0,0.0,12-07-2023,0
49,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"k satish reddy and g v prasad has submitted to the exchange a copy of disclosure under regulation 31(4) of the securities and exchange board of india (substantial acquisition of shares and takeovers) regulations, 2011.",28-Jun-2023 15:23:32,2023-06-28 15:23:32,28-Jun-2023 15:23:38,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_28062023152332_Disclosure19.pdf,28-06-2023,5025.5498046875,5119.39990234375,5004.35009765625,5107.85009765625,5068.2158203125,885268,0.0,0.0,06-07-2023,0
50,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 23, 2023, titled ""dr. reddy s enters the trade generics business in india"".",23-Jun-2023 14:35:22,2023-06-23 14:35:22,23-Jun-2023 14:35:33,00:00:11,https://nsearchives.nseindia.com/corporate/DRREDDY_23062023143522_PressRelease23062023.pdf,23-06-2023,4901.0,5015.0,4901.0,4993.89990234375,4955.14990234375,558228,0.0,0.0,03-07-2023,0
51,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," regarding allotment of 10959 securities pursuant to esop/esps at its meeting held on jun 22, 2023",22-Jun-2023 17:50:18,2023-06-22 17:50:18,22-Jun-2023 17:50:22,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_22062023175018_SEintimationESOPfinal.pdf,22-06-2023,4911.5498046875,4926.9501953125,4890.0,4899.4501953125,4861.4326171875,248570,0.0,0.0,30-06-2023,1
52,DRREDDY,Dr. Reddy's Laboratories Limited,board meeting intimation, about board meeting to be held on 26-jul-2023 to inter-alia consider and approve the unaudited financial results of the company for the quarterly ended june 2023 .,21-Jun-2023 17:04:21,2023-06-21 17:04:21,21-Jun-2023 17:04:24,00:00:03,https://nsearchives.nseindia.com/corporate/xbrl/DRREDDY_21062023170421_PRIOR_INTIMATION_6364_867822_21062023050421_WEB.xml,21-06-2023,4921.9501953125,4950.0,4893.7001953125,4910.39990234375,4872.29736328125,224710,0.0,0.0,28-06-2023,0
53,DRREDDY,Dr. Reddy's Laboratories Limited,trading window," regarding the trading window closure pursuant to sebi (prohibition of insider trading) regulations, 2015",21-Jun-2023 15:22:34,2023-06-21 15:22:34,21-Jun-2023 15:22:40,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_21062023152234_BmIntimation21062023.pdf,21-06-2023,4921.9501953125,4950.0,4893.7001953125,4910.39990234375,4872.29736328125,224710,0.0,0.0,28-06-2023,0
54,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 14, 2023, titled ""dr. reddy s laboratories limited announces filing of annual report on form 20-f"".",14-Jun-2023 15:55:39,2023-06-14 15:55:39,14-Jun-2023 15:55:50,00:00:11,https://nsearchives.nseindia.com/corporate/DRREDDY_14062023155539_PressRelease14062023.pdf,14-06-2023,4707.7998046875,4729.5498046875,4685.0,4699.0,4662.5380859375,180251,0.0,0.0,21-06-2023,0
55,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 05, 2023, titled ""dr. reddy s successfully completes phase i study (iv route) of drl_tc, a proposed biosimilar of tocilizumab"".",05-Jun-2023 09:01:46,2023-06-05 09:01:46,05-Jun-2023 09:01:50,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_05062023090146_PressRelease05062023.pdf,05-06-2023,4631.0,4652.0,4596.7001953125,4603.5498046875,4567.82861328125,226428,0.0,0.0,12-06-2023,0
56,DRREDDY,Dr. Reddy's Laboratories Limited,annual secretarial compliance report,"annual secretarial compliance report for the year ended march 31, 2023",26-May-2023 18:41:08,2023-05-26 18:41:08,26-May-2023 18:41:12,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_26052023184108_SEIntimationSecretarialcompliancereport.pdf,26-05-2023,4505.0498046875,4539.0,4499.9501953125,4530.9501953125,4495.7919921875,150587,0.0,0.0,02-06-2023,0
57,DRREDDY,Dr. Reddy's Laboratories Limited,updates, regarding 'intimation regarding completion of us fda audit of fto sez pu2'.,12-May-2023 22:37:24,2023-05-12 22:37:24,12-May-2023 22:37:27,00:00:03,https://nsearchives.nseindia.com/corporate/DRREDDY_12052023223725_SEIntimationFTOSEZPU2.pdf,12-05-2023,4544.9501953125,4544.9501953125,4445.0,4466.10009765625,4431.4453125,1048404,0.0,0.0,19-05-2023,0
58,DRREDDY,Dr. Reddy's Laboratories Limited,change in directors/ key managerial personnel/ auditor/ compliance officer/ share transfer agent, about change in directors/ key managerial personnel/ auditor/ compliance officer/ share transfer agent,11-May-2023 13:13:39,2023-05-11 13:13:39,11-May-2023 13:13:44,00:00:05,https://nsearchives.nseindia.com/corporate/xbrl/DRREDDY_11052023131340_CIM_4065_840558_11052023011339_WEB.xml,11-05-2023,4675.0,4700.0,4524.0498046875,4532.0,4496.833984375,2783359,0.0,0.0,18-05-2023,0
59,DRREDDY,Dr. Reddy's Laboratories Limited,book closure, that register of members & share transfer books of the company will remain closed from 12-jul-2023 to 14-jul-2023 for the purpose of dividend.,10-May-2023 18:31:46,2023-05-10 18:31:46,10-May-2023 18:31:50,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_10052023183146_Reg30.pdf,10-05-2023,4964.85009765625,4964.85009765625,4839.89990234375,4867.2998046875,4829.53173828125,454301,0.0,0.0,17-05-2023,-1
60,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 10, 2023, titled ""press release - audited financial results of fy23"".",10-May-2023 17:33:10,2023-05-10 17:33:10,10-May-2023 17:33:16,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_10052023173310_Pressrelease.pdf,10-05-2023,4964.85009765625,4964.85009765625,4839.89990234375,4867.2998046875,4829.53173828125,454301,0.0,0.0,17-05-2023,-1
61,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended march 31, 2023.",10-May-2023 17:14:12,2023-05-10 17:14:12,10-May-2023 17:14:15,00:00:03,https://nsearchives.nseindia.com/corporate/Outcome10052023_10052023171412.pdf,10-05-2023,4964.85009765625,4964.85009765625,4839.89990234375,4867.2998046875,4829.53173828125,454301,0.0,0.0,17-05-2023,-1
62,DRREDDY,Dr. Reddy's Laboratories Limited,dividend," that board of directors at its meeting held on may 10, 2023, recommended final dividend of 40 per equity share.",10-May-2023 17:11:48,2023-05-10 17:11:48,10-May-2023 17:11:55,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_10052023171148_Outcome10052023.pdf,10-05-2023,4964.85009765625,4964.85009765625,4839.89990234375,4867.2998046875,4829.53173828125,454301,0.0,0.0,17-05-2023,-1
63,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 05, 2023, titled ""dr. reddy's laboratories announces the launch of regadenoson injection 0.4 mg/5 ml in the u.s"".",05-May-2023 15:05:13,2023-05-05 15:05:13,05-May-2023 15:05:21,00:00:08,https://nsearchives.nseindia.com/corporate/DRREDDY_05052023150513_PressRelease05052023.pdf,05-05-2023,4974.9501953125,4989.0,4925.5498046875,4942.5,4904.1484375,92309,0.0,0.0,12-05-2023,-1
64,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 21, 2023, titled ""dr. reddy's laboratories announces the launch of treprostinil injection in the u.s"".",21-Apr-2023 11:24:06,2023-04-21 11:24:06,21-Apr-2023 11:24:15,00:00:09,https://nsearchives.nseindia.com/corporate/DRREDDY_21042023112406_Pressrelease21042023.pdf,21-04-2023,4858.10009765625,4879.0,4823.14990234375,4868.75,4830.970703125,331439,0.0,0.0,28-04-2023,0
65,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'disclosure pursuant to regulation 30 of the sebi (listing obligations and disclosure requirements) regulations, 2015'.",23-Mar-2023 21:24:21,2023-03-23 21:24:21,23-Mar-2023 21:24:25,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_23032023212421_SEintimationImperialrelated23032023.pdf,23-03-2023,4479.0,4499.5,4430.5498046875,4446.9501953125,4412.44384765625,483674,0.0,0.0,31-03-2023,0
66,DRREDDY,Dr. Reddy's Laboratories Limited,board meeting intimation," about board meeting to be held on 10-may-2023 to consider financial statements for the period ended march 2023, financial results/dividend.",23-Mar-2023 21:11:30,2023-03-23 21:11:30,23-Mar-2023 21:11:34,00:00:04,https://nsearchives.nseindia.com/corporate/xbrl/DRREDDY_23032023211130_PRIOR_INTIMATION_2351_804758_23032023091129_WEB.xml,23-03-2023,4479.0,4499.5,4430.5498046875,4446.9501953125,4412.44384765625,483674,0.0,0.0,31-03-2023,0
67,DRREDDY,Dr. Reddy's Laboratories Limited,trading window," regarding the trading window closure pursuant to sebi (prohibition of insider trading) regulations, 2015",23-Mar-2023 20:38:31,2023-03-23 20:38:31,23-Mar-2023 20:38:34,00:00:03,https://nsearchives.nseindia.com/corporate/DRREDDY_23032023203831_BoardMeetingNoticeIntimation23032023.pdf,23-03-2023,4479.0,4499.5,4430.5498046875,4446.9501953125,4412.44384765625,483674,0.0,0.0,31-03-2023,0
68,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," regarding allotment of 1022 securities pursuant to esop/esps at its meeting held on march 20, 2023",21-Mar-2023 11:28:15,2023-03-21 11:28:15,21-Mar-2023 11:28:22,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_21032023112815_SEintimationESOPfinal.pdf,21-03-2023,4441.9501953125,4480.0,4409.2001953125,4419.35009765625,4385.05810546875,396928,0.0,0.0,28-03-2023,0
69,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 16, 2023, titled ""dr. reddy s divests certain non-core brands in dermatology in india to eris lifesciences to focus on strengthening core"".",16-Mar-2023 15:35:27,2023-03-16 15:35:27,16-Mar-2023 15:35:30,00:00:03,https://nsearchives.nseindia.com/corporate/DRREDDY_16032023153527_PressRelease16032023.pdf,16-03-2023,4411.0,4430.0,4370.35009765625,4383.75,4349.734375,276928,0.0,0.0,23-03-2023,0
70,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 27, 2023, titled ""dr. reddy's laboratories announces agreement to acquire mayne pharma s u.s. generic prescription product portfolio."".",27-Feb-2023 09:27:59,2023-02-27 09:27:59,27-Feb-2023 09:28:04,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_27022023092759_PR27022023.pdf,27-02-2023,4491.10009765625,4491.10009765625,4355.0,4421.0,4386.6953125,274114,0.0,0.0,06-03-2023,0
71,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 08, 2023, titled ""dr. reddy s included in bloomberg gender-equality index for the 6th year in a row and s&p global s sustainability yearbook for the 3rd year"".",08-Feb-2023 17:30:01,2023-02-08 17:30:01,08-Feb-2023 17:30:43,00:00:42,https://nsearchives.nseindia.com/corporate/DRREDDY_08022023173000_PressRelease08022023.pdf,08-02-2023,4450.0,4496.60009765625,4432.64990234375,4487.7998046875,4452.9765625,239371,0.0,0.0,15-02-2023,0
72,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 27, 2023, titled ""dr. reddy's laboratories announces the launch of difluprednate ophthalmic emulsion 0.05% in the u.s. market."".",27-Jan-2023 11:50:50,2023-01-27 11:50:50,27-Jan-2023 11:50:53,00:00:03,https://nsearchives.nseindia.com/corporate/DRREDDY_27012023115050_PressRelease27012023.pdf,27-01-2023,4280.0,4380.89990234375,4253.35009765625,4314.0,4280.525390625,956288,0.0,0.0,03-02-2023,0
73,DRREDDY,Dr. Reddy's Laboratories Limited,outcome of board meeting,"outcome of board meeting   unaudited financial results for the quarter and nine months ended december 31, 2022",25-Jan-2023 16:17:11,2023-01-25 16:17:11,25-Jan-2023 16:17:14,00:00:03,https://nsearchives.nseindia.com/corporate/DRREDDY_25012023161710_Outcome25012023.pdf,25-01-2023,4260.0,4268.89990234375,4175.10009765625,4200.9501953125,4168.35302734375,294042,0.0,0.0,02-02-2023,0
74,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended december 31, 2022.",25-Jan-2023 16:09:21,2023-01-25 16:09:21,25-Jan-2023 16:09:26,00:00:05,https://nsearchives.nseindia.com/corporate/Outcome25012023_25012023160921.pdf,25-01-2023,4260.0,4268.89990234375,4175.10009765625,4200.9501953125,4168.35302734375,294042,0.0,0.0,02-02-2023,0
75,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 20, 2023, titled ""dr. reddy s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the u.s., europe"".",20-Jan-2023 09:14:40,2023-01-20 09:14:40,20-Jan-2023 09:14:45,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_20012023091440_PressRelease20012023.pdf,20-01-2023,4331.9501953125,4381.0498046875,4280.0,4350.60009765625,4316.841796875,236535,0.0,0.0,30-01-2023,0
76,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 13, 2023, titled ""dr. reddy s launches in-house palbociclib (primcyvￂﾮ) to widen access to high-quality breast cancer drug"".",13-Jan-2023 16:44:27,2023-01-13 16:44:27,13-Jan-2023 16:44:33,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_13012023164427_PressRelease1302023.pdf,13-01-2023,4324.0,4341.7001953125,4290.0,4320.39990234375,4286.87548828125,246926,0.0,0.0,20-01-2023,0
77,DRREDDY,Dr. Reddy's Laboratories Limited,resignation," regarding resignation of mr allan oberman as independent director of the company w.e.f. january 06, 2023.",06-Jan-2023 19:24:28,2023-01-06 19:24:28,06-Jan-2023 19:24:30,00:00:02,https://nsearchives.nseindia.com/corporate/DRREDDY_06012023192428_Intimation_Allan.pdf,06-01-2023,4299.5,4319.2998046875,4259.10009765625,4271.75,4238.603515625,126136,0.0,0.0,13-01-2023,0
78,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'intimation under regulation 30 of the securities and exchange board of india (listing obligations and disclosure requirements) regulations, 2015'.",29-Dec-2022 08:44:46,2022-12-29 08:44:46,29-Dec-2022 08:44:50,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_29122022084446_Intimation29122022.pdf,29-12-2022,4275.0,4354.64990234375,4223.0498046875,4260.60009765625,4227.5400390625,812932,0.0,0.0,05-01-2023,0
79,DRREDDY,Dr. Reddy's Laboratories Limited,trading window," regarding the trading window closure pursuant to sebi (prohibition of insider trading) regulations, 2015",27-Dec-2022 18:33:38,2022-12-27 18:33:38,27-Dec-2022 18:33:41,00:00:03,https://nsearchives.nseindia.com/corporate/DRREDDY_27122022183338_boardmeetingintimation.pdf,27-12-2022,4269.7998046875,4269.7998046875,4201.0,4250.85009765625,4217.86572265625,273249,0.0,0.0,03-01-2023,0
80,DRREDDY,Dr. Reddy's Laboratories Limited,updates, regarding 'completion of transaction by dr. reddy's research and development b. v. (drrdbv)'.,23-Dec-2022 16:39:46,2022-12-23 16:39:46,23-Dec-2022 16:39:51,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_23122022163946_SE_Intimation_Leiden_transaction_completion.pdf,23-12-2022,4325.0498046875,4418.0,4291.25,4310.4501953125,4277.00341796875,499756,0.0,0.0,30-12-2022,0
81,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 19, 2022, titled ""dr. reddy s successfully completes phase 1 study ofdrl_tc, a proposed biosimilar of tocilizumab"".",19-Dec-2022 12:12:07,2022-12-19 12:12:07,19-Dec-2022 12:12:21,00:00:14,https://nsearchives.nseindia.com/corporate/DRREDDY_19122022121207_PressRelease19122022.pdf,19-12-2022,4344.9501953125,4408.64990234375,4315.0498046875,4396.0498046875,4361.9384765625,332351,0.0,0.0,26-12-2022,0
82,DRREDDY,Dr. Reddy's Laboratories Limited,esop/esps/sbeb scheme, about allotment of equity shares on exercise of stock options under esops,16-Dec-2022 12:24:03,2022-12-16 12:24:03,16-Dec-2022 12:24:07,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_16122022122403_SEIntimationESOPallotment16122022.pdf,16-12-2022,4434.5,4458.85009765625,4261.25,4309.10009765625,4275.66357421875,3356609,0.0,0.0,23-12-2022,0
83,DRREDDY,Dr. Reddy's Laboratories Limited,press release," about press release dated 16-dec-2022 titled aurigene oncology limited,, a wholly owned subsidiary of the company, reports results of aur101 in phase ii study in patients with moderate to severe psoriasis",16-Dec-2022 11:31:06,2022-12-16 11:31:06,16-Dec-2022 11:31:10,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_16122022113106_PressRelease16122022.pdf,16-12-2022,4434.5,4458.85009765625,4261.25,4309.10009765625,4275.66357421875,3356609,0.0,0.0,23-12-2022,0
84,DRREDDY,Dr. Reddy's Laboratories Limited,general updates," about intimation under regulation 30 of the securities and exchange board of india (listing obligations and disclosure requirements) regulations, 2015",22-Nov-2022 14:07:33,2022-11-22 14:07:33,22-Nov-2022 14:07:39,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_22112022140733_Intimation22112022.pdf,22-11-2022,4371.60009765625,4402.60009765625,4326.0,4362.5,4328.64892578125,403095,0.0,0.0,29-11-2022,0
85,DRREDDY,Dr. Reddy's Laboratories Limited,newspaper advertisements, about the copy of newspaper advertisement for q2 fy23 financial results,31-Oct-2022 10:41:48,2022-10-31 10:41:48,31-Oct-2022 10:41:52,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_31102022104148_SEintimationpublicationofnewspaperadvertisement.pdf,31-10-2022,4531.0,4625.0,4344.64990234375,4433.7001953125,4399.296875,1825761,0.0,0.0,07-11-2022,0
86,DRREDDY,Dr. Reddy's Laboratories Limited,outcome of board meeting,"dr. reddy's laboratories limited  has informed the exchange about the outcome of board meeting ￢ﾀﾓ unaudited financial results for the quarter and half-year ended september 30, 2022",28-Oct-2022 16:23:52,2022-10-28 16:23:52,28-Oct-2022 21:26:06,05:02:14,https://nsearchives.nseindia.com/corporate/DRREDDY_28102022162351_Outcome.pdf,28-10-2022,4485.0,4502.75,4430.0,4459.9501953125,4425.34326171875,353586,0.0,0.0,04-11-2022,0
87,DRREDDY,Dr. Reddy's Laboratories Limited,press release, about press release dated 11-oct-2022 titled world economic forum recognises dr. reddy￢ﾀﾙs hyderabad factory as part of its global lighthouse network,11-Oct-2022 11:39:54,2022-10-11 11:39:54,11-Oct-2022 11:39:58,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_11102022113954_PressRelease11102022.pdf,11-10-2022,4387.0,4388.0,4252.0,4282.75,4249.51806640625,297382,0.0,0.0,18-10-2022,0
88,DRREDDY,Dr. Reddy's Laboratories Limited,closure of trading window," that the trading window for dealing in securities of the company will be closed from friday, september 30, 2022, to sunday, october 30, 2022 (both days inclusive).",28-Sep-2022 19:38:12,2022-09-28 19:38:12,28-Sep-2022 19:38:16,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_28092022193812_BoardMeetingNoticeIntimation002.pdf,28-09-2022,4178.14990234375,4297.0,4178.14990234375,4269.7001953125,4236.5693359375,626648,0.0,0.0,06-10-2022,0
89,DRREDDY,Dr. Reddy's Laboratories Limited,general updates, about issue of letter of confirmation in lieu of share certificate(s) reported lost/misplaced,16-Sep-2022 16:38:42,2022-09-16 16:38:42,16-Sep-2022 16:38:46,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_16092022163842_SEIntimation_IssueofSCaaproval16092022.pdf,16-09-2022,4185.0,4185.0,4060.800048828125,4077.35009765625,4045.7119140625,378704,0.0,0.0,23-09-2022,0
90,DRREDDY,Dr. Reddy's Laboratories Limited,press release," about press release dated 07-sep-2022 titled ""dr. reddy's laboratories announces the launch of lenalidomide capsules in the u.s. with two of six strengths eligible for first-to-market, 180-day exclusivity.",07-Sep-2022 21:17:45,2022-09-07 21:17:45,07-Sep-2022 21:17:47,00:00:02,https://nsearchives.nseindia.com/corporate/DRREDDY_07092022211745_PressRelease07092022.pdf,07-09-2022,4215.0,4266.0,4212.2998046875,4249.2998046875,4216.3271484375,214795,0.0,0.0,14-09-2022,0
91,DRREDDY,Dr. Reddy's Laboratories Limited,news verification,drreddy : the exchange has sought clarification from dr. reddy's laboratories limited with respect to recent news item captioned dr. reddy's aurigene ink mou with dndi on neglected tropical diseases.  the response from the company is attached.,02-Sep-2022 14:35:24,2022-09-02 14:35:24,02-Sep-2022 14:35:28,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_02092022143524_Response_to_clarification__Vf__NSE.pdf,02-09-2022,4223.14990234375,4232.0,4173.9501953125,4189.9501953125,4157.43798828125,201656,0.0,0.0,09-09-2022,0
92,DRREDDY,Dr. Reddy's Laboratories Limited,cessation,dr. reddy's laboratories limited  has informed the exchange about cessation of  dr. bruce l a carter as independent director of the company w.e.f. 30-jul-2022,01-Aug-2022 22:43:45,2022-08-01 22:43:45,01-Aug-2022 22:43:49,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_01082022224345_IntimationDrCarter01082022.pdf,01-08-2022,4139.7998046875,4139.7998046875,4100.5,4110.4501953125,4078.55517578125,427370,0.0,0.0,08-08-2022,0
93,DRREDDY,Dr. Reddy's Laboratories Limited,annual general meeting," about voting results,  scrutinizer report and  proceedings of annual general meeting held on 29-jul-2022.",29-Jul-2022 21:08:27,2022-07-29 21:08:27,29-Jul-2022 21:08:30,00:00:03,https://nsearchives.nseindia.com/corporate/DRREDDY_29072022210827_38thAGMOutcome.pdf,29-07-2022,4182.9501953125,4182.9501953125,4055.60009765625,4090.35009765625,4058.611083984375,1974495,0.0,0.0,05-08-2022,0
94,DRREDDY,Dr. Reddy's Laboratories Limited,general updates, about intimation on filing of 6k for q1 fy23 with sec,29-Jul-2022 14:40:33,2022-07-29 14:40:33,29-Jul-2022 14:40:40,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_29072022144033_6kintimation.pdf,29-07-2022,4182.9501953125,4182.9501953125,4055.60009765625,4090.35009765625,4058.611083984375,1974495,0.0,0.0,05-08-2022,0
95,DRREDDY,Dr. Reddy's Laboratories Limited,communication to shareholders as per reg 30," about audio recordings of the earnings call conducted on july 28, 2022",29-Jul-2022 07:50:30,2022-07-29 07:50:30,29-Jul-2022 07:50:34,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_29072022075030_IntimationEarningsCall29072022.pdf,29-07-2022,4182.9501953125,4182.9501953125,4055.60009765625,4090.35009765625,4058.611083984375,1974495,0.0,0.0,05-08-2022,0
96,DRREDDY,Dr. Reddy's Laboratories Limited,communication to shareholders as per reg 30, about grant of stock options to the eligible employees under the employee stock options schemes of the company.,28-Jul-2022 18:24:39,2022-07-28 18:24:39,28-Jul-2022 18:24:42,00:00:03,https://nsearchives.nseindia.com/corporate/DRREDDY_28072022182439_IntimationESOP28.07.2022.pdf,28-07-2022,4314.0,4314.89990234375,4195.0,4260.0498046875,4226.994140625,566567,0.0,0.0,04-08-2022,0
97,DRREDDY,Dr. Reddy's Laboratories Limited,esop/esps/sbeb scheme," about allotment of 7,426 equity shares of rs. 5/- each of the companv, fully paid up.",28-Jul-2022 17:44:51,2022-07-28 17:44:51,28-Jul-2022 17:44:56,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_28072022174451_IntimationESOP28.07.2022.pdf,28-07-2022,4314.0,4314.89990234375,4195.0,4260.0498046875,4226.994140625,566567,0.0,0.0,04-08-2022,0
98,DRREDDY,Dr. Reddy's Laboratories Limited,appointment,"dr. reddy's laboratories limited  has informed the exchange about appointment of mr. arun madhavan kumar (din: 09665138) as an additional director, categorized as independent, on the board of the company.",28-Jul-2022 17:08:33,2022-07-28 17:08:33,28-Jul-2022 17:08:36,00:00:03,https://nsearchives.nseindia.com/corporate/DRREDDY_28072022170833_SE_Intimation_appointment_of_Director.pdf,28-07-2022,4314.0,4314.89990234375,4195.0,4260.0498046875,4226.994140625,566567,0.0,0.0,04-08-2022,0
99,DRREDDY,Dr. Reddy's Laboratories Limited,outcome of board meeting,"dr. reddy's laboratories limited  has informed the exchange about board meeting held on 28-jul-2022 to consider unaudited financial results for the quarter ended june 30, 2022.",28-Jul-2022 16:01:42,2022-07-28 16:01:42,28-Jul-2022 16:01:45,00:00:03,https://nsearchives.nseindia.com/corporate/DRREDDY_28072022160142_OutcomeofBoardMeeting28072022.pdf,28-07-2022,4314.0,4314.89990234375,4195.0,4260.0498046875,4226.994140625,566567,0.0,0.0,04-08-2022,0
100,DRREDDY,Dr. Reddy's Laboratories Limited,press release," about press release dated 27-jul-2022 titled dr. reddy's laboratories announces the launch of bortezomib for injection, 3.5 mg single-dose vial in the u.s. market",27-Jul-2022 10:47:09,2022-07-27 10:47:09,27-Jul-2022 10:47:17,00:00:08,https://nsearchives.nseindia.com/corporate/DRREDDY_27072022104709_PressRelease27072022.pdf,27-07-2022,4207.9501953125,4300.0,4163.0,4286.0498046875,4252.7919921875,373254,0.0,0.0,03-08-2022,0
101,DRREDDY,Dr. Reddy's Laboratories Limited,press release," about press release dated 22-jul-2022 titled dr. reddy￢ﾀﾙs announces the first-to-market launch of over-the-counter, store-brand equivalent of allegra-dￂﾮ 24 hr in the u.s. market",22-Jul-2022 13:53:18,2022-07-22 13:53:18,22-Jul-2022 13:53:22,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_22072022135318_PressRelease22072022.pdf,22-07-2022,4394.0,4406.7998046875,4353.0,4373.5,4339.56396484375,361263,0.0,0.0,29-07-2022,-1
102,DRREDDY,Dr. Reddy's Laboratories Limited,press release, about press release dated 08-jul-2022 titled dr. reddy's laboratories announces the launch of  fesoterodine fumarate extended-release tablets in the u.s. market,08-Jul-2022 17:37:15,2022-07-08 17:37:15,08-Jul-2022 17:37:19,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_08072022173715_PressRelease08072022.pdf,08-07-2022,4330.0,4414.9501953125,4304.39990234375,4406.2001953125,4313.30126953125,417896,0.0,0.0,15-07-2022,0
103,DRREDDY,Dr. Reddy's Laboratories Limited,business responsibility & sustainability report (brsr)," about business responsibility & sustainability report (brsr) for the period ended march 31, 2022.",06-Jul-2022 19:36:15,2022-07-06 19:36:15,06-Jul-2022 19:36:21,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_06072022193615_SEIntimation06072022signed.pdf,06-07-2022,4395.0,4443.2998046875,4379.35009765625,4390.0,4297.4423828125,335701,0.0,0.0,13-07-2022,0
104,DRREDDY,Dr. Reddy's Laboratories Limited,annual general meeting, about notice of 38th annual general meeting (agm) and annual report 2021-22.,06-Jul-2022 19:01:06,2022-07-06 19:01:06,06-Jul-2022 19:01:10,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_06072022190106_SEIntimation06072022signed.pdf,06-07-2022,4395.0,4443.2998046875,4379.35009765625,4390.0,4297.4423828125,335701,0.0,0.0,13-07-2022,0
105,DRREDDY,Dr. Reddy's Laboratories Limited,closure of trading window," about closure of the trading window for dealing in securities of the company from thursday, june 30, 2022, to saturday, july 30, 2022 (both days inclusive).",29-Jun-2022 17:10:09,2022-06-29 17:10:09,29-Jun-2022 17:10:13,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_29062022171007_boardmeetingintimation29062022.pdf,29-06-2022,4357.10009765625,4408.75,4334.39990234375,4364.35009765625,4272.3330078125,381147,0.0,0.0,06-07-2022,0
106,DRREDDY,Dr. Reddy's Laboratories Limited,press release, about press release dated 28-jun-2022 titled dr. reddy￢ﾀﾙs laboratories limited announces filing of annual report on form 20-f,28-Jun-2022 14:42:57,2022-06-28 14:42:57,28-Jun-2022 14:43:02,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_28062022144257_PressRelease28062022form20F.pdf,28-06-2022,4329.25,4380.0,4312.0,4374.60009765625,4282.36767578125,282443,0.0,0.0,05-07-2022,0
107,DRREDDY,Dr. Reddy's Laboratories Limited,press release, about press release dated 24-jun-2022 titled dr. reddy's laboratories announces the acquisition of an injectable product portfolio from eton pharma,24-Jun-2022 16:38:13,2022-06-24 16:38:13,24-Jun-2022 16:38:18,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_24062022163813_PressRelease24062022.pdf,24-06-2022,4322.0,4372.5498046875,4292.0,4309.64990234375,4218.78662109375,303659,0.0,0.0,01-07-2022,0
108,DRREDDY,Dr. Reddy's Laboratories Limited,general updates, about intimation - settlement agreement with respect to buprenorphine and naloxone sublingual film,24-Jun-2022 15:25:25,2022-06-24 15:25:25,24-Jun-2022 15:25:28,00:00:03,https://nsearchives.nseindia.com/corporate/DRREDDY_24062022152525_SEintimation24062022.pdf,24-06-2022,4322.0,4372.5498046875,4292.0,4309.64990234375,4218.78662109375,303659,0.0,0.0,01-07-2022,0
109,DRREDDY,Dr. Reddy's Laboratories Limited,general updates, about allotment of equity shares on exercise of stock options under esops,23-Jun-2022 11:40:33,2022-06-23 11:40:33,23-Jun-2022 18:36:52,06:56:19,https://nsearchives.nseindia.com/corporate/DRREDDY_23062022114033_SEIntimationESOPAllotment.pdf,23-06-2022,4295.0,4307.7001953125,4255.0,4294.89990234375,4204.34716796875,335102,0.0,0.0,30-06-2022,0
110,DRREDDY,Dr. Reddy's Laboratories Limited,press release," about press release dated 14-jun-2022 titled dr. reddy's laboratories announces the launch of the generic version of nexavar (sorafenib) tablets, usp, 200 mg in the u.s. market",14-Jun-2022 10:34:15,2022-06-14 10:34:15,14-Jun-2022 10:34:19,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_14062022103415_PressRelease14062022.pdf,14-06-2022,4250.0,4324.9501953125,4239.0498046875,4311.0498046875,4220.1572265625,407181,0.0,0.0,21-06-2022,0
111,DRREDDY,Dr. Reddy's Laboratories Limited,schedule of analysts/institutional investor meet/con. call," about schedule of analysts/institutional investor meet/con. call - investor day on june 21, 2022",13-Jun-2022 18:55:56,2022-06-13 18:55:56,13-Jun-2022 18:55:58,00:00:02,https://nsearchives.nseindia.com/corporate/DRREDDY_13062022185556_SEIntimation13062022.pdf,13-06-2022,4323.0,4355.0,4256.5,4267.2001953125,4177.23193359375,367963,0.0,0.0,20-06-2022,0
112,DRREDDY,Dr. Reddy's Laboratories Limited,press release," about press release dated 09-jun-2022 titled press release issued by ￢ﾀﾘolema pharmaceuticals, inc (nasdaq: olma)￢ﾀﾙ announcing an exclusive collaboration and license agreement with aurigene discovery technologies limited, our wos",09-Jun-2022 17:53:14,2022-06-09 17:53:14,09-Jun-2022 17:53:17,00:00:03,https://nsearchives.nseindia.com/corporate/DRREDDY_09062022175313_PressRelease09062022.pdf,09-06-2022,4170.10009765625,4335.0,4170.10009765625,4322.89990234375,4231.7568359375,740586,0.0,0.0,16-06-2022,0
113,DRREDDY,Dr. Reddy's Laboratories Limited,schedule of analysts/institutional investor meet/con. call," about schedule of analysts/institutional investor meet/con. call in the month of june, 2022",03-Jun-2022 12:13:50,2022-06-03 12:13:50,03-Jun-2022 12:13:54,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_03062022121350_SEIntimation03062022.pdf,03-06-2022,4359.7001953125,4391.64990234375,4314.7998046875,4340.0,4248.4970703125,284773,0.0,0.0,10-06-2022,0
114,DRREDDY,Dr. Reddy's Laboratories Limited,related party transaction, about related party transaction for the half year period ended march 2022,02-Jun-2022 23:54:23,2022-06-02 23:54:23,02-Jun-2022 23:54:27,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_02062022235423_RPTDisclosureH2FY22.pdf,02-06-2022,4303.10009765625,4360.0,4290.0,4333.14990234375,4241.791015625,327935,0.0,0.0,09-06-2022,0
115,DRREDDY,Dr. Reddy's Laboratories Limited,press release," about press release dated 27-may-2022 titled dr. reddy's laboratories announces the launch of pemetrexed for injection usp, in the u.s. market",27-May-2022 18:15:53,2022-05-27 18:15:53,27-May-2022 18:15:58,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_27052022181545_PressRelease27052022.pdf,27-05-2022,4320.0,4409.0,4268.9501953125,4390.5,4297.931640625,434291,0.0,0.0,03-06-2022,0
116,DRREDDY,Dr. Reddy's Laboratories Limited,press release," about press release dated 24-may-2022 titled dr. reddy's laboratories and senores pharmaceuticals, inc. announce the launch ketorolac tromethamine tablets usp, 10 mg in the u.s. market",24-May-2022 20:38:21,2022-05-24 20:38:21,24-May-2022 20:38:30,00:00:09,https://nsearchives.nseindia.com/corporate/DRREDDY_24052022203817_PressRelease24052022.pdf,24-05-2022,4273.89990234375,4375.0,4256.4501953125,4347.10009765625,4255.447265625,1010896,0.0,0.0,31-05-2022,0
117,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure of other upsi/material event, about disclosure of presentation and the audio recording of the earnings call on company's website.,20-May-2022 15:50:18,2022-05-20 15:50:18,20-May-2022 15:50:27,00:00:09,https://nsearchives.nseindia.com/corporate/DRREDDY_20052022155014_IntimationEarningscall.pdf,20-05-2022,3975.0,4299.10009765625,3975.0,4249.10009765625,4159.513671875,2480315,0.0,0.0,27-05-2022,0
118,DRREDDY,Dr. Reddy's Laboratories Limited,re-appointment,"dr. reddy's laboratories limited  has informed the exchange about re-appointment of k satish reddy as a whole-time director, designated as chairman.",20-May-2022 13:14:29,2022-05-20 13:14:29,20-May-2022 13:14:33,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_20052022131425_SEintimation19052022_Reg_30.pdf,20-05-2022,3975.0,4299.10009765625,3975.0,4249.10009765625,4159.513671875,2480315,0.0,0.0,27-05-2022,0
119,DRREDDY,Dr. Reddy's Laboratories Limited,book closure, that register of members & share transfer books of the company will remain closed from 13-jul-2022 to 15-jul-2022 for the purpose of dividend.,20-May-2022 11:02:33,2022-05-20 11:02:33,20-May-2022 11:02:40,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_20052022110200_SEintimation19052022_Reg_30.pdf,20-05-2022,3975.0,4299.10009765625,3975.0,4249.10009765625,4159.513671875,2480315,0.0,0.0,27-05-2022,0
120,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended march 31, 2022.",19-May-2022 13:09:52,2022-05-19 13:09:52,19-May-2022 13:11:02,00:01:10,https://nsearchives.nseindia.com/corporate/SEintimation19052022_19052022130952.pdf,19-05-2022,3886.0,4014.75,3829.050048828125,3929.449951171875,3846.602783203125,1825811,0.0,0.0,26-05-2022,1
121,DRREDDY,Dr. Reddy's Laboratories Limited,outcome of board meeting,dr. reddy's laboratories limited  has informed the exchange about board meeting held on 19-may-2022 to consider financial statements for the period ended march 2022,19-May-2022 12:50:40,2022-05-19 12:50:40,19-May-2022 12:50:49,00:00:09,https://nsearchives.nseindia.com/corporate/DRREDDY_19052022125035_SEintimation19052022.pdf,19-05-2022,3886.0,4014.75,3829.050048828125,3929.449951171875,3846.602783203125,1825811,0.0,0.0,26-05-2022,1
122,DRREDDY,Dr. Reddy's Laboratories Limited,press release, about press release dated 11-may-2022 titled dr. reddy￢ﾀﾙs laboratories enters into exclusive partnership with hk inno.n corporation to commercialise novel molecule tegoprazan in india & select emerging markets,11-May-2022 09:10:29,2022-05-11 09:10:29,11-May-2022 09:10:35,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_11052022091019_PressRelease11052022.pdf,11-05-2022,3895.5,3942.949951171875,3851.0,3884.050048828125,3802.159912109375,271256,0.0,0.0,18-05-2022,0
123,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"g v prasad (on behalf of all the acquirers) has informed the exchange about disclosure under regulation 10 (6) of sebi (substantial acquisition of shares and takeovers) regulations, 2011.",25-Apr-2022 18:47:21,2022-04-25 18:47:21,25-Apr-2022 18:47:23,00:00:02,https://nsearchives.nseindia.com/corporate/DRREDDY_25042022165644_Disclosure10.pdf,25-04-2022,4150.0,4179.7001953125,4061.0,4115.4501953125,4028.681396484375,341136,0.0,0.0,02-05-2022,0
124,DRREDDY,Dr. Reddy's Laboratories Limited,press release, about press release dated 20-apr-2022 titled dr. reddy's laboratories announces the launch of  posaconazole delayed-release tablets in the u.s. market,20-Apr-2022 19:40:20,2022-04-20 19:40:20,20-Apr-2022 19:40:29,00:00:09,https://nsearchives.nseindia.com/corporate/DRREDDY_20042022194019_PressRelease20042022.pdf,20-04-2022,4217.0,4340.0,4213.0498046875,4293.39990234375,4202.87939453125,450415,0.0,0.0,27-04-2022,-1
125,DRREDDY,Dr. Reddy's Laboratories Limited,amalgamation/merger, about record date for allotment of shares pursuant to scheme for merger,08-Apr-2022 19:13:43,2022-04-08 19:13:43,08-Apr-2022 19:13:48,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_08042022191343_BMoutcome08042022.pdf,08-04-2022,4347.0,4477.64990234375,4326.85009765625,4430.35009765625,4336.9423828125,671775,0.0,0.0,19-04-2022,0
126,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,promoter/promoter group of dr. reddy's laboratories limited has submitted a disclosure under regulation 31(4) of sebi takeover regulations for the year ended 31-mar-2022,08-Apr-2022 11:22:33,2022-04-08 11:22:33,08-Apr-2022 11:22:45,00:00:12,https://nsearchives.nseindia.com/corporate/AN_O08042022112233.xlsx,08-04-2022,4347.0,4477.64990234375,4326.85009765625,4430.35009765625,4336.9423828125,671775,0.0,0.0,19-04-2022,0
127,DRREDDY,Dr. Reddy's Laboratories Limited,press release," about press release dated 05-apr-2022 titled dr. reddy's laboratories announces the launch of methylprednisolone sodium succinate for injection, usp in the u.s. market",05-Apr-2022 12:38:16,2022-04-05 12:38:16,05-Apr-2022 12:38:22,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_05042022123814_PressRelease05042022.pdf,05-04-2022,4338.89990234375,4408.0,4302.75,4329.89990234375,4238.609375,479865,0.0,0.0,12-04-2022,0
128,DRREDDY,Dr. Reddy's Laboratories Limited,news verification,drreddy : the exchange has sought clarification from dr. reddy's laboratories limited with respect to recent news item captioned himachal pradesh high court restrains drl from selling bi's diabetic drug jardiance.  the response from the company is attached.,05-Apr-2022 09:30:12,2022-04-05 09:30:12,05-Apr-2022 09:30:18,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_07042022100533_Response_to_clarification_NSE.pdf,05-04-2022,4338.89990234375,4408.0,4302.75,4329.89990234375,4238.609375,479865,0.0,0.0,12-04-2022,0
129,DRREDDY,Dr. Reddy's Laboratories Limited,closure of trading window," about closure of trading window for board meeting scheduled to be held on may 19, 2022",29-Mar-2022 13:19:08,2022-03-29 13:19:08,29-Mar-2022 13:19:13,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_29032022131903_BoardMeetingNoticeIntimation.pdf,29-03-2022,4294.0,4355.5498046875,4247.0498046875,4323.5498046875,4232.39306640625,421084,0.0,0.0,05-04-2022,0
130,DRREDDY,Dr. Reddy's Laboratories Limited,resignation,dr. reddy's laboratories limited  has informed the exchange about resignation of vivek mittal as interim compliance officer of the company w.e.f. 17-mar-2022,17-Mar-2022 13:07:20,2022-03-17 13:07:20,17-Mar-2022 13:07:35,00:00:15,https://nsearchives.nseindia.com/corporate/DRREDDY_17032022130717_SEintimationKRSappointment.pdf,17-03-2022,3965.10009765625,4050.0,3946.199951171875,4042.14990234375,3956.926513671875,772587,0.0,0.0,25-03-2022,1
131,DRREDDY,Dr. Reddy's Laboratories Limited,appointment,dr. reddy's laboratories limited  has informed the exchange about appointment of k randhir singh as compliance officer of the company w.e.f. 17-mar-2022,17-Mar-2022 12:08:00,2022-03-17 12:08:00,17-Mar-2022 12:08:13,00:00:13,https://nsearchives.nseindia.com/corporate/DRREDDY_17032022120800_SEintimationKRSappointment.pdf,17-03-2022,3965.10009765625,4050.0,3946.199951171875,4042.14990234375,3956.926513671875,772587,0.0,0.0,25-03-2022,1
132,DRREDDY,Dr. Reddy's Laboratories Limited,appointment,dr. reddy's laboratories limited  has informed the exchange about appointment of k randhir singh as company secretary of the company w.e.f. 17-mar-2022,17-Mar-2022 12:01:47,2022-03-17 12:01:47,17-Mar-2022 12:02:12,00:00:25,https://nsearchives.nseindia.com/corporate/DRREDDY_17032022120145_SEintimationKRSappointment.pdf,17-03-2022,3965.10009765625,4050.0,3946.199951171875,4042.14990234375,3956.926513671875,772587,0.0,0.0,25-03-2022,1
133,DRREDDY,Dr. Reddy's Laboratories Limited,newspaper advertisements, about a copy of newspaper advertisement given for despatch of postal ballot notice and e-voting information,28-Feb-2022 21:46:13,2022-02-28 21:46:13,28-Feb-2022 21:46:29,00:00:16,https://nsearchives.nseindia.com/corporate/DRREDDY_28022022214608_SignedSE28022022.pdf,28-02-2022,4150.0,4150.0,4052.5,4063.39990234375,3977.728271484375,982850,0.0,0.0,08-03-2022,0
134,DRREDDY,Dr. Reddy's Laboratories Limited,general updates," about audit conducted by the usfda at formulations manufacturing facilities at duvvada, visakhapatnam.",21-Feb-2022 11:25:08,2022-02-21 11:25:08,21-Feb-2022 11:25:18,00:00:10,https://nsearchives.nseindia.com/corporate/DRREDDY_21022022112508_21022022.pdf,21-02-2022,4376.0,4416.64990234375,4282.60009765625,4298.25,4207.62744140625,587951,0.0,0.0,28-02-2022,-1
135,DRREDDY,Dr. Reddy's Laboratories Limited,press release, about press release dated 21-feb-2022 titled binnopharm group enters into agreement to acquire two anti-bacterial brands from dr. reddy￢ﾀﾙs in the russia & cis region.,21-Feb-2022 11:24:06,2022-02-21 11:24:06,21-Feb-2022 11:24:18,00:00:12,https://nsearchives.nseindia.com/corporate/DRREDDY_21022022112406_PressRelease21022022.pdf,21-02-2022,4376.0,4416.64990234375,4282.60009765625,4298.25,4207.62744140625,587951,0.0,0.0,28-02-2022,-1
136,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 11, 2022, titled ""dr. reddy's laboratories enters into exclusive salesand distribution agreement with novartis india limited for select india brands"".",11-Feb-2022 19:54:40,2022-02-11 19:54:40,11-Feb-2022 19:54:45,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_11022022195440_PressRelease11022022.pdf,11-02-2022,4311.0,4349.5498046875,4280.14990234375,4325.39990234375,4234.20458984375,337538,0.0,0.0,18-02-2022,0
137,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 09, 2022, titled ""press release"".",09-Feb-2022 17:06:14,2022-02-09 17:06:14,09-Feb-2022 17:06:29,00:00:15,https://nsearchives.nseindia.com/corporate/DRREDDY_09022022170614_PressReleases09022022.pdf,09-02-2022,4322.2001953125,4395.0,4311.5,4368.75,4276.64013671875,198880,0.0,0.0,16-02-2022,0
138,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 07, 2022, titled ""dr. reddy s laboratories announces dcgi approval to the single-shot sputnik light vaccine in india "".",07-Feb-2022 08:01:04,2022-02-07 08:01:04,07-Feb-2022 08:01:08,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_07022022080104_PressRelease07022022.pdf,07-02-2022,4320.0,4350.0,4250.0498046875,4309.2001953125,4218.34619140625,255958,0.0,0.0,14-02-2022,0
139,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 03, 2022, titled ""press release"".",03-Feb-2022 15:13:47,2022-02-03 15:13:47,03-Feb-2022 15:13:55,00:00:08,https://nsearchives.nseindia.com/corporate/DRREDDY_03022022151347_PressRelease03022022.pdf,03-02-2022,4418.0,4436.9501953125,4360.0,4374.64990234375,4282.41650390625,221537,0.0,0.0,10-02-2022,0
140,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 02, 2022, titled ""dr. reddy s included in s&p global s sustainability yearbook for the 2nd year and bloomberg gender-equality index for the 5th year in a row"".",02-Feb-2022 13:26:26,2022-02-02 13:26:26,02-Feb-2022 13:26:33,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_02022022132626_PressRelease02022022.pdf,02-02-2022,4325.0,4429.75,4315.10009765625,4415.35009765625,4322.25830078125,305001,0.0,0.0,09-02-2022,0
141,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," regarding allotment of 6569 securities pursuant to esop/esps at its meeting held on january 27, 2022",28-Jan-2022 14:46:27,2022-01-28 14:46:27,28-Jan-2022 14:46:42,00:00:15,https://nsearchives.nseindia.com/corporate/DRREDDY_28012022144627_ESOPintimation.pdf,28-01-2022,4248.7998046875,4380.0,4175.4501953125,4218.60009765625,4129.65625,1302984,0.0,0.0,04-02-2022,0
142,DRREDDY,Dr. Reddy's Laboratories Limited,appointment," regarding appointment of ms penny wan as non- executive independent director of the company w.e.f. january 28, 2022.",28-Jan-2022 13:25:40,2022-01-28 13:25:40,28-Jan-2022 13:25:56,00:00:16,https://nsearchives.nseindia.com/corporate/DRREDDY_28012022132540_Directorappointment.pdf,28-01-2022,4248.7998046875,4380.0,4175.4501953125,4218.60009765625,4129.65625,1302984,0.0,0.0,04-02-2022,0
143,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended december 31, 2021.",28-Jan-2022 12:35:00,2022-01-28 12:35:00,28-Jan-2022 12:37:02,00:02:02,https://nsearchives.nseindia.com/corporate/BMoutcome28012022_28012022123500.pdf,28-01-2022,4248.7998046875,4380.0,4175.4501953125,4218.60009765625,4129.65625,1302984,0.0,0.0,04-02-2022,0
144,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 17, 2022, titled ""earnings call "".",17-Jan-2022 14:54:03,2022-01-17 14:54:03,17-Jan-2022 14:54:14,00:00:11,https://nsearchives.nseindia.com/corporate/DRREDDY_17012022145403_PressRelease17012022.pdf,17-01-2022,4665.5,4699.9501953125,4605.5,4672.39990234375,4573.88818359375,538649,0.0,0.0,24-01-2022,-1
145,DRREDDY,Dr. Reddy's Laboratories Limited,appointment," regarding appointment of mr k p krishnan as independent director of the company w.e.f. january 07, 2022.",07-Jan-2022 21:24:57,2022-01-07 21:24:57,07-Jan-2022 21:25:04,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_07012022212457_Intimationkrishnan.pdf,07-01-2022,4769.4501953125,4769.4501953125,4690.0,4708.39990234375,4609.12939453125,267123,0.0,0.0,14-01-2022,0
146,DRREDDY,Dr. Reddy's Laboratories Limited,trading window," regarding the trading window closure pursuant to sebi (prohibition of insider trading) regulations, 2015",28-Dec-2021 16:53:09,2021-12-28 16:53:09,28-Dec-2021 16:53:15,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_28122021165309_BoardMeetingNoticeIntimation.pdf,28-12-2021,4736.89990234375,4773.60009765625,4703.0498046875,4743.7998046875,4643.78271484375,668594,0.0,0.0,04-01-2022,0
147,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 28, 2021, titled ""dr. reddy's laboratories receives dcgi approval tolaunch molnupiravir capsules 200mg (molflu ) in india"".",28-Dec-2021 16:33:50,2021-12-28 16:33:50,28-Dec-2021 16:33:57,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_28122021163350_PressRelease28122021.pdf,28-12-2021,4736.89990234375,4773.60009765625,4703.0498046875,4743.7998046875,4643.78271484375,668594,0.0,0.0,04-01-2022,0
148,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 09, 2021, titled ""dr. reddy's laboratories announces the launch of venlafaxine er tablets in the u.s. market"".",09-Dec-2021 21:57:34,2021-12-09 21:57:34,09-Dec-2021 21:57:40,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_09122021215734_PressRelease09122021Venlafaxine.pdf,09-12-2021,4600.0,4617.9501953125,4565.35009765625,4594.25,4497.38623046875,226177,0.0,0.0,16-12-2021,0
149,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 09, 2021, titled ""dr. reddy's laboratories announces the launch ofvalsartan tablets, usp in the u.s. market"".",09-Dec-2021 11:46:18,2021-12-09 11:46:18,09-Dec-2021 11:46:22,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_09122021114618_PressReleases09122021Valsartan.pdf,09-12-2021,4600.0,4617.9501953125,4565.35009765625,4594.25,4497.38623046875,226177,0.0,0.0,16-12-2021,0
150,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 09, 2021, titled ""prestige biopharma and dr. reddy s announce partnership to commercialize trastuzumab biosimilar in select countries in latin america and southeast asia"".",09-Dec-2021 07:44:21,2021-12-09 07:44:21,09-Dec-2021 07:44:27,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_09122021074421_PressRelease09122021.pdf,09-12-2021,4600.0,4617.9501953125,4565.35009765625,4594.25,4497.38623046875,226177,0.0,0.0,16-12-2021,0
151,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 29, 2021, titled ""dr. reddy's laboratories announces the launch of ephedrine sulfate injection usp, 50 mg/ml, single-dose vial in the u.s. market"".",29-Oct-2021 17:51:13,2021-10-29 17:51:13,29-Oct-2021 17:51:21,00:00:08,https://nsearchives.nseindia.com/corporate/DRREDDY_29102021175113_PressRelease29102021.pdf,29-10-2021,4593.0,4917.85009765625,4526.0498046875,4659.2001953125,4560.96728515625,1945164,0.0,0.0,08-11-2021,0
152,DRREDDY,Dr. Reddy's Laboratories Limited,resignation," regarding resignation of mr sandeep poddar as company secretary & compliance officer of the company w.e.f. november 18, 2021.",29-Oct-2021 17:26:05,2021-10-29 17:26:05,29-Oct-2021 17:26:22,00:00:17,https://nsearchives.nseindia.com/corporate/DRREDDY_29102021172605_SEintimationCSResignation.pdf,29-10-2021,4593.0,4917.85009765625,4526.0498046875,4659.2001953125,4560.96728515625,1945164,0.0,0.0,08-11-2021,0
153,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended september 30, 2021.",29-Oct-2021 13:53:50,2021-10-29 13:53:50,29-Oct-2021 17:06:09,03:12:19,https://nsearchives.nseindia.com/corporate/Q2FY22Financials_29102021135350.pdf,29-10-2021,4593.0,4917.85009765625,4526.0498046875,4659.2001953125,4560.96728515625,1945164,0.0,0.0,08-11-2021,0
154,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 19, 2021, titled ""dr. reddy's laboratories announces approval for lenalidomide capsules from the u.s. food and drug administration (usfda)"".",19-Oct-2021 08:53:47,2021-10-19 08:53:47,19-Oct-2021 08:53:52,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_19102021085347_PressRelease19102021.pdf,19-10-2021,4905.0,4920.0,4790.0,4801.7998046875,4700.56005859375,539719,0.0,0.0,26-10-2021,0
155,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 07, 2021, titled ""dr. reddy's to release q2 fy 22 results on october 29th, 2021 earnings call slated for october 29th @ 5:30 pm ist / 8:00 am edt"".",07-Oct-2021 16:07:27,2021-10-07 16:07:27,07-Oct-2021 16:07:32,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_07102021160727_PressRelease07102021.pdf,07-10-2021,4975.89990234375,4989.89990234375,4882.9501953125,4891.10009765625,4787.9775390625,343974,0.0,0.0,14-10-2021,0
156,DRREDDY,Dr. Reddy's Laboratories Limited,trading window," regarding the trading window closure pursuant to sebi (prohibition of insider trading) regulations, 2015",24-Sep-2021 18:22:21,2021-09-24 18:22:21,24-Sep-2021 18:22:27,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_24092021182221_BoardMeetingNoticeIntimation.pdf,24-09-2021,4806.0,4821.10009765625,4778.0498046875,4790.35009765625,4689.3515625,251615,0.0,0.0,01-10-2021,0
157,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 07, 2021, titled ""dr. reddy s launches minoxidil for women following first-ever approval in india for the treatment of female pattern hair loss."".",07-Sep-2021 13:01:32,2021-09-07 13:01:32,07-Sep-2021 13:01:37,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_07092021130132_PressRelease07092021.pdf,07-09-2021,4915.0,4925.9501953125,4855.5498046875,4897.4501953125,4794.193359375,420214,0.0,0.0,15-09-2021,0
158,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 02, 2021, titled ""dr. reddy's laboratories canada announces the launch of reddy-lenalidomide, one of the first generic medications of its kind for the canadian market."".",02-Sep-2021 08:18:01,2021-09-02 08:18:01,02-Sep-2021 08:18:05,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_02092021081801_PressRelease02092021.pdf,02-09-2021,4811.0,4904.39990234375,4810.0,4859.7001953125,4757.23974609375,1259864,0.0,0.0,09-09-2021,0
159,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 31, 2021, titled ""dr. reddy's laboratories announces the launch of chlordiazepoxide hydrochloride and clidinium bromide capsules, usp in the u.s. market."".",31-Aug-2021 11:38:37,2021-08-31 11:38:37,31-Aug-2021 11:38:43,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_31082021113837_PressRelease31082021.pdf,31-08-2021,4677.89990234375,4721.75,4650.5,4704.0498046875,4604.87109375,645527,0.0,0.0,07-09-2021,0
160,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 04, 2021, titled ""dr. reddy s laboratories announces entry into definitive agreement with biodelivery sciences international, inc., to sell its u.s. and canada territory rights for elyxyb (celecoxib oral solution) 25 mg/ml"".",04-Aug-2021 19:21:52,2021-08-04 19:21:52,04-Aug-2021 19:21:57,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_04082021192152_PressRelease04082021.pdf,04-08-2021,4725.60009765625,4810.0,4725.60009765625,4768.7998046875,4668.255859375,1104198,0.0,0.0,11-08-2021,0
161,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 03, 2021, titled ""dr. reddy s announces the re-launch of over-the-counter naproxen sodium tablets usp, 220 mg, store-brand equivalent of aleveￂﾮ in the u.s. market."".",03-Aug-2021 17:12:25,2021-08-03 17:12:25,03-Aug-2021 17:12:31,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_03082021171225_PressRelease03082021.pdf,03-08-2021,4728.39990234375,4729.4501953125,4691.7001953125,4721.7001953125,4622.14990234375,598261,0.0,0.0,10-08-2021,0
162,DRREDDY,Dr. Reddy's Laboratories Limited,shareholders meeting," regarding proceedings of annual general meeting held on july 28, 2021. further, the company has submitted the exchange a copy of srutinizers report along with voting results.",28-Jul-2021 19:56:11,2021-07-28 19:56:11,28-Jul-2021 19:56:18,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_28072021195611_AGMOutcome.pdf,28-07-2021,4869.9501953125,4874.85009765625,4666.5,4731.75,4631.98681640625,3238130,0.0,0.0,04-08-2021,0
163,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 27, 2021, titled ""dr. reddy s and icici lombard collaborate for pilot launch of first-of-its-kind integrated and cashless digital health solution in india."".",27-Jul-2021 14:30:27,2021-07-27 14:30:27,27-Jul-2021 14:30:32,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_27072021143027_PressRelease27072021.pdf,27-07-2021,5438.0,5444.9501953125,4780.0,4843.35009765625,4741.23486328125,5873821,0.0,0.0,03-08-2021,0
164,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended june 30, 2021.",27-Jul-2021 11:23:45,2021-07-27 11:23:45,27-Jul-2021 11:25:03,00:01:18,https://nsearchives.nseindia.com/corporate/Q1FY22SEBI_27072021112345.pdf,27-07-2021,5438.0,5444.9501953125,4780.0,4843.35009765625,4741.23486328125,5873821,0.0,0.0,03-08-2021,0
165,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 07, 2021, titled ""dr. reddy's to release q1 fy 22 results on july 27th, 2021 earnings call slated for july 27th @ 5:30 pm ist / 8:00 am edt"".",07-Jul-2021 16:28:26,2021-07-07 16:28:26,07-Jul-2021 16:28:38,00:00:12,https://nsearchives.nseindia.com/corporate/DRREDDY_07072021162826_PressRelease07072021.pdf,07-07-2021,5529.0,5614.60009765625,5515.0498046875,5562.10009765625,5395.115234375,538508,0.0,0.0,14-07-2021,0
166,DRREDDY,Dr. Reddy's Laboratories Limited,news verification,the exchange has sought clarification from dr. reddy's laboratories limited with respect to recent news item captioned dr reddy's labs denied approval for final trial of russian-made sputnik light.  the response from the company is attached.,02-Jul-2021 09:34:00,2021-07-02 09:34:00,02-Jul-2021 09:34:48,00:00:48,https://nsearchives.nseindia.com/corporate/DRREDDY_02072021093443_NSEReplytoClarification.pdf,02-07-2021,5580.0,5600.0,5511.5,5575.7001953125,5408.3076171875,571738,0.0,0.0,09-07-2021,0
167,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 30, 2021, titled ""dr. reddy's laboratories announces filing of annual report on form 20-f"".",30-Jun-2021 22:40:54,2021-06-30 22:40:54,30-Jun-2021 22:41:01,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_30062021224054_PressRelease30062021.pdf,30-06-2021,5439.0,5468.7998046875,5405.0,5423.0498046875,5260.23974609375,468088,0.0,0.0,07-07-2021,0
168,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 29, 2021, titled ""pharma majors collaborate for clinical trial of investigational oral anti-viral drug molnupiravir for covid-19"".",29-Jun-2021 16:00:11,2021-06-29 16:00:11,29-Jun-2021 16:00:35,00:00:24,https://nsearchives.nseindia.com/corporate/DRREDDY_29062021160011_PressRelease29062021.pdf,29-06-2021,5411.0,5454.9501953125,5380.0,5433.10009765625,5269.98828125,576261,0.0,0.0,06-07-2021,0
169,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 28, 2021, titled ""dr. reddy s laboratories announces commercial launch of 2dg"".",28-Jun-2021 08:42:09,2021-06-28 08:42:09,28-Jun-2021 08:42:18,00:00:09,https://nsearchives.nseindia.com/corporate/DRREDDY_28062021084209_PressRelease28062021.pdf,28-06-2021,5329.0,5419.9501953125,5312.5498046875,5404.25,5242.0048828125,592963,0.0,0.0,05-07-2021,0
170,DRREDDY,Dr. Reddy's Laboratories Limited,trading window," regarding the trading window closure pursuant to sebi (prohibition of insider trading) regulations, 2015",25-Jun-2021 21:13:27,2021-06-25 21:13:27,25-Jun-2021 21:13:31,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_25062021211327_BoardMeetingNoticeIntimation.pdf,25-06-2021,5277.0,5336.0,5267.0,5309.2998046875,5149.90478515625,464073,0.0,0.0,02-07-2021,1
171,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 22, 2021, titled ""dr. reddy's laboratories announces the launch of icosapent ethyl capsules, 1 gram in the u.s. market"".",22-Jun-2021 08:38:31,2021-06-22 08:38:31,22-Jun-2021 08:38:37,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_22062021083831_PressRelease22062021.pdf,22-06-2021,5285.5,5320.0,5250.5,5308.35009765625,5148.98388671875,426855,0.0,0.0,29-06-2021,0
172,DRREDDY,Dr. Reddy's Laboratories Limited,related party transactions,"dr. reddy's laboratories limited has submitted disclosure of related party transactions for the half year ended march 31, 2021.",10-Jun-2021 17:50:01,2021-06-10 17:50:01,10-Jun-2021 17:50:12,00:00:11,https://nsearchives.nseindia.com/corporate/DRREDDY_10062021175001_RPTDisclosureMarch2021.pdf,10-06-2021,5232.5,5300.0,5232.5,5292.0498046875,5133.1728515625,367280,0.0,0.0,17-06-2021,0
173,DRREDDY,Dr. Reddy's Laboratories Limited,book closure, that register of members & share transfer books of the company will remain closed from 13-jul-2021 to 15-jul-2021 for the purpose of dividend.,19-May-2021 21:50:01,2021-05-19 21:50:01,19-May-2021 21:50:17,00:00:16,https://nsearchives.nseindia.com/corporate/DRREDDY_19052021215001_BookClosureandAGMdate.pdf,19-05-2021,5235.0,5264.0,5206.0498046875,5237.7998046875,5080.5517578125,918921,0.0,0.0,26-05-2021,0
174,DRREDDY,Dr. Reddy's Laboratories Limited,dividend," that board of directors at its meeting held on may 14, 2021, recommended final dividend of 25 per equity share.",14-May-2021 15:39:10,2021-05-14 15:39:10,14-May-2021 15:39:17,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_14052021153910_BMoutcome14052021resultsFinal.pdf,14-05-2021,5338.5498046875,5398.39990234375,5160.0,5196.85009765625,5040.83056640625,2977011,0.0,0.0,21-05-2021,0
175,DRREDDY,Dr. Reddy's Laboratories Limited,dividend," that board of directors at its meeting held on may 14, 2021, recommended final dividend of 25 per equity share.",14-May-2021 15:36:18,2021-05-14 15:36:18,14-May-2021 15:36:29,00:00:11,https://nsearchives.nseindia.com/corporate/DRREDDY_14052021153618_BMoutcome14052021resultsFinal.pdf,14-05-2021,5338.5498046875,5398.39990234375,5160.0,5196.85009765625,5040.83056640625,2977011,0.0,0.0,21-05-2021,0
176,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended march 31, 2021.",14-May-2021 12:26:27,2021-05-14 12:26:27,14-May-2021 12:28:02,00:01:35,https://nsearchives.nseindia.com/corporate/BMoutcome14052021resultsFinal_14052021122627.pdf,14-05-2021,5338.5498046875,5398.39990234375,5160.0,5196.85009765625,5040.83056640625,2977011,0.0,0.0,21-05-2021,0
177,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 14, 2021, titled ""dr. reddy s laboratories announces launch of the sputnik v vaccine in the indian market"".",14-May-2021 11:55:16,2021-05-14 11:55:16,14-May-2021 11:55:23,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_14052021115516_PressRelease14052021.pdf,14-05-2021,5338.5498046875,5398.39990234375,5160.0,5196.85009765625,5040.83056640625,2977011,0.0,0.0,21-05-2021,0
178,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 12, 2021, titled ""dr. reddy's laboratories announces the launch of ertapenem for injection in the u.s. market."".",12-May-2021 00:29:05,2021-05-12 00:29:05,12-May-2021 00:29:16,00:00:11,https://nsearchives.nseindia.com/corporate/DRREDDY_12052021002905_PressRelease12052021.pdf,12-05-2021,5318.0,5340.0,5275.0,5301.4501953125,5142.29052734375,880165,0.0,0.0,20-05-2021,0
179,DRREDDY,Dr. Reddy's Laboratories Limited,cessation," regarding cessation of mr bharat narotam doshi as independent director of the company w.e.f. may 10, 2021.",12-May-2021 00:00:22,2021-05-12 00:00:22,12-May-2021 00:00:33,00:00:11,https://nsearchives.nseindia.com/corporate/DRREDDY_12052021000022_SEIntimationDirectorChange.pdf,12-05-2021,5318.0,5340.0,5275.0,5301.4501953125,5142.29052734375,880165,0.0,0.0,20-05-2021,0
180,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 11, 2021, titled ""dr. reddy's laboratories enters into a voluntary licensing agreement with lilly to expand access to covid-19 treatment in india"".",11-May-2021 22:04:52,2021-05-11 22:04:52,11-May-2021 22:05:12,00:00:20,https://nsearchives.nseindia.com/corporate/DRREDDY_11052021220452_PressRelease11052021.pdf,11-05-2021,5325.0,5349.9501953125,5271.2998046875,5295.9501953125,5136.95654296875,944890,0.0,0.0,19-05-2021,0
181,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 29, 2021, titled ""dr. reddy's laboratories announces the launch of albendazole tablets, usp in the u.s. market."".",29-Apr-2021 17:59:26,2021-04-29 17:59:26,29-Apr-2021 17:59:33,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_29042021175926_PressRelease29042021.pdf,29-04-2021,5070.25,5144.0,5042.2998046875,5102.2998046875,4949.119140625,1071931,0.0,0.0,06-05-2021,0
182,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 23, 2021, titled ""dr. reddy's to release q4 and full year fy 21 results on may 14th, 2021 earnings call slated for may 14th @ 5:30 pm ist / 8:00 am edt"".",23-Apr-2021 16:06:24,2021-04-23 16:06:24,23-Apr-2021 16:06:28,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_23042021160624_PressRelease23042021.pdf,23-04-2021,5228.0,5266.14990234375,5030.10009765625,5066.7001953125,4914.587890625,2354899,0.0,0.0,30-04-2021,0
183,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"ￂﾠpromoter/member of the promoter group of the company has informed the exchange regarding disclosure under regulation 30 and regulation 31(4) of sebi sast regulations, 2011ￂﾠas at march 31, 2021.ￂﾠ",15-Apr-2021 09:30:10,2021-04-15 09:30:10,15-Apr-2021 09:30:17,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_15042021093010_DRREDDY.pdf,15-04-2021,4842.89990234375,4875.0498046875,4785.0,4845.5498046875,4700.0771484375,1386901,0.0,0.0,23-04-2021,0
184,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 13, 2021, titled ""dr. reddy's laboratories gets emergency use authorisation for sputnik v in india."".",13-Apr-2021 09:35:30,2021-04-13 09:35:30,13-Apr-2021 09:35:35,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_13042021093530_PressRelease13042021.pdf,13-04-2021,5144.7001953125,5144.7001953125,4751.10009765625,4777.2998046875,4633.87646484375,3937234,0.0,0.0,22-04-2021,1
185,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 07, 2021, titled ""dr. reddy's laboratories announces the launch of a generic version of sapropterin dihydrochloride powder for oral solution, 100 mg in the u.s. market."".",07-Apr-2021 12:44:02,2021-04-07 12:44:02,07-Apr-2021 12:44:14,00:00:12,https://nsearchives.nseindia.com/corporate/DRREDDY_07042021124402_PressRelease07042021.pdf,07-04-2021,4662.2998046875,4734.0,4641.0,4692.64990234375,4551.76806640625,1113612,0.0,0.0,15-04-2021,0
186,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"gunupati venkateswara prasad - huf has submitted to the exchange a copy of disclosure under regulation 10(6)ￂﾠ of sebi (substantial acquisition of shares and takeovers) regulations, 2011.ￂﾠￂﾠ",26-Mar-2021 20:05:33,2021-03-26 20:05:33,26-Mar-2021 20:05:40,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_26032021200533_GVF_10.pdf,26-03-2021,4420.0,4423.0,4347.7001953125,4406.0,4273.72314453125,725318,0.0,0.0,06-04-2021,0
187,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"promoter of  a copy of disclosure under regulation 10(5) of sebi (substantial acquisition of shares & takeover) regulations, 2011",19-Mar-2021 18:04:05,2021-03-19 18:04:05,19-Mar-2021 18:04:11,00:00:06,https://nsearchives.nseindia.com/corporate/DRREDDY_19032021180405_DRREDDY_REG10_19032021175828.zip,19-03-2021,4210.0,4305.35009765625,4135.0,4274.4501953125,4146.123046875,1412415,0.0,0.0,26-03-2021,0
188,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 22, 2021, titled ""dr. reddy's laboratories announces the launch of lansoprazole dr orally disintegrating tablets in the u.s. market."".",22-Feb-2021 10:38:51,2021-02-22 10:38:51,22-Feb-2021 10:38:56,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_22022021103851_PressRelease22022021.pdf,22-02-2021,4708.0,4726.9501953125,4443.14990234375,4469.25,4335.07470703125,1395313,0.0,0.0,01-03-2021,0
189,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 19, 2021, titled ""dr. reddy's initiates process for emergency use authorization of sputnik v"".",19-Feb-2021 14:49:21,2021-02-19 14:49:21,19-Feb-2021 14:49:25,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_19022021144921_PressRelease19022021.pdf,19-02-2021,4602.0,4728.0,4530.0,4681.4501953125,4540.904296875,1278534,0.0,0.0,26-02-2021,-1
190,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 18, 2021, titled ""dr. reddy's laboratories announces the launch of fluphenazine hydrochloride tablets, usp in the u.s. market"".",18-Feb-2021 10:35:48,2021-02-18 10:35:48,18-Feb-2021 10:35:55,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_18022021103548_PressRelease18022021.pdf,18-02-2021,4607.0,4663.85009765625,4560.0,4616.9501953125,4478.34033203125,1029506,0.0,0.0,25-02-2021,0
191,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 17, 2021, titled ""dr. reddy's laboratories announces the launch of capecitabine tablets, usp in the u.s. market."".",17-Feb-2021 10:38:18,2021-02-17 10:38:18,17-Feb-2021 10:38:23,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_17022021103818_PressRelease17022021.pdf,17-02-2021,4696.60009765625,4709.9501953125,4580.0,4600.5498046875,4462.43310546875,1021355,0.0,0.0,24-02-2021,0
192,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 02, 2021, titled ""dr. reddy's laboratories announces the launch of vigabatrin tablets, usp in the u.s. market"".",02-Feb-2021 12:42:00,2021-02-02 12:42:00,02-Feb-2021 12:42:13,00:00:13,https://nsearchives.nseindia.com/corporate/DRREDDY_02022021124200_PressRelease02022021.pdf,02-02-2021,4469.0,4528.0,4381.0,4482.5,4347.927734375,3675106,0.0,0.0,09-02-2021,1
193,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended december 31, 2020.",29-Jan-2021 11:29:11,2021-01-29 11:29:11,29-Jan-2021 11:31:02,00:01:51,https://nsearchives.nseindia.com/corporate/ResultDec2020_29012021112911.zip,29-01-2021,4890.0,4915.0,4550.0,4602.7001953125,4464.5185546875,2964195,0.0,0.0,05-02-2021,0
194,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 27, 2021, titled ""dr. reddy s and gra announces avigan pivotal studies update"".",27-Jan-2021 13:19:10,2021-01-27 13:19:10,27-Jan-2021 13:19:15,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_27012021131910_PressRelease27012021.pdf,27-01-2021,5052.39990234375,5052.39990234375,4832.7998046875,4909.2998046875,4761.9130859375,1052396,0.0,0.0,03-02-2021,-1
195,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 15, 2021, titled ""dr. reddy s receives approval to conduct phase 3 clinical trial for sputnik v vaccine in india."".",15-Jan-2021 22:08:20,2021-01-15 22:08:20,15-Jan-2021 22:08:23,00:00:03,https://nsearchives.nseindia.com/corporate/DRREDDY_15012021220820_PressRelease15012021.pdf,15-01-2021,5315.0,5315.0,5195.60009765625,5212.7998046875,5056.3017578125,515521,0.0,0.0,22-01-2021,0
196,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 11, 2021, titled ""sputnik v meets the primary endpoint of safety in the phase 2 clinical trial in india"".",11-Jan-2021 19:53:44,2021-01-11 19:53:44,11-Jan-2021 19:53:49,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_11012021195344_PressRelease11012021.pdf,11-01-2021,5344.0,5427.0,5326.0,5416.7998046875,5254.17724609375,919847,0.0,0.0,18-01-2021,-1
197,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 11, 2021, titled ""dr. reddy's laboratories to present at the 39th annual j.p. morgan healthcare conference. "".",11-Jan-2021 19:37:56,2021-01-11 19:37:56,11-Jan-2021 19:38:10,00:00:14,https://nsearchives.nseindia.com/corporate/DRREDDY_11012021193756_PressRelease11012021_2_.pdf,11-01-2021,5344.0,5427.0,5326.0,5416.7998046875,5254.17724609375,919847,0.0,0.0,18-01-2021,-1
198,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 11, 2021, titled ""dr. reddy's laboratories announces the launch of febuxostat tablets in the u.s. market."".",11-Jan-2021 14:11:03,2021-01-11 14:11:03,11-Jan-2021 14:11:07,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_11012021141103_PressRelease11012021.pdf,11-01-2021,5344.0,5427.0,5326.0,5416.7998046875,5254.17724609375,919847,0.0,0.0,18-01-2021,-1
199,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 08, 2021, titled ""dr. reddy's to release q3 fy 21 results on january 29th, 2021 earnings call slated for january 29th @ 5:30 pm ist / 7:00 am est"".",08-Jan-2021 16:22:04,2021-01-08 16:22:04,08-Jan-2021 16:22:12,00:00:08,https://nsearchives.nseindia.com/corporate/DRREDDY_08012021162204_PressRelease08012021.pdf,08-01-2021,5299.89990234375,5360.0,5279.0,5338.25,5177.98583984375,809183,0.0,0.0,15-01-2021,0
200,DRREDDY,Dr. Reddy's Laboratories Limited,trading window," regarding the trading window closure pursuant to sebi (prohibition of insider trading) regulations, 2015",28-Dec-2020 15:02:02,2020-12-28 15:02:02,28-Dec-2020 15:02:13,00:00:11,https://nsearchives.nseindia.com/corporate/DRREDDY_28122020150202_BMIntimation.pdf,28-12-2020,5228.14990234375,5235.0,5187.0,5201.7998046875,5045.63232421875,411173,0.0,0.0,04-01-2021,0
201,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 09, 2020, titled ""secondary listing of dr. reddy s adrs on nse ifsc limited (gift city, gujarat, india)"".",09-Dec-2020 13:27:04,2020-12-09 13:27:04,09-Dec-2020 13:27:13,00:00:09,https://nsearchives.nseindia.com/corporate/DRREDDY_09122020132704_PressRelease09122020.pdf,09-12-2020,5025.0,5100.0,5025.0,5056.89990234375,4905.08203125,1353498,0.0,0.0,16-12-2020,0
202,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 01, 2020, titled ""dr. reddy's and rdif commence clinical trials for sputnik v vaccine in india."".",01-Dec-2020 18:02:34,2020-12-01 18:02:34,01-Dec-2020 18:02:43,00:00:09,https://nsearchives.nseindia.com/corporate/DRREDDY_01122020180234_PressRelease01122020.pdf,01-12-2020,4870.0,4870.0,4806.0,4830.39990234375,4685.38232421875,1117190,0.0,0.0,08-12-2020,0
203,DRREDDY,Dr. Reddy's Laboratories Limited,related party transactions," about disclosure of related party transactions for the half year ended september 30, 2020.",19-Nov-2020 17:11:20,2020-11-19 17:11:20,19-Nov-2020 17:11:27,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_19112020171120_RPTSept2020.pdf,19-11-2020,4675.0,4811.7998046875,4657.0,4707.7001953125,4566.36572265625,1767289,0.0,0.0,26-11-2020,0
204,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 12, 2020, titled ""dr. reddy's laboratories announces the launch of succinylcholine chloride injection usp, 200 mg/10 ml (20 mg/ml) in the u.s. market"".",12-Nov-2020 20:22:39,2020-11-12 20:22:39,12-Nov-2020 20:22:42,00:00:03,https://nsearchives.nseindia.com/corporate/DRREDDY_12112020202239_PressRelease12112020.pdf,12-11-2020,4875.0,4925.0,4805.0,4826.85009765625,4681.9384765625,1316470,0.0,0.0,19-11-2020,0
205,DRREDDY,Dr. Reddy's Laboratories Limited,updates, regarding 'form 6k for q2 and h1 fy21 filed with us sec '.,29-Oct-2020 22:51:13,2020-10-29 22:51:13,29-Oct-2020 22:51:17,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_29102020225112_intimation29102020.pdf,29-10-2020,4920.0,5040.0,4894.9501953125,4941.9501953125,4793.58349609375,2310237,0.0,0.0,05-11-2020,0
206,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 29, 2020, titled ""dr. reddy's partners with department of biotechnology - biotechnology industry research assistance council for sputnik v vaccine clinical trials in india"".",29-Oct-2020 11:03:07,2020-10-29 11:03:07,29-Oct-2020 11:03:12,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_29102020110307_PressRelease29102020.pdf,29-10-2020,4920.0,5040.0,4894.9501953125,4941.9501953125,4793.58349609375,2310237,0.0,0.0,05-11-2020,0
207,DRREDDY,Dr. Reddy's Laboratories Limited,updates, regarding 'inprinciple board approval for secondary listing of adrs on nse ifsc subject to necessary approvals '.,28-Oct-2020 13:44:23,2020-10-28 13:44:23,28-Oct-2020 13:44:28,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_28102020134423_outcomeofBM.pdf,28-10-2020,5110.0,5150.0,4920.0,4951.0,4802.3623046875,3628282,0.0,0.0,04-11-2020,0
208,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 28, 2020, titled ""intimation regarding appointment of new chief financial officer"".",28-Oct-2020 13:36:00,2020-10-28 13:36:00,28-Oct-2020 13:36:13,00:00:13,https://nsearchives.nseindia.com/corporate/DRREDDY_28102020133600_CFOIntimation.pdf,28-10-2020,5110.0,5150.0,4920.0,4951.0,4802.3623046875,3628282,0.0,0.0,04-11-2020,0
209,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended september 30, 2020.",28-Oct-2020 13:25:44,2020-10-28 13:25:44,28-Oct-2020 13:27:01,00:01:17,https://nsearchives.nseindia.com/corporate/Q2FY21Financialresults_28102020132544.zip,28-10-2020,5110.0,5150.0,4920.0,4951.0,4802.3623046875,3628282,0.0,0.0,04-11-2020,0
210,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 20, 2020, titled ""dr. reddy s announces the re-launch of over-the-counter famotidine tablets usp, 10 mg and 20 mg, store-brand equivalent of pepcid acￂﾮ in the u.s. market"".",20-Oct-2020 12:32:25,2020-10-20 12:32:25,20-Oct-2020 12:32:30,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_20102020123225_PressRelease20102020.pdf,20-10-2020,5056.9501953125,5110.0,5030.9501953125,5071.14990234375,4918.90380859375,1380290,0.0,0.0,27-10-2020,0
211,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 12, 2020, titled ""dr. reddy's to release q2 fy 21 results on october 28th, 2020earnings call slated for october 28th @ 5:30 pm ist / 8:00 am edt"".",12-Oct-2020 16:34:06,2020-10-12 16:34:06,12-Oct-2020 16:34:11,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_12102020163406_PressRelease12102020.pdf,12-10-2020,5158.10009765625,5238.0,5111.0,5220.5,5063.771484375,1935797,0.0,0.0,19-10-2020,0
212,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 05, 2020, titled ""dr. reddy s laboratories joins science based targets initiative (sbti) and sets 2030 ghg emission targets"".",05-Oct-2020 13:56:09,2020-10-05 13:56:09,05-Oct-2020 13:56:13,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_05102020135609_PressRelease05102020.pdf,05-10-2020,5170.0,5190.0,5103.0,5159.5,5004.6025390625,1837678,0.0,0.0,12-10-2020,0
213,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 01, 2020, titled """"dr. reddy's laboratories announces the launch of cinacalcet tablets in the u.s. market"""".",01-Oct-2020 12:23:23,2020-10-01 12:23:23,01-Oct-2020 12:23:28,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_01102020122323_PressRelease01102020.pdf,01-10-2020,5225.0,5256.0,5088.39990234375,5112.0498046875,4958.57666015625,2277137,0.0,0.0,09-10-2020,0
214,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 25, 2020, titled ""dr. reddy's announces the launch of dexmedetomidine hydrochloride in 0.9% sodium chloride injection in the u.s. market"".",25-Sep-2020 11:48:44,2020-09-25 11:48:44,25-Sep-2020 11:48:49,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_25092020114844_PressRelease25092020.pdf,25-09-2020,5120.0,5153.0,5044.0,5112.2001953125,4958.72216796875,3514223,0.0,0.0,05-10-2020,0
215,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 17, 2020, titled ""dr. reddy's laboratories announces settlement ofu.s. revlimidￂﾮ (lenalidomide) capsules patent litigation with celgene, a bristol myerssquibb company"".",17-Sep-2020 16:29:42,2020-09-17 16:29:42,17-Sep-2020 16:29:45,00:00:03,https://nsearchives.nseindia.com/corporate/DRREDDY_17092020162942_PressRelease17092020celegene.pdf,17-09-2020,4704.0,4845.5498046875,4654.9501953125,4827.25,4682.32763671875,8429918,0.0,0.0,24-09-2020,0
216,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 17, 2020, titled ""dr. reddy s announces the launch of over-the-counter olopatadine hydrochloride ophthalmic solution usp, 0.2% and 0.1%, the storebrandequivalent of patadayￂﾮ, the eye allergy drop in the u.s. market. "".",17-Sep-2020 10:38:32,2020-09-17 10:38:32,17-Sep-2020 10:38:36,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_17092020103832_PressRelease17092020.pdf,17-09-2020,4704.0,4845.5498046875,4654.9501953125,4827.25,4682.32763671875,8429918,0.0,0.0,24-09-2020,0
217,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 16, 2020, titled ""rdif and dr. reddy s to cooperate on clinical trials and supply of 100 million doses of sputnik v vaccine to india"".",16-Sep-2020 14:56:32,2020-09-16 14:56:32,16-Sep-2020 14:56:37,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_16092020145632_PressRelease16092020.pdf,16-09-2020,4455.0,4650.7998046875,4411.0,4627.89990234375,4488.9619140625,2979789,0.0,0.0,23-09-2020,1
218,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 09, 2020, titled ""press releases on  dr. reddy's laboratories announces the launch of redyx in india.  and  dr. reddy's laboratories announces the launch of over-the-counter diclofenac sodium topical gel 1%, the store brand version of voltarenￂﾮ arthritis pain in the u.s. market. "".",09-Sep-2020 10:06:58,2020-09-09 10:06:58,09-Sep-2020 10:07:03,00:00:05,https://nsearchives.nseindia.com/corporate/DRREDDY_09092020100658_PressRelease09092020.pdf,09-09-2020,4349.89990234375,4444.0,4335.60009765625,4429.4501953125,4296.47021484375,1235087,0.0,0.0,16-09-2020,0
219,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 07, 2020, titled ""dr. reddy's laboratories announces the launch offulvestrant injection, 250 mg/5 ml (50 mg/ml) per single-dose syringe in the u.s. market"".",07-Sep-2020 17:21:23,2020-09-07 17:21:23,07-Sep-2020 17:21:27,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_07092020172123_PressRelease07092020.pdf,07-09-2020,4344.14990234375,4436.0,4295.25,4419.85009765625,4287.158203125,1230797,0.0,0.0,14-09-2020,0
220,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 03, 2020, titled """"dr. reddy's laboratories announces the launch of methylphenidate hydrochloride extended-release tablets usp, in the u.s. market"""".",03-Sep-2020 11:47:18,2020-09-03 11:47:18,03-Sep-2020 11:47:22,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_03092020114718_PressRelease03092020.pdf,03-09-2020,4374.5498046875,4466.0,4340.14990234375,4433.14990234375,4300.0576171875,938394,0.0,0.0,10-09-2020,0
221,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 27, 2020, titled ""dr. reddy's laboratories announces the launch of penicillamine capsules usp, 250 mg in the u.s. market"".",27-Aug-2020 12:33:59,2020-08-27 12:33:59,27-Aug-2020 12:34:03,00:00:04,https://nsearchives.nseindia.com/corporate/DRREDDY_27082020123359_PressRelease27082020.pdf,27-08-2020,4442.39990234375,4468.2998046875,4417.0,4437.0,4303.79345703125,903663,0.0,0.0,03-09-2020,0
222,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 19, 2020, titled ""dr. reddy's laboratories announces the launch of aviganￂﾮ (favipiravir) in india. "".",19-Aug-2020 11:47:52,2020-08-19 11:47:52,19-Aug-2020 11:47:59,00:00:07,https://nsearchives.nseindia.com/corporate/DRREDDY_19082020114752_PressRelease19082020.pdf,19-08-2020,4540.0,4558.9501953125,4476.10009765625,4489.25,4354.47412109375,807214,0.0,0.0,26-08-2020,0
223,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," regarding allotment of 22479 securities pursuant to esop/esps at its meeting held on august 17, 2020",17-Aug-2020 18:56:04,2020-08-17 18:56:04,17-Aug-2020 18:56:12,00:00:08,https://nsearchives.nseindia.com/corporate/DRREDDY_17082020185604_ESOPIntimation17082020.pdf,17-08-2020,4519.4501953125,4570.0,4500.2001953125,4519.14990234375,4383.47607421875,677666,0.0,0.0,24-08-2020,0
224,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 11, 2020, titled ""dr. reddy's laboratories announces the first-to-market launch of the generic version of ciprodexￂﾮ (ciprofloxacin 0.3% and dexamethasone 0.1%) otic suspension, usp in the u.s. market."".",11-Aug-2020 08:58:59,2020-08-11 08:58:59,11-Aug-2020 08:59:02,00:00:03,https://nsearchives.nseindia.com/corporate/DRREDDY_11082020085859_PressRelease11082020.pdf,11-08-2020,4715.0498046875,4738.5498046875,4565.0,4595.89990234375,4457.9228515625,1291521,0.0,0.0,18-08-2020,0
225,DRREDDY,Dr. Reddy's Laboratories Limited,shareholders meeting," regarding proceedings of annual general meeting held on july 30, 2020. further, the company has submitted the exchange a copy of srutinizers report along with voting results.",30-Jul-2020 17:24:00,2020-07-30 17:24:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_30072020172412_OutcomeOfAGM30072020.pdf,30-07-2020,4393.89990234375,4560.0,4340.0,4516.60009765625,4381.0029296875,6294410,0.0,0.0,06-08-2020,0
226,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'intimation regarding filing of form 6-k for the quarter ended june 30, 2020'.",30-Jul-2020 08:11:00,2020-07-30 08:11:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_30072020081116_Intimation30072020.pdf,30-07-2020,4393.89990234375,4560.0,4340.0,4516.60009765625,4381.0029296875,6294410,0.0,0.0,06-08-2020,0
227,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended june 30, 2020.",29-Jul-2020 13:21:16,2020-07-29 13:21:16,-,-,https://nsearchives.nseindia.com/corporate/Q1FY21SEBI_29072020132116.zip,29-07-2020,4082.449951171875,4336.0,4075.39990234375,4302.2001953125,4173.04052734375,4953233,0.0,0.0,05-08-2020,1
228,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 27, 2020, titled ""dr. reddy's laboratories received approval of xeglyze (abametapir) lotion, 0.74%, in the u.s."".",27-Jul-2020 10:35:00,2020-07-27 10:35:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_27072020103551_PressRelease27072020.pdf,27-07-2020,4085.0,4085.64990234375,3962.949951171875,4015.699951171875,3895.14111328125,581848,0.0,0.0,03-08-2020,1
229,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 20, 2020, titled ""dr. reddy's to release q1 fy 21 results on july 29th,2020 earnings call slated for july 29th @ 5:30 pm ist / 8:00 am edt"".",20-Jul-2020 16:09:00,2020-07-20 16:09:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_20072020160944_PressRelease20072020.pdf,20-07-2020,4139.35009765625,4154.0,4072.39990234375,4092.10009765625,3969.24755859375,628872,0.0,0.0,27-07-2020,0
230,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 14, 2020, titled ""dr. reddy's laboratories announces the launch of over-the-counter nicotine polacrilex lozenges, 2 mg and 4 mg, the store brand version of nicoretteￂﾮ lozenges in the u.s. market "".",14-Jul-2020 13:16:00,2020-07-14 13:16:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_14072020131648_PressRelease14072020.pdf,14-07-2020,3904.0,3996.050048828125,3874.0,3983.14990234375,3863.568359375,1208945,0.0,0.0,21-07-2020,0
231,DRREDDY,Dr. Reddy's Laboratories Limited,shareholders meeting," regarding notice of annual general meeting to be held on july 30, 2020",06-Jul-2020 11:06:00,2020-07-06 11:06:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_06072020110615_SEIntimationNoticeOfAGMAnnualReportFY2020.pdf,06-07-2020,3925.0,3940.0,3877.0,3892.0,3750.989013671875,569617,0.0,0.0,13-07-2020,0
232,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 01, 2020, titled ""dr. reddy s partners with fujifilm and global response aid for aviganￂﾮ (favipiravir), a potential treatment of covid-19"".",01-Jul-2020 12:25:00,2020-07-01 12:25:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_01072020122520_PressRelease01072020.pdf,01-07-2020,3965.199951171875,3966.0,3885.85009765625,3911.449951171875,3769.73388671875,623565,0.0,0.0,08-07-2020,0
233,DRREDDY,Dr. Reddy's Laboratories Limited,press release (revised)," regarding a revised press release dated jun 23, 2020, titled ""dr. reddy's laboratories to present at the barclaysspec pharma fireside chat series (revised pr with conference id)"".",23-Jun-2020 21:59:00,2020-06-23 21:59:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_23062020215915_PressRelease23062020revised.pdf,23-06-2020,4047.89990234375,4130.0,4040.10009765625,4108.85009765625,3959.982177734375,959883,0.0,0.0,30-06-2020,0
234,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 23, 2020, titled ""dr. reddy's laboratories to present at the barclays spec pharma fireside chat series"".",23-Jun-2020 15:21:00,2020-06-23 15:21:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_23062020152127_PressRelease23062020.pdf,23-06-2020,4047.89990234375,4130.0,4040.10009765625,4108.85009765625,3959.982177734375,959883,0.0,0.0,30-06-2020,0
235,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 19, 2020, titled ""dr. reddy's laboratories announces the launch of abiraterone acetate tablets usp, 250 mg in the u.s. market"".",19-Jun-2020 14:22:00,2020-06-19 14:22:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_19062020142241_PressRelease19062020.pdf,19-06-2020,4020.25,4044.89990234375,3992.0,4005.60009765625,3860.472900390625,730943,0.0,0.0,26-06-2020,0
236,DRREDDY,Dr. Reddy's Laboratories Limited,book closure, that register of members & share transfer books of the company will remain closed from 15-jul-2020 to 17-jul-2020 for the purpose of dividend.,17-Jun-2020 20:11:00,2020-06-17 20:11:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_17062020201129_BookclosureandAGMnotice.pdf,17-06-2020,4005.449951171875,4042.75,3972.0,3985.199951171875,3840.81201171875,637363,0.0,0.0,24-06-2020,0
237,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 16, 2020, titled ""dr. reddy's laboratories limited announces filing of annual report on form 20-f"".",16-Jun-2020 10:16:00,2020-06-16 10:16:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_16062020101616_PressRelease16062020.pdf,16-06-2020,4065.0,4080.0,3952.75,4005.449951171875,3860.328369140625,780026,0.0,0.0,23-06-2020,0
238,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 12, 2020, titled ""dr. reddy's laboratories announces the launch of colchicinetablets usp, 0.6 mg in the u.s. market"".",12-Jun-2020 16:00:00,2020-06-12 16:00:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_12062020160051_PressRelease12062020.pdf,12-06-2020,3992.0,4036.60009765625,3981.0,4007.949951171875,3862.738037109375,782304,0.0,0.0,19-06-2020,0
239,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 10, 2020, titled ""press release"".",10-Jun-2020 13:55:00,2020-06-10 13:55:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_10062020135545_PR10062020.pdf,10-06-2020,4145.0,4190.0,4087.699951171875,4112.5,3963.500244140625,1553968,0.0,0.0,17-06-2020,0
240,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended march 31, 2020.",20-May-2020 13:25:28,2020-05-20 13:25:28,-,-,https://nsearchives.nseindia.com/corporate/SEINTIMATIONFinalQ4FY20_20052020132528.zip,20-05-2020,3720.89990234375,3930.0,3693.14990234375,3910.199951171875,3768.529296875,4216709,0.0,0.0,28-05-2020,0
241,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 06, 2020, titled ""dr. reddy's laboratories received approval for their nda, elyxyb  (celecoxib oral solution) 25 mg/ml, in the u.s"".",06-May-2020 17:08:00,2020-05-06 17:08:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_06052020170843_PressRelease06052020II.pdf,06-05-2020,3851.0,3880.0,3805.050048828125,3852.5,3712.92041015625,955903,0.0,0.0,13-05-2020,0
242,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 06, 2020, titled ""dr. reddy's laboratories announces the launch of desmopressin acetate injection usp, 4 mcg/ml in the u.s. market"".",06-May-2020 12:24:00,2020-05-06 12:24:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_06052020122455_PressRelease06052020.pdf,06-05-2020,3851.0,3880.0,3805.050048828125,3852.5,3712.92041015625,955903,0.0,0.0,13-05-2020,0
243,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 27, 2020, titled ""dr. reddy's laboratories announces the launch of fenofibrate tablets usp, in the u.s. market"".",27-Apr-2020 11:42:00,2020-04-27 11:42:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_27042020114218_PressRelease27042020.pdf,27-04-2020,4002.800048828125,4065.10009765625,3955.050048828125,3980.300048828125,3836.08984375,1124897,0.0,0.0,05-05-2020,0
244,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"promoters of  regarding disclosures under regulations 30(3) and 31(5) of the securities and exchange board of india (substantial acquisition of shares and takeover) regulations, 2011",13-Apr-2020 12:36:00,2020-04-13 12:36:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_13042020123604_DRREDDY.pdf,13-04-2020,3694.0,3856.0,3607.199951171875,3746.60009765625,3610.857177734375,2322389,0.0,0.0,21-04-2020,1
245,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 20, 2020, titled ""dr. reddy's laboratories announces the launch ofpyrimethamine tablets usp, 25 mg, first-wave generic version of daraprimￂﾮ in the u.s. market"".",20-Mar-2020 09:07:00,2020-03-20 09:07:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_20032020090702_PressRelease20032020.pdf,20-03-2020,2641.0,2949.0,2641.0,2897.25,2792.27978515625,1554571,0.0,0.0,27-03-2020,0
246,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 19, 2020, titled ""dr. reddy's laboratories announces first-to-market launch of naloxone hydrochloride injection usp, 2 mg/2 ml (1 mg/ml) single-dose prefilled syringe in the u.s. market"".",19-Mar-2020 11:13:00,2020-03-19 11:13:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_19032020111338_PressRelease19032020.pdf,19-03-2020,2608.0,2679.89990234375,2495.050048828125,2623.949951171875,2528.881591796875,967602,0.0,0.0,26-03-2020,1
247,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 17, 2020, titled ""dr. reddy's laboratories announces the launch of ziprasidone mesylate for injection in the u.s. market"".",17-Mar-2020 14:30:00,2020-03-17 14:30:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_17032020143011_PressRelease17032020.pdf,17-03-2020,2830.0,2904.0,2757.75,2781.199951171875,2680.434326171875,936803,0.0,0.0,24-03-2020,0
248,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 27, 2020, titled ""dr. reddy's laboratories announces the first generic launch of naproxen and esomeprazole magnesium delayed-release tablets in the u.s. market"".",27-Feb-2020 12:52:00,2020-02-27 12:52:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_27022020125243_PressRelease27022020.pdf,27-02-2020,3094.0,3094.0,3029.10009765625,3067.050048828125,2955.927734375,935416,0.0,0.0,05-03-2020,0
249,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 12, 2020, titled ""dr. reddy s laboratories to acquire select business divisions of wockhardt in india"".",12-Feb-2020 12:28:00,2020-02-12 12:28:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_12022020122829_PressRelease12022020.pdf,12-02-2020,3172.14990234375,3213.60009765625,3164.050048828125,3195.699951171875,3079.91650390625,568633,0.0,0.0,19-02-2020,0
250,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 07, 2020, titled ""press release issued by our wholly owned subsidiary  aurigene discovery technologies limited  regarding amendment of collaboration with  curis, inc. (nasdaq: cris)  for development and commercialization of ca-170"".",07-Feb-2020 16:17:00,2020-02-07 16:17:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_07022020161726_PressRelease07022020Auri.pdf,07-02-2020,3159.85009765625,3185.0,3137.0,3166.699951171875,3051.966796875,535233,0.0,0.0,14-02-2020,0
251,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 07, 2020, titled ""dr. reddy's laboratories announces the launch oftrientine hydrochloride capsules usp, 250 mg, in the u.s. market"".",07-Feb-2020 11:42:00,2020-02-07 11:42:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_07022020114251_PressRelease07022020.pdf,07-02-2020,3159.85009765625,3185.0,3137.0,3166.699951171875,3051.966796875,535233,0.0,0.0,14-02-2020,0
252,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'unaudited financial results for the quarter and nine months ended december 31, 2019 - advertisement '.",28-Jan-2020 20:52:00,2020-01-28 20:52:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_28012020204959_Stxintimationnewspaperfinancials_344.pdf,28-01-2020,3190.0,3249.949951171875,3157.75,3189.14990234375,3073.60400390625,2302269,0.0,0.0,04-02-2020,0
253,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended december 31, 2019.",27-Jan-2020 11:52:51,2020-01-27 11:52:51,-,-,https://nsearchives.nseindia.com/corporate/ResultDec2019_27012020115251.zip,27-01-2020,3029.0,3209.0,2997.5,3188.75,3073.21826171875,4139808,0.0,0.0,03-02-2020,0
254,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 13, 2020, titled ""dr. reddy's laboratories limited to present at the 38th annual j.p. morgan healthcare conference"".",13-Jan-2020 14:55:00,2020-01-13 14:55:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_13012020145458_PressRelease13012020_004.pdf,13-01-2020,2932.89990234375,2966.5,2915.699951171875,2954.699951171875,2847.6484375,441864,0.0,0.0,20-01-2020,0
255,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 10, 2020, titled ""dr. reddy's to release q3 fy 20 results on january 27, 2020  earnings call slated for january 27, 2020 @ 6:30 pm ist / 8:00 am est"".",10-Jan-2020 16:39:00,2020-01-10 16:39:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_10012020163917_PressRelease10012020_014.pdf,10-01-2020,2930.0,3008.0,2925.14990234375,2933.0,2826.734375,1127147,0.0,0.0,17-01-2020,0
256,DRREDDY,Dr. Reddy's Laboratories Limited,shareholders meeting," regarding proceedings of court convened general meeting held on january 02, 2020. further, the company has submitted the exchange a copy of srutinizers report along with voting results.",03-Jan-2020 12:15:00,2020-01-03 12:15:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_03012020121444_OutcomeofNCLTmeeting_005.pdf,03-01-2020,2864.89990234375,2897.0,2852.050048828125,2883.89990234375,2779.4130859375,344678,0.0,0.0,10-01-2020,0
257,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 30, 2019, titled ""dr. reddy's laboratories announces the launch of sodium nitroprusside injection, 50 mg/2 ml (25 mg/ml) single-dose vial in the u.s. market"".",30-Dec-2019 14:15:00,2019-12-30 14:15:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_30122019141538_PressRelease30122019_008.pdf,30-12-2019,2882.300048828125,2928.0,2875.0,2888.85009765625,2784.18408203125,379879,0.0,0.0,06-01-2020,0
258,DRREDDY,Dr. Reddy's Laboratories Limited,trading window," regarding the trading window closure pursuant to sebi (prohibition of insider trading) regulations, 2015",26-Dec-2019 17:16:00,2019-12-26 17:16:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_26122019171631_BMNotice_011.pdf,26-12-2019,2896.550048828125,2914.75,2860.0,2865.60009765625,2761.77685546875,256960,0.0,0.0,02-01-2020,0
259,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 06, 2019, titled ""dr. reddy's laboratories announces the launch of deferasirox film-coated tablets, in the u.s. market"".",06-Dec-2019 12:58:00,2019-12-06 12:58:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_06122019125541_PressRelease06122019filmcoatedtabs_004.pdf,06-12-2019,2887.699951171875,2949.0,2871.64990234375,2890.800048828125,2786.0634765625,988519,0.0,0.0,13-12-2019,0
260,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 06, 2019, titled ""dr. reddy's laboratories announces the launch of deferasirox tablets for oral suspension, in the u.s. market"".",06-Dec-2019 12:58:00,2019-12-06 12:58:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_06122019125810_PressRelease06122019oraltabs_005.pdf,06-12-2019,2887.699951171875,2949.0,2871.64990234375,2890.800048828125,2786.0634765625,988519,0.0,0.0,13-12-2019,0
261,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 04, 2019, titled ""dr. reddy's laboratories announces the launch of bortezomib for injection 3.5 mg/vial for intravenous use only in the u.s. market"".",04-Dec-2019 11:49:00,2019-12-04 11:49:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_04122019113840_PressRelease04122019_003.pdf,04-12-2019,2860.0,2885.89990234375,2858.199951171875,2877.85009765625,2773.58251953125,476162,0.0,0.0,11-12-2019,0
262,DRREDDY,Dr. Reddy's Laboratories Limited,amalgamation/merger, about newspaper publication and notice for nclt convened unsecured creditors meeting,02-Dec-2019 16:59:00,2019-12-02 16:59:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_02122019165931_NewspaperadtoexchangesUnsecuredCreditors_015.pdf,02-12-2019,2918.0,2918.0,2852.0,2871.699951171875,2767.6552734375,598055,0.0,0.0,09-12-2019,0
263,DRREDDY,Dr. Reddy's Laboratories Limited,amalgamation/merger, about newspaper publication and notice for nclt convened equity shareholder meeting,02-Dec-2019 16:54:00,2019-12-02 16:54:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_02122019165358_NewspaperadtoexchangesEquityShareholders_014.pdf,02-12-2019,2918.0,2918.0,2852.0,2871.699951171875,2767.6552734375,598055,0.0,0.0,09-12-2019,0
264,DRREDDY,Dr. Reddy's Laboratories Limited,shareholders meeting," regarding notice of court covened general meeting to be held on january 02, 2020",02-Dec-2019 10:08:00,2019-12-02 10:08:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract1_02122019095024_DrReddy_105.pdf,02-12-2019,2918.0,2918.0,2852.0,2871.699951171875,2767.6552734375,598055,0.0,0.0,09-12-2019,0
265,DRREDDY,Dr. Reddy's Laboratories Limited,related party transactions," a copy of  disclosure of related party transactions for the period ended september 30, 2019.",28-Nov-2019 08:24:00,2019-11-28 08:24:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract1_2811201975839_Sept2019_005.pdf,28-11-2019,2968.10009765625,2982.60009765625,2943.050048828125,2976.75,2868.8994140625,256436,0.0,0.0,05-12-2019,0
266,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 22, 2019, titled ""dr. reddy's laboratories announces launch of doxercalciferol injection in the u.s. market"".",22-Nov-2019 14:39:00,2019-11-22 14:39:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_22112019143937_PressRelease22112019_004.pdf,22-11-2019,2855.0,2904.75,2843.0,2871.25,2767.221923828125,549551,0.0,0.0,29-11-2019,0
267,DRREDDY,Dr. Reddy's Laboratories Limited,news verification,"the exchange has sought clarification from dr. reddy's laboratories limited with respect to recent news item captioned wockhardt: cipla, dr reddy's labs, carlyle & asian investment fund pag are in the fray to acquire select business segments of the company, said sources..  the response from the company is attached.",19-Nov-2019 12:44:00,2019-11-19 12:44:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_18112019145541_Replytoclarification18112019_081.pdf,19-11-2019,2741.0,2760.449951171875,2724.5,2743.0,2643.61865234375,476925,0.0,0.0,26-11-2019,1
268,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 14, 2019, titled ""dr. reddy s laboratories enters nutrition segment with celevida in india."".",14-Nov-2019 15:10:00,2019-11-14 15:10:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_14112019151013_PressRelease14112019_012.pdf,14-11-2019,2775.0,2777.35009765625,2724.949951171875,2734.050048828125,2634.99267578125,648568,0.0,0.0,21-11-2019,1
269,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'newspaper publication of unaudited financial results for the quarter and half-year ended september 30, 2019'.",04-Nov-2019 16:06:00,2019-11-04 16:06:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_04112019160629_NewspaperAdfinancials04112019_045.pdf,04-11-2019,2765.25,2810.0,2748.550048828125,2797.800048828125,2696.432861328125,808849,0.0,0.0,11-11-2019,0
270,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'intimation regarding filing of form 6k for quarter and half-year ended september 30, 2019'.",01-Nov-2019 22:29:00,2019-11-01 22:29:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_01112019222900_PressRelase01112019_022.pdf,01-11-2019,2784.0,2829.14990234375,2735.85009765625,2756.60009765625,2656.725341796875,3000855,0.0,0.0,08-11-2019,0
271,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended september 30, 2019.",01-Nov-2019 11:25:00,2019-11-01 11:25:00,-,-,https://nsearchives.nseindia.com/corporate/Q2FY20financials_01112019112500.zip,01-11-2019,2784.0,2829.14990234375,2735.85009765625,2756.60009765625,2656.725341796875,3000855,0.0,0.0,08-11-2019,0
272,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 23, 2019, titled ""dr. reddy s confirms its voluntary nationwide recall of allranitidine products in the u.s. market"".",23-Oct-2019 12:51:00,2019-10-23 12:51:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_23102019125139_PressRelease23102019_044.pdf,23-10-2019,2806.800048828125,2841.949951171875,2755.050048828125,2826.699951171875,2724.2861328125,979592,0.0,0.0,30-10-2019,0
273,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 14, 2019, titled ""dr. reddy's to release q2 fy 20 results on november 1, 2019 earnings call slated for november 1, 2019 @ 6:30 pm ist / 9:00 am edt"".",14-Oct-2019 14:59:00,2019-10-14 14:59:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_14102019145439_PressRelease14102019_066.pdf,14-10-2019,2652.0,2682.60009765625,2621.0,2651.89990234375,2555.81884765625,301437,0.0,0.0,22-10-2019,1
274,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding ''further to intimation dated july 12, 2019 with regard to the audit of our api manufacturing plant 2 at bollaram, hyderabad, the company would like to inform that the company have received the establishment inspection report (eir) from us fda, for the above-referred facility, indicating closure of the audit and the inspection classification of this facility is determined as voluntary action initiated (vai)'",09-Oct-2019 12:06:00,2019-10-09 12:06:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract1_09102019115002_DRREDDY_068.pdf,09-10-2019,2624.75,2676.0,2600.300048828125,2663.39990234375,2566.902587890625,466444,0.0,0.0,16-10-2019,0
275,DRREDDY,Dr. Reddy's Laboratories Limited,trading window," regarding the trading window closure pursuant to sebi (prohibition of insider trading) regulations, 2015",24-Sep-2019 15:35:00,2019-09-24 15:35:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_24092019153517_BMIntimation_097.pdf,24-09-2019,2766.699951171875,2845.0,2715.0,2785.25,2684.337646484375,679650,0.0,0.0,01-10-2019,0
276,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 16, 2019, titled ""dr. reddyￂﾒs announces the launch of over-the-counter, store-brand equivalent of prevacidￂﾮ 24hr capsules (lansoprazole delayed-release capsules usp, 15 mg) in the u.s. market"".",16-Sep-2019 11:48:00,2019-09-16 11:48:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_16092019114803_PressRelease16092019_076.pdf,16-09-2019,2731.0,2762.60009765625,2703.10009765625,2725.300048828125,2626.559814453125,818425,0.0,0.0,23-09-2019,0
277,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 11, 2019, titled ""dr. reddy's laboratories announces the launch of fosaprepitant for injection in the u.s. market"".",11-Sep-2019 14:23:00,2019-09-11 14:23:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_11092019142058_PressRelease11092019_141.pdf,11-09-2019,2752.0,2778.39990234375,2741.0,2761.0,2660.966064453125,634349,0.0,0.0,18-09-2019,0
278,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 06, 2019, titled ""dr. reddy's laboratories limited to present at the morgan stanley annual global healthcare conference"".",06-Sep-2019 17:29:00,2019-09-06 17:29:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_06092019172930_PressRelease06092019_321.pdf,06-09-2019,2684.10009765625,2746.949951171875,2675.050048828125,2739.949951171875,2640.6787109375,791834,0.0,0.0,16-09-2019,0
279,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 05, 2019, titled ""dr. reddy's laboratories announces the launch of bupropion hydrochloride extended-release tablets, usp (sr) in the u.s. market"".",05-Sep-2019 12:37:00,2019-09-05 12:37:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_05092019123624_PressRelease05092019_168.pdf,05-09-2019,2636.75,2694.800048828125,2636.75,2682.449951171875,2585.261962890625,897710,0.0,0.0,13-09-2019,0
280,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 20, 2019, titled ""dr. reddy's laboratories announces the launch ofvigabatrin powder for oral solution, usp in the u.s. market"".",20-Aug-2019 10:55:00,2019-08-20 10:55:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_20082019105502_PressRelease20082019_023.pdf,20-08-2019,2524.75,2564.449951171875,2515.5,2554.60009765625,2462.04443359375,609510,0.0,0.0,27-08-2019,0
281,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 19, 2019, titled ""dr. reddy's laboratories announcesthe launch of versavoￂﾮ (bevacizumab biosimilar) in india"".",19-Aug-2019 12:41:00,2019-08-19 12:41:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_19082019123719_PressRelease19082019_134.pdf,19-08-2019,2540.0,2568.949951171875,2495.0,2509.10009765625,2418.193115234375,711303,0.0,0.0,26-08-2019,0
282,DRREDDY,Dr. Reddy's Laboratories Limited,news verification,the exchange has sought clarification from dr. reddy's laboratories limited with respect to recent news item captioned setback for dr. reddys as u.s. fda hands out complete response letter for nuvaring.  the response from the company is attached.,14-Aug-2019 15:36:00,2019-08-14 15:36:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_14082019140159_Response14082019_324.pdf,14-08-2019,2525.050048828125,2537.800048828125,2351.199951171875,2511.949951171875,2420.939453125,1609457,0.0,0.0,22-08-2019,0
283,DRREDDY,Dr. Reddy's Laboratories Limited,shareholders meeting," regarding proceedings of annual general meeting held on july 30, 2019. further, the company has submitted the exchange a copy of srutinizers report along with voting results.",30-Jul-2019 19:21:00,2019-07-30 19:21:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_30072019192131_AGMOutcome_426.pdf,30-07-2019,2648.0,2693.5,2549.10009765625,2560.0,2467.248779296875,2197242,0.0,0.0,06-08-2019,0
284,DRREDDY,Dr. Reddy's Laboratories Limited,updates, regarding 'intimation regarding filing of form 6k for q1fy20 with sec'.,30-Jul-2019 14:22:00,2019-07-30 14:22:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_30072019142055_PressRelease30072096kfiling_140.pdf,30-07-2019,2648.0,2693.5,2549.10009765625,2560.0,2467.248779296875,2197242,0.0,0.0,06-08-2019,0
285,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 30, 2019, titled ""dr. reddy's laboratories announces the launch of pregabalin capsules in the u.s. market"".",30-Jul-2019 14:12:00,2019-07-30 14:12:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_30072019140407_PressRelease30072019_133.pdf,30-07-2019,2648.0,2693.5,2549.10009765625,2560.0,2467.248779296875,2197242,0.0,0.0,06-08-2019,0
286,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 29, 2019, titled ""intimation regarding change of ceo"".",29-Jul-2019 16:06:00,2019-07-29 16:06:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_29072019160627_CEOintimation_264.pdf,29-07-2019,2709.89990234375,2726.800048828125,2621.300048828125,2653.949951171875,2557.794677734375,919633,0.0,0.0,05-08-2019,-1
287,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended june 30, 2019.",29-Jul-2019 15:54:44,2019-07-29 15:54:44,-,-,https://nsearchives.nseindia.com/corporate/Financials_29072019155444.zip,29-07-2019,2709.89990234375,2726.800048828125,2621.300048828125,2653.949951171875,2557.794677734375,919633,0.0,0.0,05-08-2019,-1
288,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 23, 2019, titled ""dr. reddy's laboratories announces the launch of ramelteon tablets, in the u.s. market"".",23-Jul-2019 15:05:00,2019-07-23 15:05:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_23072019150503_PressRelease23072019_160.pdf,23-07-2019,2640.0,2644.64990234375,2580.449951171875,2599.35009765625,2505.173095703125,480116,0.0,0.0,30-07-2019,0
289,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 19, 2019, titled ""dr. reddyￂﾒs announces the launch of over-the-counter,store-brand equivalent of allegra-dￂﾮ 12 hr allergy and congestion extended-release tablets (fexofenadine hcl 60 mg and pseudoephedrine hcl 120 mg) in the u.s. market"".",19-Jul-2019 11:06:00,2019-07-19 11:06:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_19072019110022_PressRelease19072019_028.pdf,19-07-2019,2659.949951171875,2680.0,2604.050048828125,2613.14990234375,2518.47314453125,468248,0.0,0.0,26-07-2019,0
290,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 10, 2019, titled ""dr. reddy's to release q1 fy 20 results on july 29, 2019 earnings call slated for july 29, 6:30 pm ist / 9:00 am edt"".",10-Jul-2019 12:23:00,2019-07-10 12:23:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_10072019122237_PressReleases10072019_056.pdf,10-07-2019,2594.0,2602.89990234375,2572.39990234375,2584.64990234375,2472.05224609375,311159,0.0,0.0,17-07-2019,0
291,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 09, 2019, titled ""dr. reddyￂﾒs announces the launch of the over-the-counter store brand equivalent of mucinexￂﾮ d extended release tablets in two strengths in the u.s. marketￂﾔ"".",09-Jul-2019 11:32:00,2019-07-09 11:32:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_09072019113203_PressRelease09072019_043.pdf,09-07-2019,2592.0,2625.0,2571.300048828125,2598.85009765625,2485.6337890625,408296,0.0,0.0,16-07-2019,0
292,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 03, 2019, titled ""dr. reddy's laboratories announces first-to-market launch of carboprost tromethamine injection usp, 250 mcg/ml (1ml) single-dose vial in the u.s. market"".",03-Jul-2019 12:22:00,2019-07-03 12:22:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_03072019122138_PressReleases03072019_065.pdf,03-07-2019,2636.949951171875,2636.949951171875,2580.0,2596.699951171875,2483.57763671875,626598,0.0,0.0,10-07-2019,0
293,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 25, 2019, titled ""dr. reddy's laboratories announces the launch of tobramycin inhalation solution, usp in the u.s. market"".",25-Jun-2019 14:17:00,2019-06-25 14:17:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_25062019141507_PressRelease25062019_137.pdf,25-06-2019,2502.10009765625,2552.449951171875,2488.050048828125,2536.050048828125,2425.56982421875,437218,0.0,0.0,02-07-2019,0
294,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 14, 2019, titled ""dr. reddyￂﾒs laboratories announces entering into a definitive agreement to sell its neurology branded products to upsher-smith laboratories, llcￂﾔ"".",14-Jun-2019 09:13:00,2019-06-14 09:13:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_14062019091318_PressRelease14062019_022.pdf,14-06-2019,2582.0,2582.0,2529.0,2565.14990234375,2453.40185546875,689207,0.0,0.0,21-06-2019,0
295,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 14, 2019, titled ""dr. reddyￂﾒs laboratories announces entering into a definitive agreement to sell its neurology branded products to upsher-smith laboratories, llcￂﾔ"".",14-Jun-2019 09:13:00,2019-06-14 09:13:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_14062019091318_PressRelease14062019_022.pdf,14-06-2019,2582.0,2582.0,2529.0,2565.14990234375,2453.40185546875,689207,0.0,0.0,21-06-2019,0
296,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 12, 2019, titled ""dr. reddy's laboratories limited to present at theￂﾠgoldman sachs 40th annual global healthcare conference"".",12-Jun-2019 12:14:00,2019-06-12 12:14:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_12062019121151_PressRelease12062019_067.pdf,12-06-2019,2612.0,2628.800048828125,2572.5,2589.699951171875,2476.882568359375,528873,0.0,0.0,19-06-2019,0
297,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 10, 2019, titled ""dr. reddy's laboratories limited through its wholly owned subsidiary, dr. reddyￂﾒs laboratories sa, announces positive topline results from phase 2b study of ppc-06 in patients with moderate to severe plaque psoriasis"".",10-Jun-2019 11:22:00,2019-06-10 11:22:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_10062019112138_PressRelease10062019_057.pdf,10-06-2019,2608.10009765625,2637.800048828125,2569.64990234375,2629.25,2514.70947265625,622985,0.0,0.0,17-06-2019,0
298,DRREDDY,Dr. Reddy's Laboratories Limited,agm/book closure," that the register of members and share transfer books of the company shall remain closed from july 17, 2019 to july 19, 2019 ( both days inclusive) for the purpose of annual general meeting to be held on july 30, 2019 and declaration of final dividend.",07-Jun-2019 12:48:00,2019-06-07 12:48:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract1_762019123448_Bookclosurenotice_070.pdf,07-06-2019,2650.0,2656.14990234375,2555.25,2580.699951171875,2468.274658203125,782434,0.0,0.0,14-06-2019,0
299,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 03, 2019, titled ""dr. reddy's laboratories announces filing of annual report on form 20-f"".",03-Jun-2019 21:55:00,2019-06-03 21:55:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_03062019215405_PressRelease0306201920F_532.pdf,03-06-2019,2679.800048828125,2739.0,2652.39990234375,2724.10009765625,2605.427734375,558848,0.0,0.0,11-06-2019,0
300,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 03, 2019, titled ""dr. reddy's laboratories announces the re-launch of zenataneￂﾮ (isotretinoin capsules, usp), 10 mg, 20 mg, 30 mg and 40 mg in the u.s. market"".",03-Jun-2019 19:27:00,2019-06-03 19:27:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_03062019192559_PressRelease03062019Iso_498.pdf,03-06-2019,2679.800048828125,2739.0,2652.39990234375,2724.10009765625,2605.427734375,558848,0.0,0.0,11-06-2019,0
301,DRREDDY,Dr. Reddy's Laboratories Limited,dividend," that board of directors at its meeting held on may 17, 2019, recommended final dividend of 20 per equity share.",17-May-2019 15:08:00,2019-05-17 15:08:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_17052019150732_Q4andFY19financialresults_183.pdf,17-05-2019,2791.0,2810.0,2667.449951171875,2745.0,2625.417236328125,1160721,0.0,0.0,24-05-2019,0
302,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended march 31, 2019.",17-May-2019 15:00:38,2019-05-17 15:00:38,-,-,https://nsearchives.nseindia.com/corporate/Q4andFY19financialresults_17052019150038.zip,17-05-2019,2791.0,2810.0,2667.449951171875,2745.0,2625.417236328125,1160721,0.0,0.0,24-05-2019,0
303,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 15, 2019, titled ""dr. reddy's laboratories announces the launch ofdaptomycin for injection, 500mg/vial single-dose vial in the u.s. market"".",15-May-2019 10:12:00,2019-05-15 10:12:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_15052019101122_PressRelease15052019_036.pdf,15-05-2019,2811.0,2853.85009765625,2792.0,2813.550048828125,2690.980712890625,478805,0.0,0.0,22-05-2019,-1
304,DRREDDY,Dr. Reddy's Laboratories Limited,news clarification,"drreddy: the exchange had sought clarification from the company with respect to news item captioned- titled ""pharma stocks bleed as us states file lawsuit against generic drug firms"". in this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) whether such event stated in published news were taking place? if so, you are advised to provide the said information along with the sequence of events in chronological order. b) the material impact of this article on the company. c) whether company was aware of any information that has not been announced to the exchanges under regulation 30 of listing regulations. if so, you are advised to provide the said information and the reasons for not disclosing the same to the exchange earlier as required under regulation 30 of the listing regulations. the response from the company is attached.",14-May-2019 17:06:00,2019-05-14 17:06:00,-,-,https://nsearchives.nseindia.com/corporate/zrizvi_145201917554_14052019replytoclarification_067.pdf,14-05-2019,2785.800048828125,2827.0,2760.050048828125,2807.60009765625,2685.290283203125,484950,0.0,0.0,21-05-2019,-1
305,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 06, 2019, titled ""dr. reddy's laboratories announces the launch oftestosterone gel, 1.62% (20.25 mg/1.25 g pump actuation) in the u.s. market"".",06-May-2019 10:28:00,2019-05-06 10:28:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_06052019102753_PressRelease06052019_037.pdf,06-05-2019,2896.949951171875,2929.949951171875,2888.0,2920.60009765625,2793.3671875,411016,0.0,0.0,13-05-2019,0
306,DRREDDY,Dr. Reddy's Laboratories Limited,news clarification,"drreddy:ￂﾠthe exchange had sought clarification from the company with respect to news item captioned- "" dr reddy's gets chinese regulator nod for anti-blood clotting drug "". in this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) whether such event stated in published news were taking place? if so, you are advised to provide the said information along with the sequence of events in chronological order. b) the material impact of this article on the company. c) whether company are aware of any information that has not been announced to the exchanges under regulation 30 of listing regulations. if so, you are advised to provide the said information and the reasons for not disclosing the same to the exchange earlier as required under regulation 30 of the listing regulations. the response from the company is attached.",25-Apr-2019 16:48:00,2019-04-25 16:48:00,-,-,https://nsearchives.nseindia.com/corporate/zrizvi_2542019164656_Replytoclarification25042019_734.pdf,25-04-2019,2851.64990234375,2940.0,2839.449951171875,2924.89990234375,2797.479736328125,1087724,0.0,0.0,06-05-2019,0
307,DRREDDY,Dr. Reddy's Laboratories Limited,disc. under reg.30 of sebi (sast) reg.2011,"the promoter along with pac has submitted to the exchange a copy of annual disclosure under regulation 30(1) and 30(2) of sebi (substantial acquisition of shares and takeovers), regulations, 2011 as on march 31, 2019.",18-Apr-2019 14:36:00,2019-04-18 14:36:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract1_18042019113656_DRREDDYSLABORATORIESLIMITED_154.pdf,18-04-2019,2827.949951171875,2827.949951171875,2791.35009765625,2799.10009765625,2677.160400390625,433608,0.0,0.0,26-04-2019,0
308,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 02, 2019, titled ""promius pharma, llc. (a wholly owned subsidiary of dr. reddyￂﾒs laboratories ltd.) announces the sale and assignment of the us rights for its marketed dermatology brands to encore dermatology"".",02-Apr-2019 09:00:00,2019-04-02 09:00:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_02042019085938_02042019_005.pdf,02-04-2019,2804.0,2820.0,2780.0,2798.75,2676.82568359375,588391,0.0,0.0,09-04-2019,0
309,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 27, 2019, titled ""dr. reddy's laboratories launches tadalafil tablets usp in the u.s. market"".",27-Mar-2019 11:42:00,2019-03-27 11:42:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_27032019114145_PressRelease27032019_033.pdf,27-03-2019,2781.050048828125,2814.0,2744.10009765625,2765.050048828125,2644.59375,659032,0.0,0.0,04-04-2019,0
310,DRREDDY,Dr. Reddy's Laboratories Limited,appointment," regarding appointment of mr allan oberman as non- executive independent director of the company w.e.f. march 26, 2019.",26-Mar-2019 17:08:00,2019-03-26 17:08:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_26032019170723_AllanObermanAppointmentSEintimation_204.pdf,26-03-2019,2791.0,2793.949951171875,2762.5,2782.35009765625,2661.139892578125,484102,0.0,0.0,03-04-2019,0
311,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 22, 2019, titled ""postal ballot notice-advertisement"".",22-Feb-2019 13:09:00,2019-02-22 13:09:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_22022019130808_Newspaperintimation_064.pdf,22-02-2019,2584.75,2650.0,2555.699951171875,2639.5,2524.5126953125,1378159,0.0,0.0,01-03-2019,0
312,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 20, 2019, titled """"dr. reddy's laboratories announces the re-launch ofits buprenorphine and naloxone sublingual film after favorable ruling in patent litigation"""".",20-Feb-2019 21:40:00,2019-02-20 21:40:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_20022019213940_PR20022019_243.pdf,20-02-2019,2574.89990234375,2584.0,2508.550048828125,2525.14990234375,2415.144287109375,1559722,0.0,0.0,27-02-2019,0
313,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 12, 2019, titled ""dr. reddy's laboratories limited to present at the edelweiss india conference 2019."".",12-Feb-2019 17:43:00,2019-02-12 17:43:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_12022019174212_PressRelease12022019_366.pdf,12-02-2019,2619.0,2676.449951171875,2584.0,2652.5,2536.94677734375,1309324,0.0,0.0,20-02-2019,0
314,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 12, 2019, titled ""dr. reddy's laboratories launches tadalafil tablets usp in the u.s. market"".",12-Feb-2019 11:01:00,2019-02-12 11:01:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_12022019110012_PressRelease12022019_027.pdf,12-02-2019,2619.0,2676.449951171875,2584.0,2652.5,2536.94677734375,1309324,0.0,0.0,20-02-2019,0
315,DRREDDY,Dr. Reddy's Laboratories Limited,news clarification,"the exchange had sought clarification from the company with respect to news item captioned- ""us firm names drl in price- fixing plaint "". in this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) whether such event stated in published news were taking place? if so, you are advised to provide the said information along with the sequence of events in chronological order. b) the material impact of this article on the company. c) whether company are aware of any information that has not been announced to the exchanges under regulation 30 of listing regulations. if so, you are advised to provide the said information and the reasons for not disclosing the same to the exchange earlier as required under regulation 30 of the listing regulations. the response from the company is attached.",06-Feb-2019 13:05:00,2019-02-06 13:05:00,-,-,https://nsearchives.nseindia.com/corporate/Mchheda_62201913416_Replytoclarification_080.pdf,06-02-2019,2816.0,2816.0,2761.0,2789.699951171875,2668.169677734375,881795,0.0,0.0,14-02-2019,0
316,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended december 31, 2018.",01-Feb-2019 14:43:18,2019-02-01 14:43:18,-,-,https://nsearchives.nseindia.com/corporate/Q3FY19Result_01022019144318.zip,01-02-2019,2717.699951171875,2819.0,2715.14990234375,2791.25,2669.652099609375,1450995,0.0,0.0,08-02-2019,0
317,DRREDDY,Dr. Reddy's Laboratories Limited,appointment," regarding appointment of mrs shikha sanjaya sharma as independent director of the company w.e.f. january 31, 2019.",31-Jan-2019 18:17:00,2019-01-31 18:17:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_31012019181607_ShikhaSharmaIntimation31012019_379.pdf,31-01-2019,2665.0,2728.550048828125,2651.0,2720.800048828125,2602.271240234375,1231518,0.0,0.0,07-02-2019,0
318,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 28, 2019, titled ""dr. reddy's and its us subsidiary, promius pharma, announce fda approval for tosymra (sumatriptan nasal spray) 10mg in the us market"".",28-Jan-2019 08:21:00,2019-01-28 08:21:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_28012019082011_PressRelease28012019_011.pdf,28-01-2019,2671.89990234375,2671.89990234375,2597.050048828125,2624.75,2510.4052734375,684994,0.0,0.0,04-02-2019,0
319,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 24, 2019, titled ""dr. reddy's laboratories announces the launch ofpropofol injectable emulsion, usp in the u.s. market"".",24-Jan-2019 11:51:00,2019-01-24 11:51:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_24012019115024_PressRelease24012019_034.pdf,24-01-2019,2642.050048828125,2674.699951171875,2642.050048828125,2668.449951171875,2552.20166015625,611565,0.0,0.0,31-01-2019,0
320,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 11, 2019, titled ""dr. reddy's to release q3 fy19 results on february 1, 2019, earnings call slated for february 1, 6:30 pm ist / 8:00 am est"".",11-Jan-2019 13:22:00,2019-01-11 13:22:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_11012019132046_PressRelease11012019_047.pdf,11-01-2019,2610.800048828125,2610.800048828125,2580.0,2588.14990234375,2475.39990234375,316787,0.0,0.0,18-01-2019,0
321,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 07, 2019, titled ""dr. reddy's laboratories limited to present at the 37th annual j.p. morgan healthcare conference"".",07-Jan-2019 17:17:00,2019-01-07 17:17:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_07012019171651_PressRelease07012019_177.pdf,07-01-2019,2613.85009765625,2613.85009765625,2537.300048828125,2558.64990234375,2447.184814453125,542415,0.0,0.0,14-01-2019,0
322,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 27, 2018, titled ""dr. reddy's laboratories announces the launch ofsevelamer carbonate for oral suspension in the u.s. market"".",27-Dec-2018 11:28:00,2018-12-27 11:28:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_27122018112637_PressRelease27122018_015.pdf,27-12-2018,2641.0,2645.0,2581.35009765625,2587.449951171875,2474.73046875,587578,0.0,0.0,03-01-2019,0
323,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 24, 2018, titled ""press release"".",24-Dec-2018 11:08:00,2018-12-24 11:08:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_24122018110621_PressRelease24122018_030.pdf,24-12-2018,2610.0,2623.10009765625,2578.199951171875,2599.800048828125,2486.54248046875,504639,0.0,0.0,01-01-2019,0
324,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 11, 2018, titled ""dr. reddyￂﾒs announces the launch of over-the-counter store brand equivalent of prilosec otcￂﾮ  (omeprazole delayed-release) tablets, 20 mg in the u.s. market."".",11-Dec-2018 10:29:00,2018-12-11 10:29:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_11122018102843_PressRelease11122018_011.pdf,11-12-2018,2668.5,2749.949951171875,2666.10009765625,2716.14990234375,2597.823974609375,840779,0.0,0.0,18-12-2018,0
325,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 28, 2018, titled ""press release"".",28-Nov-2018 10:52:00,2018-11-28 10:52:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_28112018105024_PressRelease28112018_021.pdf,28-11-2018,2595.0,2595.35009765625,2547.75,2572.300048828125,2460.24072265625,644293,0.0,0.0,05-12-2018,0
326,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 20, 2018, titled ""dr. reddy's laboratories announces favorable outcome in buprenorphine and naloxone sublingual film patent litigation "".",20-Nov-2018 23:50:00,2018-11-20 23:50:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_20112018234833_20112018_351.pdf,20-11-2018,2520.10009765625,2520.10009765625,2437.550048828125,2443.14990234375,2336.716796875,541117,0.0,0.0,28-11-2018,1
327,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'form 6-k for the quarter ended september 30, 2018, filed with united states securities and exchange commission'.",01-Nov-2018 18:52:00,2018-11-01 18:52:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_01112018184955_Pressrelease6k01112018_043.pdf,01-11-2018,2560.0,2574.449951171875,2446.5,2461.60009765625,2354.363037109375,1370566,0.0,0.0,09-11-2018,0
328,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 31, 2018, titled ""dr. reddy's laboratories announces the launch ofatomoxetine capsules, usp in the u.s. market"".",31-Oct-2018 11:58:00,2018-10-31 11:58:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_31102018115756_PressRelease31102018_061.pdf,31-10-2018,2438.949951171875,2554.39990234375,2423.050048828125,2542.449951171875,2431.69091796875,2272822,0.0,0.0,07-11-2018,0
329,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended september 30, 2018.",26-Oct-2018 14:50:05,2018-10-26 14:50:05,-,-,https://nsearchives.nseindia.com/corporate/Q2_26102018145005.zip,26-10-2018,2391.39990234375,2450.0,2368.050048828125,2404.550048828125,2299.79833984375,1125652,0.0,0.0,02-11-2018,0
330,DRREDDY,Dr. Reddy's Laboratories Limited,reply to clarification sought,"drreddy:the exchange had sought clarification from dr. reddy's laboratories limited with respect to announcement dated 15-oct-2018, regarding regarding a press release dated october 15, 2018, titled ""dr. reddy's laboratories announces the sale of its api manufacturing business unit in jeedimetla, hyderabad ""."". on basis of above the company is required to clarify following: 1. additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.2. whether the transaction would fall within related party transactions? if yes, whether the same is done at ""arm's length"";3. brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. if yes, details thereof.4. consideration received from such sale/disposal;5. the expected date of completion of sale/disposal;6. date on which the agreement for sale has been entered into;7. the amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year;the response of the company is attached.",22-Oct-2018 16:55:00,2018-10-22 16:55:00,-,-,https://nsearchives.nseindia.com/corporate/Mchheda_22102018165455_Replytoclarification22102018_751.pdf,22-10-2018,2562.5,2582.64990234375,2496.25,2519.39990234375,2409.64501953125,556392,0.0,0.0,29-10-2018,0
331,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 15, 2018, titled ""dr. reddy's laboratories receives approval foraspirin and extended-release dipyridamole capsules in the u.s. market"".",15-Oct-2018 14:47:00,2018-10-15 14:47:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_15102018144639_Pressrelease15102018_201.pdf,15-10-2018,2461.10009765625,2579.949951171875,2443.39990234375,2566.85009765625,2455.028076171875,1123276,0.0,0.0,23-10-2018,0
332,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 15, 2018, titled ""dr. reddy's laboratories announces the sale of itsapi manufacturing business unit in jeedimetla, hyderabad "".",15-Oct-2018 08:43:00,2018-10-15 08:43:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_15102018084232_15102018_097.pdf,15-10-2018,2461.10009765625,2579.949951171875,2443.39990234375,2566.85009765625,2455.028076171875,1123276,0.0,0.0,23-10-2018,0
333,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 09, 2018, titled ""dr. reddy's laboratories announces the launch ofcolesevelam hydrochloride tablets in the u.s. market"".",09-Oct-2018 17:39:00,2018-10-09 17:39:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_09102018173744_PressRelease09102018_119.pdf,09-10-2018,2357.64990234375,2477.0,2341.949951171875,2454.14990234375,2347.2373046875,1127674,0.0,0.0,16-10-2018,0
334,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 03, 2018, titled ""earnings call press release"".",03-Oct-2018 17:57:00,2018-10-03 17:57:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_03102018175636_PressRelease03102018_231.pdf,03-10-2018,2517.0,2549.0,2482.0,2489.550048828125,2381.095703125,705888,0.0,0.0,10-10-2018,0
335,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 01, 2018, titled ""dr. reddy's laboratories announces that it hasregained worldwide rights to df a-02."".",01-Oct-2018 08:56:00,2018-10-01 08:56:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_01102018085554_PR3_465.pdf,01-10-2018,2531.0,2540.699951171875,2440.35009765625,2508.60009765625,2399.315673828125,762356,0.0,0.0,09-10-2018,0
336,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 01, 2018, titled ""dr. reddy's laboratories announces the sale of itsantibiotic manufacturing site and its related assets in bristol, tennessee"".",01-Oct-2018 08:54:00,2018-10-01 08:54:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_01102018085357_PR2_463.pdf,01-10-2018,2531.0,2540.699951171875,2440.35009765625,2508.60009765625,2399.315673828125,762356,0.0,0.0,09-10-2018,0
337,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 01, 2018, titled ""dr. reddy's laboratories announces the launch ofimatinib mesylate tablets, usp in the u.s. market"".",01-Oct-2018 08:52:00,2018-10-01 08:52:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_01102018085129_PR1_459.pdf,01-10-2018,2531.0,2540.699951171875,2440.35009765625,2508.60009765625,2399.315673828125,762356,0.0,0.0,09-10-2018,0
338,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"dr. reddy's holdings limited has submitted to the exchange vide letter dated september 26, 2018 a copy of disclosure under regulation 10(6) of securities and exchange board of india (substantial acquisition of shares and takeovers) regulations, 2011.",26-Sep-2018 19:33:00,2018-09-26 19:33:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract3_26092018185400_DR_106_584.pdf,26-09-2018,2617.699951171875,2664.199951171875,2591.0,2600.85009765625,2487.546875,1206238,0.0,0.0,04-10-2018,-1
339,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"dr. reddy's holdings ltd has submitted to the exchange a copy of disclosure under regulation 10(5) in respect of acquisition under regulation 10(1)(a) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",19-Sep-2018 10:28:00,2018-09-19 10:28:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract1_19092018101200_Reg30disclosuresFY2018_Redacted_268.zip,19-09-2018,2603.39990234375,2636.0,2571.0,2607.10009765625,2493.524658203125,869947,0.0,0.0,27-09-2018,0
340,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 12, 2018, titled ""dr. reddy's laboratories announces the launch ofneostigmine methylsulfate injection, usp in the u.s. market"".",12-Sep-2018 16:55:00,2018-09-12 16:55:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_12092018165434_12092018PR_433.PDF,12-09-2018,2526.0,2574.449951171875,2487.60009765625,2529.14990234375,2418.97021484375,1248825,0.0,0.0,21-09-2018,0
341,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 12, 2018, titled ""dr. reddy's laboratories limited to present at the morgan stanley annual global healthcare conference"".",12-Sep-2018 11:49:00,2018-09-12 11:49:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_12092018114534_PR12092018_325.pdf,12-09-2018,2526.0,2574.449951171875,2487.60009765625,2529.14990234375,2418.97021484375,1248825,0.0,0.0,21-09-2018,0
342,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"dr. reddy's holdings limited has submitted to the exchange, vide letter dated september 10, 2018, a copy of disclosure under regulation 10(6) of the sebi (substantial acquisition of shares & takeovers) regulations, 2011.",11-Sep-2018 09:12:00,2018-09-11 09:12:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract1_11092018072629_DRH_REG10_008.pdf,11-09-2018,2578.449951171875,2586.449951171875,2507.10009765625,2524.449951171875,2414.474853515625,1136931,0.0,0.0,19-09-2018,0
343,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"dr. reddy's holdings limited has submitted to the exchange, vide letter dated september 03, 2018 a copy of disclosure under regulation 10(5) in respect of acquisition under regulation 10(1)(a) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",05-Sep-2018 13:23:00,2018-09-05 13:23:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract4_05092018122835_67_DR_216.pdf,05-09-2018,2549.300048828125,2590.0,2518.5,2567.699951171875,2455.8408203125,1127153,0.0,0.0,12-09-2018,0
344,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations," a copy disclosure under regulation 10(5) of sebi (substantial acquisition of shares and takeovers regulations, 2011)",04-Sep-2018 09:42:00,2018-09-04 09:42:00,-,-,https://nsearchives.nseindia.com/corporate/cdharod_04092018094133_sast_290.zip,04-09-2018,2595.0,2615.0,2537.050048828125,2543.10009765625,2432.3125,1036459,0.0,0.0,11-09-2018,0
345,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"dr. reddy's holdings limited has submitted to the exchange, vide letter dated august 13, 2018 a copy of disclosure under regulation 10(6) in respect of acquisition under regulation 10 of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",14-Aug-2018 08:43:00,2018-08-14 08:43:00,-,-,https://nsearchives.nseindia.com/corporate/DRH_Reg10_14082018084345.zip,14-08-2018,2254.0,2291.0,2239.050048828125,2278.449951171875,2179.191650390625,482038,0.0,0.0,23-08-2018,1
346,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 07, 2018, titled ""form 6-k for the quarter ended june 30, 2018, filed with us sec"".",07-Aug-2018 11:57:00,2018-08-07 11:57:00,-,-,https://nsearchives.nseindia.com/corporate/Form6K07082018_07082018115754_683.zip,07-08-2018,2249.89990234375,2281.449951171875,2245.050048828125,2258.800048828125,2160.398193359375,499910,0.0,0.0,14-08-2018,0
347,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"dr. reddyￂﾒs holdings limited has submitted to the exchange a copy of disclosure under regulation 10(5) in respect of acquisition under regulation 10(1)(a) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",07-Aug-2018 10:25:00,2018-08-07 10:25:00,-,-,https://nsearchives.nseindia.com/corporate/DRHL10_05_07082018101754_07082018102454.zip,07-08-2018,2249.89990234375,2281.449951171875,2245.050048828125,2258.800048828125,2160.398193359375,499910,0.0,0.0,14-08-2018,0
348,DRREDDY,Dr. Reddy's Laboratories Limited,shareholders meeting," regarding proceedings of annual general meeting held on july 27, 2018. further, the company has submitted the exchange a copy of srutinizers report along with voting results.",27-Jul-2018 19:52:00,2018-07-27 19:52:00,-,-,https://nsearchives.nseindia.com/corporate/OutcomeAGM27072018_27072018195220_459.zip,27-07-2018,2135.0,2135.0,2067.39990234375,2083.199951171875,1992.447509765625,896318,0.0,0.0,03-08-2018,1
349,DRREDDY,Dr. Reddy's Laboratories Limited,news clarification,the exchange had sought clarification from the company with respect to news item captioned- astrazeneca sues drl on patent. the response from the company is attached.,27-Jul-2018 08:53:00,2018-07-27 08:53:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_27072018084521_27072018085236_27072018085310.zip,27-07-2018,2135.0,2135.0,2067.39990234375,2083.199951171875,1992.447509765625,896318,0.0,0.0,03-08-2018,1
350,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended june 30, 2018.",26-Jul-2018 14:55:26,2018-07-26 14:55:26,-,-,https://nsearchives.nseindia.com/corporate/Q1FY19financialsresults_26072018145526.zip,26-07-2018,2075.699951171875,2191.0,2074.89990234375,2132.75,2039.8394775390625,1913049,0.0,0.0,02-08-2018,0
351,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 26, 2018, titled ""dr. reddy's laboratories announces the launch of hervyctaￂﾮ (trastuzumab biosimilar) in india"".",26-Jul-2018 09:26:00,2018-07-26 09:26:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease26072018_26072018092608_804.zip,26-07-2018,2075.699951171875,2191.0,2074.89990234375,2132.75,2039.8394775390625,1913049,0.0,0.0,02-08-2018,0
352,DRREDDY,Dr. Reddy's Laboratories Limited,reply to clarification sought,"the exchange had sought clarification from the company with respect to news item captioned- astrazeneca sues drl on patent. in this regard, exchange has advised the company to provide clarification/confirmation on the news item in detail including the following: a) whether such event/negotiations/article stated in published news were taking place? if so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the company. b) whether company is aware of any information that has not been announced to the exchanges under regulation 30 of listing regulations. the response from the company is attached.",25-Jul-2018 19:46:00,2018-07-25 19:46:00,-,-,https://nsearchives.nseindia.com/corporate/Replytoclarification_25072018194658.zip,25-07-2018,2087.0,2097.5,2061.550048828125,2088.199951171875,1997.2298583984373,538614,0.0,0.0,01-08-2018,0
353,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 20, 2018, titled ""dr. reddyￂﾒs announces the launch of esomeprazole magnesium delayed-release capsules usp, 20 mg in the u.s. market"".",20-Jul-2018 10:58:00,2018-07-20 10:58:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease20072018_20072018105806_012.zip,20-07-2018,2026.0,2073.0,2020.0,2051.89990234375,1962.51123046875,755783,0.0,0.0,27-07-2018,0
354,DRREDDY,Dr. Reddy's Laboratories Limited,reply to clarification sought,"the exchange had sought clarification from dr. reddy's laboratories limited with respect to announcement dated 14-jul-2018, regarding a press release dated july 14, 2018, titled ""press release"".on basis of above the company is required to clarify following:1. quantum of claims, if any2. expected financial implications, if any, due to compensation, penalty etc;3. brief details of litigation viz. name(s) of the opposing party, court/ tribunal/agency where litigation is filed, brief details of dispute/litigation;the response of the company is attached.",17-Jul-2018 19:43:00,2018-07-17 19:43:00,-,-,https://nsearchives.nseindia.com/corporate/17072018clarification_17072018194316.zip,17-07-2018,2060.0,2119.0,2057.050048828125,2065.300048828125,1975.3275146484373,1422184,0.0,0.0,24-07-2018,0
355,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 11, 2018, titled ""dr. reddy's laboratories announces the launch ofhydroxychloroquine sulfate tablets, usp in the u.s. market"".",11-Jul-2018 11:28:00,2018-07-11 11:28:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease11072018_11072018112830_057.zip,11-07-2018,2301.0,2333.0,2275.0,2301.35009765625,2182.117919921875,820067,0.0,0.0,18-07-2018,-1
356,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 09, 2018, titled ""dr. reddyￂﾒs and ucb india enter into an agreement to co-promote and distribute briviactￂﾮ for the treatment of epilepsy in india"".",09-Jul-2018 14:59:00,2018-07-09 14:59:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease09072018_09072018145931_224.zip,09-07-2018,2282.0,2335.0,2281.949951171875,2330.050048828125,2209.3310546875,729897,0.0,0.0,16-07-2018,-1
357,DRREDDY,Dr. Reddy's Laboratories Limited,updates, regarding 'newspaper advertisement regarding notice of 34th annual general meeting of the company and e-voting information'.,05-Jul-2018 18:40:00,2018-07-05 18:40:00,-,-,https://nsearchives.nseindia.com/corporate/Newspaperadvertisement_05072018184026_341.zip,05-07-2018,2329.949951171875,2348.699951171875,2287.75,2298.64990234375,2179.55810546875,830939,0.0,0.0,12-07-2018,0
358,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 05, 2018, titled ""press release"".",05-Jul-2018 12:39:00,2018-07-05 12:39:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease05072018_05072018123932_098.zip,05-07-2018,2329.949951171875,2348.699951171875,2287.75,2298.64990234375,2179.55810546875,830939,0.0,0.0,12-07-2018,0
359,DRREDDY,Dr. Reddy's Laboratories Limited,trading window," regarding the trading window closure pursuant to sebi (prohibition of insider trading) regulations, 2015",04-Jul-2018 13:33:00,2018-07-04 13:33:00,-,-,https://nsearchives.nseindia.com/corporate/BMintimation_04072018133352_414.zip,04-07-2018,2273.800048828125,2338.0,2273.800048828125,2317.25,2197.19384765625,1065535,0.0,0.0,11-07-2018,0
360,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 02, 2018, titled ""press release"".",02-Jul-2018 17:17:00,2018-07-02 17:17:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease02072018_02072018171748_832.zip,02-07-2018,2230.0,2260.550048828125,2202.25,2240.35009765625,2124.2783203125,774325,0.0,0.0,09-07-2018,0
361,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 19, 2018, titled ""dr. reddy's laboratories announces the launch oflevetiracetam in sodium chloride injection in the u.s. market"".",19-Jun-2018 11:59:00,2018-06-19 11:59:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease19062018_19062018115911_048.zip,19-06-2018,2403.199951171875,2429.60009765625,2376.550048828125,2393.0,2269.01953125,2106466,0.0,0.0,26-06-2018,-1
362,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 15, 2018, titled ""as attached"".",15-Jun-2018 07:42:00,2018-06-15 07:42:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease15062018_15062018074248_247.zip,15-06-2018,2303.0,2385.800048828125,2296.25,2349.85009765625,2228.105224609375,4456911,0.0,0.0,22-06-2018,0
363,DRREDDY,Dr. Reddy's Laboratories Limited,resignation," regarding resignation of mr hans peter hasler as independent director of the company w.e.f. jun 14, 2018.",14-Jun-2018 16:26:00,2018-06-14 16:26:00,-,-,https://nsearchives.nseindia.com/corporate/Intimation14062018_14062018162658_134.zip,14-06-2018,2260.050048828125,2299.64990234375,2246.550048828125,2269.39990234375,2151.8232421875,1588963,0.0,0.0,21-06-2018,0
364,DRREDDY,Dr. Reddy's Laboratories Limited,financial results updates," that intimation under regulation 33(3)(b)(i) of the sebi (listing obligations and disclosure requirements) regulations, 2015",08-Jun-2018 16:57:00,2018-06-08 16:57:00,-,-,https://nsearchives.nseindia.com/corporate/CFSIntimation08062018_08062018165752_188.zip,08-06-2018,1973.0,2072.60009765625,1973.0,2062.89990234375,1956.0220947265625,1113559,0.0,0.0,15-06-2018,1
365,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 05, 2018, titled ""press release"".",05-Jun-2018 17:58:00,2018-06-05 17:58:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease05062018_05062018175832_959.zip,05-06-2018,1980.0,1987.550048828125,1954.0,1963.4000244140625,1861.677001953125,365344,0.0,0.0,12-06-2018,1
366,DRREDDY,Dr. Reddy's Laboratories Limited,agm/book closure," that the register of members and share transfer books of the company shall remain closed from july 18, 2018 to july 20, 2018(both days inclusive) for the purpose of annual general meeting of the company is scheduled to be held on july 27, 2018 and dividend",04-Jun-2018 19:46:00,2018-06-04 19:46:00,-,-,https://nsearchives.nseindia.com/corporate/DR_AGMBOOK_04062018194625.zip,04-06-2018,1978.0,2027.9000244140625,1965.0,1996.0,1892.587890625,1400421,0.0,0.0,11-06-2018,0
367,DRREDDY,Dr. Reddy's Laboratories Limited,dividend," that the board of directors of the company at its meeting held on may 22, 2018  have recommended a final dividend of rs. 20/- (400%) per equity share of rs. 5/- face value for the financial year 2017-18.",22-May-2018 13:45:00,2018-05-22 13:45:00,-,-,https://nsearchives.nseindia.com/corporate/Drreddy_22052018134013.zip,22-05-2018,1902.5,2036.0,1890.0,2009.5999755859373,1905.483154296875,2019136,0.0,0.0,29-05-2018,0
368,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended march 31, 2018.",22-May-2018 13:06:06,2018-05-22 13:06:06,-,-,https://nsearchives.nseindia.com/corporate/Q4FY2018Financialresults_22052018130606.zip,22-05-2018,1902.5,2036.0,1890.0,2009.5999755859373,1905.483154296875,2019136,0.0,0.0,29-05-2018,0
369,DRREDDY,Dr. Reddy's Laboratories Limited,press release (revised)," regarding a revised press release dated april 25, 2018, titled ""dr. reddy's to release q4 and full year fy18 results on may 22, 2018, earnings call slated for may 22, 6:30 pm ist / 9:00 am edt"".",25-Apr-2018 17:41:00,2018-04-25 17:41:00,-,-,https://nsearchives.nseindia.com/corporate/RevisedPressRelease25042018_25042018174139_242.zip,25-04-2018,2151.449951171875,2155.949951171875,2113.0,2118.0,2008.267333984375,288899,0.0,0.0,03-05-2018,0
370,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 25, 2018, titled ""dr. reddy's to release q4 and full year fy18 results on may 22, 2018, earnings call slated for may 22, 6:30 pm ist / 9:00 am edt"".",25-Apr-2018 12:09:00,2018-04-25 12:09:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease25042018_25042018120924_079.zip,25-04-2018,2151.449951171875,2155.949951171875,2113.0,2118.0,2008.267333984375,288899,0.0,0.0,03-05-2018,0
371,DRREDDY,Dr. Reddy's Laboratories Limited,disc. under reg.30 of sebi (sast) reg.2011,"promoter of the company has submitted to the exchange a copy of disclosure under regulation 30(1) and 30(2) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",12-Apr-2018 09:24:00,2018-04-12 09:24:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDYS_12042018092413.zip,12-04-2018,2078.0,2078.0,2054.300048828125,2060.5,1953.7462158203125,679256,0.0,0.0,19-04-2018,0
372,DRREDDY,Dr. Reddy's Laboratories Limited,trading window," regarding the trading window closure pursuant to sebi (prohibition of insider trading) regulations, 2015",10-Apr-2018 20:05:00,2018-04-10 20:05:00,-,-,https://nsearchives.nseindia.com/corporate/BMNotice_10042018200552_437.zip,10-04-2018,2123.0,2135.0,2082.75,2112.10009765625,2002.6728515625,515981,0.0,0.0,17-04-2018,0
373,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 02, 2018, titled ""as attached"".",02-Apr-2018 12:53:00,2018-04-02 12:53:00,-,-,https://nsearchives.nseindia.com/corporate/PressReleases02042018_02042018125341_198.zip,02-04-2018,2080.0,2138.0,2080.0,2132.10009765625,2021.6368408203125,245975,0.0,0.0,09-04-2018,0
374,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 26, 2018, titled ""press release"".",26-Mar-2018 10:05:00,2018-03-26 10:05:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease26032018_26032018100527_038.zip,26-03-2018,2072.0,2109.75,2050.300048828125,2104.0,1994.99267578125,500280,0.0,0.0,04-04-2018,0
375,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 16, 2018, titled ""dr. reddy's laboratories announces the launch oflevocetirizine dihydrochloride tablets usp, 5 mg in the u.s. market"".",16-Mar-2018 11:24:00,2018-03-16 11:24:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease16032018_16032018112449_283.zip,16-03-2018,2180.0,2209.0,2118.300048828125,2142.14990234375,2031.166015625,594361,0.0,0.0,23-03-2018,0
376,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 05, 2018, titled ""form 6-k for the quarter ended december 31, 2017, filed with united states securities and exchange commission"".",05-Feb-2018 12:45:00,2018-02-05 12:45:00,-,-,https://nsearchives.nseindia.com/corporate/05022018_05022018124537_193.zip,05-02-2018,2110.199951171875,2139.0,2088.64990234375,2116.5,2006.8448486328125,603638,0.0,0.0,12-02-2018,0
377,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 02, 2018, titled ""dr. reddy's laboratories announces the launch oftetrabenazine tablets in the u.s. market"".",02-Feb-2018 11:25:00,2018-02-02 11:25:00,-,-,https://nsearchives.nseindia.com/corporate/Pressreleases02022018_02022018112508_078.zip,02-02-2018,2150.0,2211.050048828125,2110.050048828125,2123.550048828125,2013.529541015625,959646,0.0,0.0,09-02-2018,0
378,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended december 31, 2017.",25-Jan-2018 11:55:57,2018-01-25 11:55:57,-,-,https://nsearchives.nseindia.com/corporate/Q3FY18financialresults_25012018115557.zip,25-01-2018,2554.0,2597.10009765625,2453.199951171875,2507.75,2377.824462890625,2652030,0.0,0.0,02-02-2018,-1
379,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 16, 2018, titled ""dr. reddy's to release q3 fy18 results on january 25, 2018 earnings call slated for january 25, 6.30 pm ist / 8.00 am est"".",16-Jan-2018 11:56:00,2018-01-16 11:56:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease16012018_16012018115634_398.zip,16-01-2018,2436.0,2484.0,2431.75,2468.699951171875,2340.797607421875,372133,0.0,0.0,23-01-2018,0
380,DRREDDY,Dr. Reddy's Laboratories Limited,news verification,"the exchange has sought clarification from dr. reddy's laboratories limited with respect to recent news item captioned ""dr reddy's cracks on buzz of issues raised in eir for duvvada plant"". the exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. dr. reddy's laboratories limited has submitted their response.",03-Jan-2018 14:37:00,2018-01-03 14:37:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_7252_reply_03012018143740.zip,03-01-2018,2386.5,2386.5,2292.10009765625,2339.0,2217.817138671875,886002,0.0,0.0,10-01-2018,0
381,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 26, 2017, titled ""dr. reddy's laboratories announces the launch of melphalan hydrochloride for injection in the u.s. market."".",26-Dec-2017 14:21:00,2017-12-26 14:21:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease26122017_26122017142147_467.zip,26-12-2017,2334.949951171875,2367.0,2329.0,2360.300048828125,2238.013671875,410936,0.0,0.0,02-01-2018,0
382,DRREDDY,Dr. Reddy's Laboratories Limited,updates, regarding 'newspaper advertisement regarding despatch of postal ballot notice and form'.,21-Dec-2017 15:50:00,2017-12-21 15:50:00,-,-,https://nsearchives.nseindia.com/corporate/Newspaperadvertisement20122017_21122017155050_891.zip,21-12-2017,2365.0,2374.699951171875,2341.0,2351.75,2229.906982421875,249941,0.0,0.0,29-12-2017,0
383,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 19, 2017, titled ""dr. reddyￂﾒs announces it has reached a settlement with the us government regarding companyￂﾒs compliance with the consumer product safety act"".",19-Dec-2017 08:26:00,2017-12-19 08:26:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease19122017_19122017082654_334.zip,19-12-2017,2404.5,2421.60009765625,2391.199951171875,2399.5,2275.182861328125,448959,0.0,0.0,27-12-2017,0
384,DRREDDY,Dr. Reddy's Laboratories Limited,news verification,"the exchange has sought clarification from dr. reddy's laboratories limited with respect to recent news item captioned ""aurobindo, drl lead race to buy orchid"". the exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. dr. reddy's laboratories limited has submitted their response.",18-Dec-2017 14:47:00,2017-12-18 14:47:00,-,-,https://nsearchives.nseindia.com/corporate/NSE_clarification_18122017144730.zip,18-12-2017,2365.0,2428.0,2332.949951171875,2395.0,2270.915771484375,528351,0.0,0.0,26-12-2017,0
385,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 01, 2017, titled ""dr. reddyￂﾒs announces approval of impoyzￂﾙ (clobetasol propionate) cream, 0.025% first-cycle nda approval"".",01-Dec-2017 09:56:00,2017-12-01 09:56:00,-,-,https://nsearchives.nseindia.com/corporate/PR_01122017095655_366.zip,01-12-2017,2280.0,2286.0,2222.5,2233.89990234375,2118.162353515625,529288,0.0,0.0,08-12-2017,0
386,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 14, 2017, titled ""dr. reddy's laboratories announces the launch of clofarabine injection in the u.s. market"".",14-Nov-2017 13:12:00,2017-11-14 13:12:00,-,-,https://nsearchives.nseindia.com/corporate/PR14112017_14112017131253_612.zip,14-11-2017,2348.699951171875,2349.949951171875,2310.050048828125,2320.300048828125,2200.08642578125,279262,0.0,0.0,21-11-2017,0
387,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'this is to inform you that the company has filed its unaudited condensed consolidated interim financial statements prepared under ifrs in form 6-k for the quarter ended september 30, 2017, with the united states securities and exchange commission on november 8, 2017. '.",09-Nov-2017 08:57:00,2017-11-09 08:57:00,-,-,https://nsearchives.nseindia.com/corporate/6k09112017_09112017085724_497.zip,09-11-2017,2368.60009765625,2384.10009765625,2340.199951171875,2370.10009765625,2247.305908203125,345854,0.0,0.0,16-11-2017,0
388,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 02, 2017, titled ""dr. reddy's laboratories announces the launch ofgeneric azacitidine for injection in the canadian market."".",02-Nov-2017 19:18:00,2017-11-02 19:18:00,-,-,https://nsearchives.nseindia.com/corporate/PR02112017_02112017191835_764.zip,02-11-2017,2354.199951171875,2440.0,2354.199951171875,2411.39990234375,2286.466064453125,1239887,0.0,0.0,09-11-2017,0
389,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended september 30, 2017.",31-Oct-2017 11:26:36,2017-10-31 11:26:36,-,-,https://nsearchives.nseindia.com/corporate/ResultQ2FY18_31102017112636.zip,31-10-2017,2420.0,2504.0,2390.0,2428.14990234375,2302.348388671875,1957333,0.0,0.0,07-11-2017,0
390,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'appointment of mr. prasad r menon as an additional director, categorized as independent, on the board of the company.'.",30-Oct-2017 16:00:00,2017-10-30 16:00:00,-,-,https://nsearchives.nseindia.com/corporate/Appointment_30102017160023_176.zip,30-10-2017,2396.0,2465.0,2367.050048828125,2438.5,2312.162109375,832219,0.0,0.0,06-11-2017,0
391,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 16, 2017, titled ""dr. reddy's to release q2 fy18 results on october 31, 2017 earnings call slated for october 31, 6.30 pm ist / 9.00 am edt"".",16-Oct-2017 18:29:00,2017-10-16 18:29:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease16102017_16102017182901_742.zip,16-10-2017,2356.0,2411.0,2356.0,2403.5,2278.9755859375,386658,0.0,0.0,24-10-2017,0
392,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," regarding allotment of 7987 securities pursuant to esop/esps at its meeting held on october 12, 2017",12-Oct-2017 13:48:00,2017-10-12 13:48:00,-,-,https://nsearchives.nseindia.com/corporate/Drreddy3_12102017134826.zip,12-10-2017,2397.0,2397.0,2358.5,2379.85009765625,2256.55078125,416094,0.0,0.0,19-10-2017,0
393,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"dr. reddy's holdings ltd has submitted to the exchange, vide letter dated october 05, 2017 a copy of disclosure under regulation 10(6) in respect of acquisition under regulation 10 of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",05-Oct-2017 10:56:00,2017-10-05 10:56:00,-,-,https://nsearchives.nseindia.com/corporate/0837_10_05102017105602.zip,05-10-2017,2392.0,2428.39990234375,2376.0,2389.14990234375,2265.368896484375,759504,0.0,0.0,12-10-2017,0
394,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 29, 2017, titled ""dr. reddy's laboratories announces the launch of sevelamer carbonate tablets in the u.s. market"".",29-Sep-2017 21:42:00,2017-09-29 21:42:00,-,-,https://nsearchives.nseindia.com/corporate/29092017_29092017214227_386.zip,29-09-2017,2375.39990234375,2390.699951171875,2320.10009765625,2328.75,2208.09814453125,1133595,0.0,0.0,09-10-2017,0
395,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"dr. reddy's holdings ltd has submitted to the exchange, vide letter dated september 26, 2017 a copy of disclosure under regulation 10(5) in respect of acquisition under regulation 10(1)(a) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",26-Sep-2017 15:38:00,2017-09-26 15:38:00,-,-,https://nsearchives.nseindia.com/corporate/0801_001_26092017153825.zip,26-09-2017,2414.0,2415.0,2322.64990234375,2370.75,2247.92236328125,1424436,0.0,0.0,04-10-2017,0
396,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'intimation regarding audit by usfda of our custom pharmaceutical services (cps) facility, technology development centre (tdc-1) at miyapur, hyderabad'.",21-Sep-2017 12:21:00,2017-09-21 12:21:00,-,-,https://nsearchives.nseindia.com/corporate/Intimation21092017Miyapur_21092017122107_072.zip,21-09-2017,2346.25,2500.0,2346.25,2486.550048828125,2357.72314453125,4057364,0.0,0.0,28-09-2017,0
397,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'intimation regarding audit of our formulation srikakulam plant (sez) unit ii, andhra pradesh, '.",21-Sep-2017 10:03:00,2017-09-21 10:03:00,-,-,https://nsearchives.nseindia.com/corporate/Intimation21092017_21092017100342_029.zip,21-09-2017,2346.25,2500.0,2346.25,2486.550048828125,2357.72314453125,4057364,0.0,0.0,28-09-2017,0
398,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding 'audit of our api mirfield plant, united kingdom, by the us fda'.",15-Sep-2017 20:42:00,2017-09-15 20:42:00,-,-,https://nsearchives.nseindia.com/corporate/Intimation15092017_15092017204259_634.zip,15-09-2017,2225.199951171875,2245.0,2201.10009765625,2211.199951171875,2096.638427734375,672801,0.0,0.0,22-09-2017,1
399,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 12, 2017, titled "" aurigene discovery technologies limited, a wholly owned subsidiary of dr reddy s laboratories limited, and curis inc., announce ca-170 program update following data presented at esmo 2017.  "".",12-Sep-2017 17:52:00,2017-09-12 17:52:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease12092017aurigene_12092017175222_311.zip,12-09-2017,2165.0,2197.39990234375,2135.39990234375,2165.75,2053.543212890625,517997,0.0,0.0,19-09-2017,0
400,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 12, 2017, titled ""please find enclosed a press release on  dr. reddy's laboratories limited to present at the morgan stanley annual global healthcare conference. "".",12-Sep-2017 17:44:00,2017-09-12 17:44:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease12092017morgan_12092017174432_305.zip,12-09-2017,2165.0,2197.39990234375,2135.39990234375,2165.75,2053.543212890625,517997,0.0,0.0,19-09-2017,0
401,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 06, 2017, titled ""press releases"".",06-Sep-2017 11:32:00,2017-09-06 11:32:00,-,-,https://nsearchives.nseindia.com/corporate/PressReleases06092017_06092017113211_022.zip,06-09-2017,2185.35009765625,2208.0,2175.75,2196.89990234375,2083.079345703125,527252,0.0,0.0,13-09-2017,0
402,DRREDDY,Dr. Reddy's Laboratories Limited,news verification,"the exchange has sought clarification from dr. reddy's laboratories limited with respect to recent news item captioned ""dr reddy's settles patent row with vivus"". the exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. dr. reddy's laboratories limited has submitted their response.",01-Sep-2017 14:48:00,2017-09-01 14:48:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_6955_reply_01092017144856.zip,01-09-2017,2115.0,2233.0,2115.0,2217.550048828125,2102.65966796875,3613589,0.0,0.0,08-09-2017,0
403,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 01, 2017, titled ""intimation about judgment issued by the united states district court, for the district of delaware"".",01-Sep-2017 12:53:00,2017-09-01 12:53:00,-,-,https://nsearchives.nseindia.com/corporate/Intimation01092017_01092017125337_073.zip,01-09-2017,2115.0,2233.0,2115.0,2217.550048828125,2102.65966796875,3613589,0.0,0.0,08-09-2017,0
404,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 28, 2017, titled ""dr. reddy's laboratories announces the launch ofcefixime for oral suspension, usp in the u.s. market"".",28-Aug-2017 11:31:00,2017-08-28 11:31:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease28082017_28082017113157_014.zip,28-08-2017,2084.0,2089.75,2027.0999755859373,2049.39990234375,1943.2213134765625,844176,0.0,0.0,04-09-2017,1
405,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"dr. reddy s holdings ltd. has submitted to the exchange, vide letter dated august 22, 2017 a copy of disclosure under regulation 10(6) in respect of acquisition under regulation 10 of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",22-Aug-2017 16:26:00,2017-08-22 16:26:00,-,-,https://nsearchives.nseindia.com/corporate/Drreddys_10_22082017162612.zip,22-08-2017,1945.0,2014.0,1935.0,1984.1500244140625,1881.3519287109373,772164,0.0,0.0,30-08-2017,0
406,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 22, 2017, titled ""dr. reddy s laboratories announces the out-licensing of dfd-06 to encore dermatology"".",22-Aug-2017 10:11:00,2017-08-22 10:11:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease22082017_22082017101126_625.zip,22-08-2017,1945.0,2014.0,1935.0,1984.1500244140625,1881.3519287109373,772164,0.0,0.0,30-08-2017,0
407,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"dr. reddy's holdings ltd has submitted to the exchange, vide letter dated august 11, 2017 a copy of disclosure under regulation 10(5) in respect of acquisition under regulation 10(1)(a) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",11-Aug-2017 17:43:00,2017-08-11 17:43:00,-,-,https://nsearchives.nseindia.com/corporate/Reg30disclosuresFY2015_11082017174241.zip,11-08-2017,1925.050048828125,2029.949951171875,1901.1500244140625,2011.1500244140625,1906.9530029296875,1857913,0.0,0.0,21-08-2017,0
408,DRREDDY,Dr. Reddy's Laboratories Limited,updates," that intimation regarding betapharm arzneimittel gmbh, germany (our wholly-owned subsidiary) .",10-Aug-2017 14:42:00,2017-08-10 14:42:00,-,-,https://nsearchives.nseindia.com/corporate/10082017intimation_10082017144246_942.zip,10-08-2017,2042.0,2099.0,1934.0999755859373,1944.449951171875,1843.708740234375,1540007,0.0,0.0,18-08-2017,0
409,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 09, 2017, titled ""form 6-k for the quarter ended june 30, 2017, filed with united states securities exchange commission"".",09-Aug-2017 13:07:00,2017-08-09 13:07:00,-,-,https://nsearchives.nseindia.com/corporate/PressReleases09082017_09082017130719_164.zip,09-08-2017,2090.89990234375,2105.0,2032.5,2048.35009765625,1942.2259521484373,1124987,0.0,0.0,17-08-2017,0
410,DRREDDY,Dr. Reddy's Laboratories Limited,shareholders meeting," regarding proceedings of annual general meeting held on july 28, 2017. further, the company has submitted the exchange a copy of srutinizers report along with voting results.",28-Jul-2017 18:17:00,2017-07-28 18:17:00,-,-,https://nsearchives.nseindia.com/corporate/OutcomeAGM28072017_28072017181753_463.zip,28-07-2017,2499.5,2506.550048828125,2451.10009765625,2464.949951171875,2337.241943359375,1548997,0.0,0.0,04-08-2017,-1
411,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 27, 2017, titled ""please find enclosed a press release on  dr. reddy s and chd bioscience announce global license and commercialization agreement for phase iii clinical trial candidate for mitigation of surgical site infections ."".",27-Jul-2017 16:21:00,2017-07-27 16:21:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease27072017_27072017162100_327.zip,27-07-2017,2710.0,2723.0,2587.0,2620.35009765625,2484.590576171875,1822665,0.0,0.0,03-08-2017,-1
412,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended june 30, 2017.",27-Jul-2017 14:26:43,2017-07-27 14:26:43,-,-,https://nsearchives.nseindia.com/corporate/Q1FY18Outcome_27072017142643.zip,27-07-2017,2710.0,2723.0,2587.0,2620.35009765625,2484.590576171875,1822665,0.0,0.0,03-08-2017,-1
413,DRREDDY,Dr. Reddy's Laboratories Limited,updates," that the audit of api cuernavaca plant at mexico, by the us fda, has been completed with zero observations.",21-Jul-2017 11:05:00,2017-07-21 11:05:00,-,-,https://nsearchives.nseindia.com/corporate/Announcement21072017_21072017110558_048.zip,21-07-2017,2738.0,2780.0,2727.0,2762.550048828125,2619.42333984375,282516,0.0,0.0,28-07-2017,-1
414,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 14, 2017, titled ""dr. reddy's to release q1 fy18 results on july 27, 2017. earnings call slated for july 27, 6.30 pm ist / 9.00 am edt.  "".",14-Jul-2017 16:33:00,2017-07-14 16:33:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease14072017_14072017163318_217.zip,14-07-2017,2699.14990234375,2725.0,2686.39990234375,2703.0,2543.99462890625,195286,0.0,0.0,21-07-2017,0
415,DRREDDY,Dr. Reddy's Laboratories Limited,updates, regarding notice of annual general meeting (agm) and annual report 2016-17 .,05-Jul-2017 19:40:00,2017-07-05 19:40:00,-,-,https://nsearchives.nseindia.com/corporate/AR201617_05072017194011_203.zip,05-07-2017,2621.5,2669.0,2621.5,2664.949951171875,2508.182861328125,181326,0.0,0.0,12-07-2017,0
416,DRREDDY,Dr. Reddy's Laboratories Limited,shareholders meeting," regarding notice of annual general meeting to be held on july 28, 2017",05-Jul-2017 19:40:00,2017-07-05 19:40:00,-,-,https://nsearchives.nseindia.com/corporate/Nsp_05072017194012_204.zip,05-07-2017,2621.5,2669.0,2621.5,2664.949951171875,2508.182861328125,181326,0.0,0.0,12-07-2017,0
417,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 20, 2017, titled "" dr. reddy s laboratories limited announces filing of annual report on form 20-f for fy2017 ."".",20-Jun-2017 11:07:00,2017-06-20 11:07:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease20062017_20062017110706_315.zip,20-06-2017,2660.35009765625,2695.0,2653.60009765625,2676.050048828125,2518.6298828125,196527,0.0,0.0,28-06-2017,0
418,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 16, 2017, titled ""intimation on completion of usfda audit"".",16-Jun-2017 18:10:00,2017-06-16 18:10:00,-,-,https://nsearchives.nseindia.com/corporate/16062017_16062017181052_673.zip,16-06-2017,2714.199951171875,2718.14990234375,2631.0,2682.60009765625,2524.795166015625,370538,0.0,0.0,23-06-2017,0
419,DRREDDY,Dr. Reddy's Laboratories Limited,news clarification,"the exchange had sought clarification from the company with respect to news item captioned ""dr reddy's recalls 3.25l cartons cipla-made acne drug from us"". the response from the company is attached.",15-Jun-2017 11:35:00,2017-06-15 11:35:00,-,-,https://nsearchives.nseindia.com/corporate/Replytoclarification15062017_15062017113503_181.zip,15-06-2017,2662.699951171875,2720.949951171875,2655.0,2700.5,2541.641845703125,694652,0.0,0.0,22-06-2017,0
420,DRREDDY,Dr. Reddy's Laboratories Limited,updates," vide letter dated june 13, 2017 that ""this is in reference to our intimation dated february 21,2017 with regard to the audit of our api manufacturing plant at miryalaguda, by the us fda, wherein we were issued a form 483 with three observations. in this regard, we would now like to inform you that we have received an establishment inspection report (eir) from the us fda today as closure of audit, for the above-referred facility.""",14-Jun-2017 08:22:00,2017-06-14 08:22:00,-,-,https://nsearchives.nseindia.com/corporate/13June2017_14062017082242_857.zip,14-06-2017,2668.0,2699.0,2645.39990234375,2669.300048828125,2512.277099609375,748839,0.0,0.0,21-06-2017,0
421,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 06, 2017, titled ""dr. reddy's laboratories announces the launch of bivalirudin for injection in the u.s. market"".",06-Jun-2017 11:19:00,2017-06-06 11:19:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease06062017_06062017111920_080.zip,06-06-2017,2534.949951171875,2565.5,2516.0,2549.300048828125,2399.33642578125,172111,0.0,0.0,13-06-2017,0
422,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated jun 05, 2017, titled ""dr. reddy's laboratories limited to present at the jefferies 2017 global healthcare conference"".",05-Jun-2017 18:35:00,2017-06-05 18:35:00,-,-,https://nsearchives.nseindia.com/corporate/PressReleases01062017_05062017183502_637.zip,05-06-2017,2543.14990234375,2568.0,2520.10009765625,2535.85009765625,2386.67724609375,224677,0.0,0.0,12-06-2017,0
423,DRREDDY,Dr. Reddy's Laboratories Limited,agm/book closure," that the register of members and share transfer books of the company shall remain closed from july 19, 2017 to july 21, 2017(both days inclusive) for the purpose of annual general meeting of the shareholders of the company and for determining the shareholders who would be entitled for the payment of dividend, if declared at the annual general meeting, scheduled to be held on july 28, 2017.",01-Jun-2017 15:27:00,2017-06-01 15:27:00,-,-,https://nsearchives.nseindia.com/corporate/AGMBookClosure2017_01062017152754_670.zip,01-06-2017,2540.0,2567.75,2513.89990234375,2522.800048828125,2374.394775390625,324502,0.0,0.0,08-06-2017,0
424,DRREDDY,Dr. Reddy's Laboratories Limited,updates," that the audit of company formulations srikakulum plant (sez) unit ii, andhra pradesh by the us fda, has been completed on may 25, 2017 with zero observations.",25-May-2017 17:53:00,2017-05-25 17:53:00,-,-,https://nsearchives.nseindia.com/corporate/Intimation_25052017175322_193.zip,25-05-2017,2507.39990234375,2508.35009765625,2398.0,2427.699951171875,2284.88916015625,808310,0.0,0.0,01-06-2017,0
425,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 17, 2017, titled ""dr. reddy's laboratories announces usfda approval for the launch of doxorubicin hydrochloride liposome injection in the u.s. market."".",17-May-2017 12:46:00,2017-05-17 12:46:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease17052017_17052017124625_208.zip,17-05-2017,2720.0,2760.0,2686.550048828125,2736.89990234375,2575.900146484375,409818,0.0,0.0,24-05-2017,-1
426,DRREDDY,Dr. Reddy's Laboratories Limited,esop/esos/esps," regarding grant of 214516  options. this is to inform you that the nomination, governance & compensation committee of the board of directors of the company in their meeting held on may 11, 2017, has granted 151,212 stock options, exercisable at par value of rs.5/- under  dr. reddy s employees stock option scheme, 2002  and 63,304 stock options, exercisable at par value of rs.5/- under  dr. reddy s employees adr stock option scheme, 2007  to the employees of the company.this is for your information and records.",12-May-2017 18:29:00,2017-05-12 18:29:00,-,-,https://nsearchives.nseindia.com/corporate/GrantofStockOptions2017_12052017182902_507.zip,12-05-2017,2603.0,2615.0,2521.949951171875,2580.800048828125,2428.9833984375,1230471,0.0,0.0,19-05-2017,0
427,DRREDDY,Dr. Reddy's Laboratories Limited,dividend," that board of directors at its meeting held on may 12, 2017, recommended final dividend of rs. 20 per equity share.",12-May-2017 13:21:00,2017-05-12 13:21:00,-,-,https://nsearchives.nseindia.com/corporate/FY2017Results_12052017132150_172.zip,12-05-2017,2603.0,2615.0,2521.949951171875,2580.800048828125,2428.9833984375,1230471,0.0,0.0,19-05-2017,0
428,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended march 31, 2017.",12-May-2017 13:10:50,2017-05-12 13:10:50,-,-,https://nsearchives.nseindia.com/corporate/FY2017Results_12052017131050.zip,12-05-2017,2603.0,2615.0,2521.949951171875,2580.800048828125,2428.9833984375,1230471,0.0,0.0,19-05-2017,0
429,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 28, 2017, titled ""this is to inform you that the audit of our formulations manufacturing plant   3 at bachupally, hyderabad by the us fda, has been completed today. we have been issued a form 483 with 11 observations. these observations are mostly procedural in nature, reflecting the need to improve people capabilities and strengthen documentation and laboratory systems. we will address them comprehensively within the stipulated time. "".",28-Apr-2017 19:18:00,2017-04-28 19:18:00,-,-,https://nsearchives.nseindia.com/corporate/28042017_28042017191818_447.zip,28-04-2017,2610.25,2612.85009765625,2583.550048828125,2599.14990234375,2446.253662109375,136374,0.0,0.0,08-05-2017,0
430,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 27, 2017, titled ""dr. reddy's laboratories announces the launch of ezetimibe and simvastatin tablets in the u.s. market."".",27-Apr-2017 10:08:00,2017-04-27 10:08:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease27042017_27042017100852_011.zip,27-04-2017,2611.39990234375,2625.0,2587.25,2596.550048828125,2443.806884765625,402022,0.0,0.0,05-05-2017,0
431,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 25, 2017, titled ""please find enclosed a press release on  dr. reddy's to release q4 and full year fy17 results on may 12, 2017 earnings call slated for may 12, 6.00 pm ist / 8.30 am edt. "".",25-Apr-2017 14:37:00,2017-04-25 14:37:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease25042017_25042017143720_177.zip,25-04-2017,2628.0,2651.60009765625,2617.14990234375,2645.949951171875,2490.30029296875,275155,0.0,0.0,03-05-2017,0
432,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 21, 2017, titled ""dr. reddy's laboratories announces the launch ofprogesterone capsules in the u.s. market"".",21-Apr-2017 18:34:00,2017-04-21 18:34:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease21042017_21042017183441_397.zip,21-04-2017,2630.0,2635.0,2607.0,2609.64990234375,2456.1357421875,110154,0.0,0.0,28-04-2017,0
433,DRREDDY,Dr. Reddy's Laboratories Limited,disc. under reg.30 of sebi (sast) reg.2011,"satish reddy has submitted to the exchange a copy of disclosure under regulation 30(1) and 30(2) of sebi (substantial acquisition of shares & takeovers) regulations, 2011",12-Apr-2017 11:33:00,2017-04-12 11:33:00,-,-,https://nsearchives.nseindia.com/corporate/DrReaddy_30_12042017113357.zip,12-04-2017,2633.0,2651.89990234375,2615.300048828125,2644.85009765625,2489.265380859375,245231,0.0,0.0,20-04-2017,0
434,DRREDDY,Dr. Reddy's Laboratories Limited,updates,"dr. reddy's laboratories limited has submitted the exchange a copies of newspaper advertisement dated april 8, 2017 regarding transfer of equity shares to iepf.",10-Apr-2017 19:02:00,2017-04-10 19:02:00,-,-,https://nsearchives.nseindia.com/corporate/Newspaperadtoexchanges_10042017190229_318.zip,10-04-2017,2655.0,2670.75,2632.449951171875,2635.85009765625,2480.794677734375,190492,0.0,0.0,18-04-2017,0
435,DRREDDY,Dr. Reddy's Laboratories Limited,news verification,"the exchange has sought clarification from dr. reddy's laboratories limited with respect to recent news item captioned  usfda started srikakulam inspection on march 27. no major observation from usfda yet on srikakulam plant. . the exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. dr. reddy's laboratories limited has submitted their response.",03-Apr-2017 15:43:00,2017-04-03 15:43:00,-,-,https://nsearchives.nseindia.com/corporate/Replytoclarification03042017_03042017154333.zip,03-04-2017,2644.800048828125,2754.0,2627.10009765625,2744.449951171875,2583.006591796875,688429,0.0,0.0,11-04-2017,0
436,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 27, 2017, titled ""dr. reddy s and integra lifesciences enter into an agreement to market and distribute duragen plus  and suturable duragen  dural regeneration in india."".",27-Mar-2017 12:24:00,2017-03-27 12:24:00,-,-,https://nsearchives.nseindia.com/corporate/pressrelease27032017_27032017122422_400.zip,27-03-2017,2617.0,2647.800048828125,2615.0,2631.949951171875,2477.124267578125,356219,0.0,0.0,03-04-2017,0
437,DRREDDY,Dr. Reddy's Laboratories Limited,news verification,"the exchange has sought clarification from dr. reddy's laboratories limited with respect to recent news item captioned ""us fda finds repeat observations from 2015 warning letter. failed to maintain complete data to ensure compliance."". the exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. dr. reddy's laboratories limited has submitted their response.",21-Mar-2017 12:30:00,2017-03-21 12:30:00,-,-,https://nsearchives.nseindia.com/corporate/Replytoclarification21032017_21032017123058.zip,21-03-2017,2730.0,2730.0,2600.0,2623.25,2468.936279296875,1453633,0.0,0.0,28-03-2017,0
438,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 08, 2017, titled ""intimation regarding completion of audit of our formulation manufacturing facility at duvvada, visakhapatnam, by the us fda."".",08-Mar-2017 19:43:00,2017-03-08 19:43:00,-,-,https://nsearchives.nseindia.com/corporate/Intimation08032017_08032017194357_674.zip,08-03-2017,2849.0,2872.75,2823.0,2846.800048828125,2679.335693359375,366171,0.0,0.0,16-03-2017,0
439,DRREDDY,Dr. Reddy's Laboratories Limited,reply to clarification sought,"drreddy:the exchange had sought clarification from dr. reddy's laboratories limited with respect to announcement dated march 03, 2017, regarding a press release dated march 03, 2017, titled ""dr. reddy's laboratories announces acquisition of 100% stake in imperial credit private limited, a non-banking finance company (nbfc). on basis of above the company was required to clarify following: 1. name of the target entity, details in brief such as size, turnover etc;2. whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? if yes, nature of interest and details thereof and whether the same is done at ""arm's length"";3. brief details of any governmental or regulatory approvals required for the acquisition;4. indicative time period for completion of the acquisition;5. nature of consideration - whether cash consideration or share swap and details of the same;6. percentage of shareholding / control acquired and / or number of shares acquired;7. brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).the response of the company is attached.",06-Mar-2017 15:58:00,2017-03-06 15:58:00,-,-,https://nsearchives.nseindia.com/corporate/Clarification06032017_06032017155856_400.zip,06-03-2017,2884.0,2884.0,2851.0,2858.85009765625,2690.677001953125,212010,0.0,0.0,14-03-2017,0
440,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 03, 2017, titled ""dr. reddy's laboratories announces acquisition of 100% stake in imperial credit private limited, a non-banking finance company (nbfc)"".",03-Mar-2017 20:01:00,2017-03-03 20:01:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease03032017_03032017200100_159.zip,03-03-2017,2881.550048828125,2893.800048828125,2863.60009765625,2871.10009765625,2702.206298828125,291202,0.0,0.0,10-03-2017,-1
441,DRREDDY,Dr. Reddy's Laboratories Limited,updates," ""the audit of  api manufacturing plant at miryalaguda, by the us fda, has been completed on february 21, 2017. we have been issued a form 483 with three observations, which we are addressing""",21-Feb-2017 18:32:00,2017-02-21 18:32:00,-,-,https://nsearchives.nseindia.com/corporate/21022017_21022017183214_564.zip,21-02-2017,2898.0,2935.10009765625,2885.10009765625,2894.050048828125,2723.80615234375,1524490,0.0,0.0,01-03-2017,0
442,DRREDDY,Dr. Reddy's Laboratories Limited,reply to clarification sought,"drreddy:the exchange had sought clarification from dr. reddy's laboratories limited with respect to announcement dated 16-feb-2017, regarding a press release dated february 16, 2017, titled ""dr. reddy's announces us district court's opinion relating to patent infringement.""on basis of above the company is required to clarify following: 1. expected financial implications, if any, due to compensation, penalty etc;2. quantum of claims, if anythe response of the company is attached.",17-Feb-2017 12:48:00,2017-02-17 12:48:00,-,-,https://nsearchives.nseindia.com/corporate/Clarification17022017_17022017124842_494.zip,17-02-2017,2926.0,2953.75,2900.0,2912.699951171875,2741.359130859375,897496,0.0,0.0,27-02-2017,0
443,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 16, 2017, titled ""dr. reddy's announces us district court's opinion relating to patent infringement"".",16-Feb-2017 09:32:00,2017-02-16 09:32:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease16022017_16022017093232_050.zip,16-02-2017,2914.10009765625,2942.5,2798.949951171875,2923.199951171875,2751.2412109375,1367869,0.0,0.0,23-02-2017,0
444,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 13, 2017, titled ""form 6-k for the quarter ended december 31, 2016, filed with united states securities exchange commission"".",13-Feb-2017 13:42:00,2017-02-13 13:42:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease13022017_13022017134221_190.zip,13-02-2017,2980.949951171875,2988.25,2955.449951171875,2966.949951171875,2792.41796875,150555,0.0,0.0,20-02-2017,0
445,DRREDDY,Dr. Reddy's Laboratories Limited,news clarification,the exchange had sought clarification from the company with respect to recent news item captioned  korean company files suit against drl the response from the company is enclosed.,27-Jan-2017 15:22:00,2017-01-27 15:22:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease27012017_27012017152237_338.zip,27-01-2017,2970.0,3011.550048828125,2960.0,2994.550048828125,2818.39404296875,192111,0.0,0.0,03-02-2017,1
446,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 23, 2017, titled ""dr. reddy's q3-fy17 earnings call notification"".dr. reddy's to release q3 fy17 results on feb 4, 2017  earnings call slated for feb 4, 6.30 pm ist / 8.00 am est",23-Jan-2017 11:24:00,2017-01-23 11:24:00,-,-,https://nsearchives.nseindia.com/corporate/PressReleases23012017_23012017112453_188.zip,23-01-2017,2939.0,2959.949951171875,2904.0,2923.64990234375,2751.664794921875,239373,0.0,0.0,31-01-2017,0
447,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"dr. reddy's holdings limited has submitted to the exchange, vide letter dated january 16, 2017 a copy of disclosure under regulation 10(6) in respect of acquisition under regulation 10 f sebi (substantial acquisition of shares & takeovers) regulations, 2011.",16-Jan-2017 17:20:00,2017-01-16 17:20:00,-,-,https://nsearchives.nseindia.com/corporate/DRHL_10_16012017172026.zip,16-01-2017,2999.0,3007.0,2965.35009765625,2985.300048828125,2809.688232421875,201640,0.0,0.0,23-01-2017,0
448,DRREDDY,Dr. Reddy's Laboratories Limited,news verification,"the exchange has sought clarification from dr. reddy's laboratories limited with respect to recent news item captioned ""fda to re-audit three dr.reddy's labs plants"". the exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. dr. reddy's laboratories limited has submitted their response.",12-Jan-2017 13:37:00,2017-01-12 13:37:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_6589_reply_12012017133736.zip,12-01-2017,2977.0,3019.10009765625,2943.0,3008.5,2831.523681640625,434390,0.0,0.0,19-01-2017,0
449,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 09, 2017, titled ""dr. reddy's laboratories limited to present at the j.p. morgan 35th annual healthcare conference"".",09-Jan-2017 18:29:00,2017-01-09 18:29:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease09012017_09012017182904_453.zip,09-01-2017,3154.0,3154.0,3051.85009765625,3060.199951171875,2880.18212890625,280298,0.0,0.0,16-01-2017,0
450,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"dr. reddy's holdings limited has submitted to the exchange, vide letter dated january 06, 2017 a copy of disclosure under regulation 10(5) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",06-Jan-2017 18:35:00,2017-01-06 18:35:00,-,-,https://nsearchives.nseindia.com/corporate/02.zip,06-01-2017,3148.800048828125,3203.85009765625,3145.699951171875,3159.14990234375,2973.3115234375,354039,0.0,0.0,13-01-2017,-1
451,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 05, 2016, titled ""dr. reddy's laboratories announces the launch ofnystatin and triamcinolone acetonide cream, usp in the u.s. market"".",05-Dec-2016 11:07:00,2016-12-05 11:07:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease05122016_05122016110731_036.zip,05-12-2016,3197.5,3197.5,3118.550048828125,3168.14990234375,2981.7822265625,406294,0.0,0.0,12-12-2016,0
452,DRREDDY,Dr. Reddy's Laboratories Limited,esops/esos/esps," that the nomination, governance & compensation committee of the board of directors of the company vide a circular resolution passed on november 15, 2016, has granted 496 stock options, exercisable at par value of rs.5/- under ''dr. reddy s employees stock option scheme, 2002 to an employee of the company''.",16-Nov-2016 12:19:00,2016-11-16 12:19:00,-,-,https://nsearchives.nseindia.com/corporate/Grantof496stockoptions_16112016121902_070.zip,16-11-2016,3335.0,3354.949951171875,3195.0,3210.949951171875,3022.064453125,336964,0.0,0.0,23-11-2016,0
453,DRREDDY,Dr. Reddy's Laboratories Limited,updates," regarding form 6-k for the quarter ended september 30, 2016, filed with the united states securities exchange commission",11-Nov-2016 14:50:00,2016-11-11 14:50:00,-,-,https://nsearchives.nseindia.com/corporate/11112016_11112016145043_841.zip,11-11-2016,3228.0,3300.85009765625,3228.0,3256.25,3064.699462890625,334735,0.0,0.0,21-11-2016,0
454,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 11, 2016, titled ""dr. reddy's laboratories announces the launch ofraloxifene hcl tablets, usp in the u.s. market"".",11-Nov-2016 14:27:00,2016-11-11 14:27:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease11112016_11112016142748_807.zip,11-11-2016,3228.0,3300.85009765625,3228.0,3256.25,3064.699462890625,334735,0.0,0.0,21-11-2016,0
455,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,", the financial results for the period ended september 30, 2016.",07-Nov-2016 13:15:21,2016-11-07 13:15:21,-,-,https://nsearchives.nseindia.com/corporate/Q2FY17financialresults_07112016131521.zip,07-11-2016,3124.0,3154.949951171875,3081.050048828125,3106.64990234375,2923.899658203125,229170,0.0,0.0,15-11-2016,1
456,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 26, 2016 titled ""dr. reddy's laboratories announces new strategic deal with gland pharma in the u.s. market"".",26-Oct-2016 17:46:00,2016-10-26 17:46:00,-,-,https://nsearchives.nseindia.com/corporate/Pressreleases26102016_26102016174624_146.zip,26-10-2016,3206.0,3254.89990234375,3153.14990234375,3242.300048828125,3051.570068359375,492547,0.0,0.0,03-11-2016,0
457,DRREDDY,Dr. Reddy's Laboratories Limited,financial results updates," a copy of unaudited financial results for the quarter ended september 30, 2016.",25-Oct-2016 11:34:00,2016-10-25 11:34:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_B_25102016113449.zip,25-10-2016,3108.89990234375,3209.0,3068.5,3200.60009765625,3012.3232421875,1112884,0.0,0.0,02-11-2016,0
458,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 14, 2016 titled "" dr. reddy's to release q2 fy17 results on october 25, 2016, earnings call slated for october 25, 6.30 pm ist / 9.00 am edt."".",14-Oct-2016 18:02:00,2016-10-14 18:02:00,-,-,https://nsearchives.nseindia.com/corporate/PressReleases14102016_14102016180225_304.zip,14-10-2016,3062.949951171875,3062.949951171875,3021.60009765625,3031.25,2852.935302734375,412160,0.0,0.0,21-10-2016,0
459,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 13, 2016 titled ""dr. reddy's laboratories announces the launch of aripiprazole tablets, usp tablets in the u.s. market"".",13-Oct-2016 11:44:00,2016-10-13 11:44:00,-,-,https://nsearchives.nseindia.com/corporate/Pressrelease13102016_13102016114458_092.zip,13-10-2016,3070.800048828125,3084.75,3027.60009765625,3050.14990234375,2870.72314453125,387997,0.0,0.0,20-10-2016,0
460,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 10, 2016 titled ""dr. reddy's laboratories announces the launch of lamotrigine orally disintegrating tablets in the u.s. market"".",10-Oct-2016 17:01:00,2016-10-10 17:01:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease10102016_10102016170121_422.zip,10-10-2016,3054.0,3098.800048828125,3039.0,3078.64990234375,2897.547119140625,317015,0.0,0.0,19-10-2016,0
461,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 7,  2016  titled ""leading global pharmaceutical company, dr. reddys laboratories now in colombia"".",07-Oct-2016 18:44:00,2016-10-07 18:44:00,-,-,https://nsearchives.nseindia.com/corporate/Pressreleases07102016_07102016184414_670.zip,07-10-2016,3070.0,3082.0,3045.0,3054.300048828125,2874.62939453125,180517,0.0,0.0,18-10-2016,0
462,DRREDDY,Dr. Reddy's Laboratories Limited,esops/esos/esps," that nomination, governance & compensation committee of the board of directors of the company has allotted 13,188 equity shares of rs.5/- each of the company, fully paid up, on september 22, 2016, to employee on exercise of the stock options.",23-Sep-2016 11:39:00,2016-09-23 11:39:00,-,-,https://nsearchives.nseindia.com/corporate/ESOPIntimation22092016_23092016113958_096.zip,23-09-2016,3169.0,3186.949951171875,3150.39990234375,3182.199951171875,2995.005859375,155117,0.0,0.0,30-09-2016,0
463,DRREDDY,Dr. Reddy's Laboratories Limited,esops/esos/esps," that the nomination, governance and compensation committee vide a circular resolution dated september 20, 2016 has granted 292 stock options, exercisable at par value of rs. 5/- under ""dr. reddy's employee stock option scheme, 2002"" to an employee of the company.",21-Sep-2016 13:31:00,2016-09-21 13:31:00,-,-,https://nsearchives.nseindia.com/corporate/4431_001_21092016133158_152.zip,21-09-2016,3162.0,3179.0,3135.0,3153.0,2967.5234375,250048,0.0,0.0,28-09-2016,0
464,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 19 , 2016 titled ""dr. reddy's laboratories announces the launch of paricalcitol injection in the u.s. market"".",19-Sep-2016 17:21:00,2016-09-19 17:21:00,-,-,https://nsearchives.nseindia.com/corporate/PressReleases19092016_19092016172125_564.zip,19-09-2016,3167.0,3174.89990234375,3141.0,3157.35009765625,2971.61767578125,132885,0.0,0.0,26-09-2016,0
465,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 16, 2016, titled ""dr. reddy''s expands strategic collaboration with amgen in india"".",16-Sep-2016 14:12:00,2016-09-16 14:12:00,-,-,https://nsearchives.nseindia.com/corporate/PressReleases16092016_16092016141223_625.zip,16-09-2016,3141.0,3178.14990234375,3135.0,3150.14990234375,2964.840576171875,208363,0.0,0.0,23-09-2016,0
466,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 13, 2016, titled ""dr reddy s listed on dow jones sustainability indices 2016"".",14-Sep-2016 08:27:00,2016-09-14 08:27:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease13092016_14092016082748_784.zip,14-09-2016,3149.949951171875,3170.0,3135.0,3157.800048828125,2972.041015625,140534,0.0,0.0,21-09-2016,0
467,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding press release dated september 02, 2016 titled "" dr. reddy's laboratories announces the launch of bupropion hcl extended-release tablets, usp (sr) in the u.s. market .""",02-Sep-2016 19:59:00,2016-09-02 19:59:00,-,-,https://nsearchives.nseindia.com/corporate/Pressrelease02092016_02092016195926_785.zip,02-09-2016,3097.10009765625,3139.0,3082.10009765625,3123.050048828125,2939.335205078125,196230,0.0,0.0,12-09-2016,0
468,DRREDDY,Dr. Reddy's Laboratories Limited,press release,"dr. reddy's laboratories limitedhas informed the exchange regarding a press release dated september 1, 2016 titled ""dr. reddy s announces purple health, a unique patient-centric platform that takes care beyond the pill"".",01-Sep-2016 11:50:00,2016-09-01 11:50:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease01092016_01092016115056_189.zip,01-09-2016,3070.050048828125,3108.89990234375,3066.300048828125,3097.64990234375,2915.42919921875,272305,0.0,0.0,09-09-2016,0
469,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 29, 2016 titled ""dr. reddy's laboratories launches nitroglycerin sublingual tablets usp in the u.s. market"".",29-Aug-2016 12:16:00,2016-08-29 12:16:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease29082016_29082016121640_378.zip,29-08-2016,3055.0,3059.0,3017.5,3052.14990234375,2872.60595703125,145863,0.0,0.0,06-09-2016,0
470,DRREDDY,Dr. Reddy's Laboratories Limited,press release, that dr. reddy s completes acquisition of product portfolio from teva,04-Aug-2016 08:03:00,2016-08-04 08:03:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease03082016_04082016080335_003.zip,04-08-2016,2958.60009765625,2981.800048828125,2931.10009765625,2962.449951171875,2788.1826171875,300510,0.0,0.0,11-08-2016,0
471,DRREDDY,Dr. Reddy's Laboratories Limited,"regulation 44(3) of sebi (lodr), reg., 2015"," the details of voting results of the annual general meeting of the company held on the july 27, 2016 along with scrutinizer's report.",28-Jul-2016 09:03:00,2016-07-28 09:03:00,-,-,https://nsearchives.nseindia.com/corporate/PostAGMintimation_28072016090305_029.zip,28-07-2016,2989.0,3018.800048828125,2952.89990234375,2959.75,2785.64111328125,1143813,0.0,0.0,04-08-2016,0
472,DRREDDY,Dr. Reddy's Laboratories Limited,esops/esos/esps," that the nomination, governance & compensation committee of the board of directors of the company in their meeting held on july 26, 2016, had granted 157,272 equity shares of rs.5/- to employees, pursuant to 'employee stock option schemes'.",28-Jul-2016 08:46:00,2016-07-28 08:46:00,-,-,https://nsearchives.nseindia.com/corporate/ESOPGrant26072016_28072016084601_019.zip,28-07-2016,2989.0,3018.800048828125,2952.89990234375,2959.75,2785.64111328125,1143813,0.0,0.0,04-08-2016,0
473,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 26, 2016 titled ""dr.reddy's q1 fy17 financial results"".",27-Jul-2016 08:45:00,2016-07-27 08:45:00,-,-,https://nsearchives.nseindia.com/corporate/Q1FY17financialresultsFinal_27072016084504_716.zip,27-07-2016,3020.10009765625,3069.39990234375,2958.25,2980.199951171875,2804.888427734375,4718843,0.0,0.0,03-08-2016,0
474,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 26, 2016 with respect to the unaudited financial result for the quarter ended june 30, 2016.",26-Jul-2016 14:48:00,2016-07-26 14:48:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_26072016144808.zip,26-07-2016,3488.0,3517.949951171875,3290.10009765625,3319.64990234375,3124.369873046875,1535245,0.0,0.0,02-08-2016,-1
475,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates," the standalone & consolidated financial results along with the limited review report for the period ended june 30, 2016.",26-Jul-2016 14:40:27,2016-07-26 14:40:27,-,-,https://nsearchives.nseindia.com/corporate/Q1FY17financialresults_26072016144027.zip,26-07-2016,3488.0,3517.949951171875,3290.10009765625,3319.64990234375,3124.369873046875,1535245,0.0,0.0,02-08-2016,-1
476,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 18, 2016, titled ""dr. reddy's laboratories announces the launch of omeprazole and sodium bicarbonate capsules in the u.s. market"".",18-Jul-2016 11:02:00,2016-07-18 11:02:00,-,-,https://nsearchives.nseindia.com/corporate/Pressrelease18072016_18072016110252_877.zip,18-07-2016,3586.25,3610.0,3544.0,3567.75,3357.87548828125,227145,20.0,0.0,25-07-2016,0
477,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release titled ""dr. reddy's to release q1 fy17 results on july 26, 2016. earnings call slated for july 26, 6.30 pm ist / 9.00 am edt.""",12-Jul-2016 20:41:00,2016-07-12 20:41:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease12072016_12072016204114_698.zip,12-07-2016,3627.0,3631.89990234375,3566.050048828125,3596.35009765625,3365.92578125,281101,0.0,0.0,19-07-2016,0
478,DRREDDY,Dr. Reddy's Laboratories Limited,esops/esos/esps," that nomination, governance & compensation committee of the board of directors of the company has allotted 90,290 equity shares of rs.5/- each of the company, fully paid up, on july 11, 2016, to employees on exercise of their stock options.",12-Jul-2016 11:11:00,2016-07-12 11:11:00,-,-,https://nsearchives.nseindia.com/corporate/ESOPIntimation_12072016111141_331.zip,12-07-2016,3627.0,3631.89990234375,3566.050048828125,3596.35009765625,3365.92578125,281101,0.0,0.0,19-07-2016,0
479,DRREDDY,Dr. Reddy's Laboratories Limited,annual general meeting updates,dr. reddy's laboratories limited has submitted the exchange a notice of annual general meeting and e-voting instructions published in newspapers,04-Jul-2016 17:34:00,2016-07-04 17:34:00,-,-,https://nsearchives.nseindia.com/corporate/Evotinginstructions_04072016173408_534.zip,04-07-2016,3555.60009765625,3558.449951171875,3418.300048828125,3435.0,3214.913818359375,340516,0.0,0.0,12-07-2016,0
480,DRREDDY,Dr. Reddy's Laboratories Limited,post buyback public announcement,kotak mahindra capital company limited  has submitted to the exchange a copy of post buyback public advertisement for the attention of the equity shareholders/beneficial owners of equity shares of dr. reddy's laboratories limited.(target company).,30-Jun-2016 13:08:00,2016-06-30 13:08:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_02.zip,30-06-2016,3328.199951171875,3393.10009765625,3316.0,3381.699951171875,3165.028564453125,612595,0.0,0.0,08-07-2016,1
481,DRREDDY,Dr. Reddy's Laboratories Limited,post buyback public announcement, a copy of post buyback public advertisement for the attention of the equity shareholders/beneficial owners of equity shares of the company.,30-Jun-2016 09:37:00,2016-06-30 09:37:00,-,-,https://nsearchives.nseindia.com/corporate/DRLPostbuybackPA_30062016093734_761.zip,30-06-2016,3328.199951171875,3393.10009765625,3316.0,3381.699951171875,3165.028564453125,612595,0.0,0.0,08-07-2016,1
482,DRREDDY,Dr. Reddy's Laboratories Limited,closure of buy back, regarding the closure of buyback of equity shares of rs. 5/- each ( equity shares ) of dr. reddy s laboratories limited ( company ).,28-Jun-2016 14:37:00,2016-06-28 14:37:00,-,-,https://nsearchives.nseindia.com/corporate/IntimationofBuybackClosure_28062016143701_045.zip,28-06-2016,3240.0,3285.0,3235.14990234375,3273.050048828125,3063.34033203125,401840,0.0,0.0,05-07-2016,1
483,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated june 24, 2016, titled ""dr. reddy s laboratories limited announces filing of annual report on form 20-f"" .",24-Jun-2016 11:06:00,2016-06-24 11:06:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease24062016_24062016110623_938.zip,24-06-2016,3110.0,3166.949951171875,3085.0,3153.25,2951.216064453125,298357,0.0,0.0,01-07-2016,1
484,DRREDDY,Dr. Reddy's Laboratories Limited,appointment of director," regarding ""appointment of mr. hans peter hasler as an additional director, categorized as independent on the board of the company"".",17-Jun-2016 19:11:00,2016-06-17 19:11:00,-,-,https://nsearchives.nseindia.com/corporate/HanspeterIntimation_17062016191150_298.zip,17-06-2016,3081.0,3094.89990234375,2999.800048828125,3002.949951171875,2810.5458984375,1066355,0.0,0.0,24-06-2016,1
485,DRREDDY,Dr. Reddy's Laboratories Limited,agm/book closure," that the register of members and share transfer books of the company shall remain closed from july 20, 2016 to july 22, 2016(both days inclusive) for the purpose of payment of dividend and annual general meeting of the company is scheduled to be held on july 27, 2016.",03-Jun-2016 16:18:00,2016-06-03 16:18:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_AGM_03062016161801.zip,03-06-2016,3187.0,3196.949951171875,3142.300048828125,3160.10009765625,2957.626953125,338635,0.0,0.0,10-06-2016,0
486,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated june 01, 2016, titled ""promius pharma launches sernivo (betamethasone dipropionate) spray, 0.05% new product for mild to moderate plaque psoriasis"".",01-Jun-2016 11:10:00,2016-06-01 11:10:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease01062016_01062016111007_142.zip,01-06-2016,3190.0,3219.89990234375,3172.10009765625,3183.14990234375,2979.2001953125,194240,0.0,0.0,08-06-2016,0
487,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 25, 2016 titled ""dr. reddy''s enters the branded consumer health arena through the acquisition of six otc brands"".",25-May-2016 15:00:00,2016-05-25 15:00:00,-,-,https://nsearchives.nseindia.com/corporate/pressrelease25052016_25052016150028_264.zip,25-05-2016,3020.0,3075.0,3020.0,3051.550048828125,2856.0322265625,209454,0.0,0.0,01-06-2016,0
488,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates, the standalone financial results along with the auditors report for the period ended 31-mar-2016.,12-May-2016 13:16:55,2016-05-12 13:16:55,-,-,https://nsearchives.nseindia.com/corporate/Q4andFY16_12052016131655.zip,12-05-2016,2871.0,2988.0,2844.050048828125,2971.449951171875,2781.06396484375,1731193,0.0,0.0,19-05-2016,0
489,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 12, 2016, titled ""dr. reddy' q4 and fy 16 financial results"".",12-May-2016 13:16:00,2016-05-12 13:16:00,-,-,https://nsearchives.nseindia.com/corporate/DREDDY_12052016131635.zip,12-05-2016,2871.0,2988.0,2844.050048828125,2971.449951171875,2781.06396484375,1731193,0.0,0.0,19-05-2016,0
490,DRREDDY,Dr. Reddy's Laboratories Limited,dividend," that the board of directors of the company at its meeting held on may 12, 2016 have recommended a final dividend of rs.20/- (400%) per equity share of rs.5/- face value, for the financial year 2015-16.",12-May-2016 13:15:00,2016-05-12 13:15:00,-,-,https://nsearchives.nseindia.com/corporate/DREDDY_12052016131505.zip,12-05-2016,2871.0,2988.0,2844.050048828125,2971.449951171875,2781.06396484375,1731193,0.0,0.0,19-05-2016,0
491,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates," the standalone & consolidated financial results along with the auditors report for the period ended march 31, 2016.",12-May-2016 13:14:15,2016-05-12 13:14:15,-,-,https://nsearchives.nseindia.com/corporate/Q4andFY16_12052016131415.zip,12-05-2016,2871.0,2988.0,2844.050048828125,2971.449951171875,2781.06396484375,1731193,0.0,0.0,19-05-2016,0
492,DRREDDY,Dr. Reddy's Laboratories Limited,appointment of director," that  mr. bharat doshi as has been appointed as an additional independent director on the board of the company effective may 11, 2016.",11-May-2016 15:02:00,2016-05-11 15:02:00,-,-,https://nsearchives.nseindia.com/corporate/IntimationofBharatDoshiappointment_11052016150236_827.zip,11-05-2016,2913.60009765625,2913.60009765625,2855.050048828125,2868.699951171875,2684.8974609375,363176,0.0,0.0,18-05-2016,1
493,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 26, 2016, titled ""dr. reddy's to release q4 and full year fy16 results on may 12, 2016 //earnings call slated for may 12, 6.30 pm ist / 9.00 am edt"".",26-Apr-2016 16:59:00,2016-04-26 16:59:00,-,-,https://nsearchives.nseindia.com/corporate/26042016_26042016165937_474.zip,26-04-2016,3117.0,3134.85009765625,3100.5,3120.25,2920.330322265625,177384,0.0,0.0,03-05-2016,-1
494,DRREDDY,Dr. Reddy's Laboratories Limited,trading window," that, the trading window for dealing in equity shares of the company will remain closed from april 25, 2016 till may 14, 2016 (both days inclusive).",25-Apr-2016 07:56:00,2016-04-25 07:56:00,-,-,https://nsearchives.nseindia.com/corporate/Tradingwindow_25042016075607_666.zip,25-04-2016,3158.449951171875,3168.89990234375,3097.550048828125,3116.14990234375,2916.49267578125,180448,0.0,0.0,02-05-2016,0
495,DRREDDY,Dr. Reddy's Laboratories Limited,disc. under reg.30 of sebi (sast) reg.2011,"satish reddy has submitted to the exchange vide letter dated april 11, 2016 a copy of disclosure under regulation 30(1) and 30(2) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",18-Apr-2016 09:23:00,2016-04-18 09:23:00,-,-,https://nsearchives.nseindia.com/corporate/Dr_30_18042016092339.zip,18-04-2016,3104.0,3109.0,3021.89990234375,3091.050048828125,2893.001220703125,452004,0.0,0.0,26-04-2016,0
496,DRREDDY,Dr. Reddy's Laboratories Limited,public announcement - buyback of shares," regarding the public announcement made in relation to the buyback of equity shares by dr. reddy's laboratories limited (the ""company"") from the bse limited (""bse"") and the national stock exchange of india limited (""nse"" and together with the bse, the ""stock exchanges""), pursuant to the provisions of regulation 15(c) and 15(d) of, and in compliance with, the securities and exchange board of india (buy back of securities) regulations, 1998 (including any statutory modification(s), or re-enactment for the time being in force) (""buyback regulations"").",12-Apr-2016 08:53:00,2016-04-12 08:53:00,-,-,https://nsearchives.nseindia.com/corporate/PAbuybackfullAd_12042016085308_700.zip,12-04-2016,3050.0,3098.0,3050.0,3082.75,2885.232666015625,287065,0.0,0.0,22-04-2016,0
497,DRREDDY,Dr. Reddy's Laboratories Limited,buyback," regarding a copy of the special resolution passed by the members of the company through postal ballot conducted as per section 110 of the companies act, 2013 and the corresponding rules thereunder.",07-Apr-2016 19:22:00,2016-04-07 19:22:00,-,-,https://nsearchives.nseindia.com/corporate/BSENSEPBResolution_07042016192225_645.zip,07-04-2016,3005.0,3075.0,3005.0,3035.75,2841.244140625,358564,0.0,0.0,18-04-2016,0
498,DRREDDY,Dr. Reddy's Laboratories Limited,"regulation 44(3) of sebi (lodr), reg., 2015"," regarding the details of voting results of postal ballot along with scrutinizer's reports pursuant to regulation 44 (3) of sebi (listing obligation and disclosure requirement) regulation, 2015 .",04-Apr-2016 08:05:00,2016-04-04 08:05:00,-,-,https://nsearchives.nseindia.com/corporate/PBResults02042016_04042016080520_107.zip,04-04-2016,3008.0,3044.300048828125,2997.0,3011.75,2818.781982421875,306428,0.0,0.0,11-04-2016,0
499,DRREDDY,Dr. Reddy's Laboratories Limited,press release," that regarding a press release dated march 31, 2016 titled "" dr. reddy s laboratories acquires the rights to investigational anticancer agent e7777 for u.s, europe and certain emerging markets from eisai"".",31-Mar-2016 11:52:00,2016-03-31 11:52:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease31032016_31032016115230_992.zip,31-03-2016,3022.0,3063.0,3003.5,3035.199951171875,2840.7294921875,662246,0.0,0.0,07-04-2016,0
500,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 28, 2016, titled ""dr. reddy's laboratories and xenoport enter into a u.s. licensing agreement for xp23829"".",28-Mar-2016 09:59:00,2016-03-28 09:59:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease28032016_28032016095944_298.zip,28-03-2016,3038.0,3074.550048828125,3014.10009765625,3035.64990234375,2841.150634765625,380473,0.0,0.0,04-04-2016,0
501,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 11, 2016 titled ""dr. reddy's and tr-pharm announce strategic collaboration in turkey "".",11-Mar-2016 11:07:00,2016-03-11 11:07:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease11032016_11032016110735_235.zip,11-03-2016,3180.0,3222.199951171875,3178.0,3210.85009765625,3005.1259765625,308167,0.0,0.0,18-03-2016,0
502,DRREDDY,Dr. Reddy's Laboratories Limited,postal ballot updates," a copy of the postal ballot notice, pursuant to section 110 of the companies act, 2013.",01-Mar-2016 14:47:00,2016-03-01 14:47:00,-,-,https://nsearchives.nseindia.com/corporate/PBNoticedespatch_01032016144718_793.zip,01-03-2016,3040.0,3049.449951171875,3000.0,3024.550048828125,2830.761962890625,319452,0.0,0.0,09-03-2016,1
503,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 17, 2016 titled ""dr. reddy's laboratories limited's (""company"") board approves the proposal for buyback of its equity shares"".",17-Feb-2016 14:55:00,2016-02-17 14:55:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease17022016_17022016145559_475.zip,17-02-2016,2879.10009765625,2989.0,2879.10009765625,2960.699951171875,2771.002197265625,727660,0.0,0.0,24-02-2016,0
504,DRREDDY,Dr. Reddy's Laboratories Limited,updates," the form 6k for the quarter and nine months ended december 31, 2015.",10-Feb-2016 20:16:00,2016-02-10 20:16:00,-,-,https://nsearchives.nseindia.com/corporate/Form6Knoticetoexchanges_10022016201634_021.zip,10-02-2016,2900.0,2937.64990234375,2825.0,2885.050048828125,2700.199951171875,639905,0.0,0.0,17-02-2016,0
505,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 09, 2016, titled "" dr.reddy's q3 and 9m fy16 financial results"".",09-Feb-2016 13:22:00,2016-02-09 13:22:00,-,-,https://nsearchives.nseindia.com/corporate/DReddy_pr_09022016132251.zip,09-02-2016,3058.0,3115.0,2948.0,2959.60009765625,2769.97314453125,1121969,0.0,0.0,16-02-2016,0
506,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates," the standalone & consolidated financial results along with the limited review report for the period ended december 31, 2015.",09-Feb-2016 13:20:03,2016-02-09 13:20:03,-,-,https://nsearchives.nseindia.com/corporate/Q3FY16results_09022016132003.zip,09-02-2016,3058.0,3115.0,2948.0,2959.60009765625,2769.97314453125,1121969,0.0,0.0,16-02-2016,0
507,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 08, 2016 titled ""promius pharma receives fda approval for sernivo (betamethasone dipropionate) spray, 0.05%"".",08-Feb-2016 09:12:00,2016-02-08 09:12:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease08022016_08022016091238_034.zip,08-02-2016,3099.0,3124.0,3032.0,3070.35009765625,2873.62744140625,340587,0.0,0.0,15-02-2016,-1
508,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 01, 2016, titled ""dr. reddy's laboratories receives usfda tentative approval for zenavodtm (doxycycline) capsules, 40 mg for the treatment of rosacea in adults"".",01-Feb-2016 12:41:00,2016-02-01 12:41:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease01022016_01022016124139_142.zip,01-02-2016,3085.0,3138.0,3041.25,3050.5,2855.049560546875,565741,0.0,0.0,08-02-2016,0
509,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 29, 2016 titled ""dr. reddy's laboratories ltd. receives fda approval for zembracetmsymtouchtm (sumatriptan succinate) injection for the acute treatment of migraines in adults"".",29-Jan-2016 13:44:00,2016-01-29 13:44:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease29012016_29012016134456_183.zip,29-01-2016,2997.949951171875,3119.949951171875,2971.0,3105.39990234375,2906.431640625,869984,0.0,0.0,05-02-2016,0
510,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 30, 2015 titled "" dr. reddy's announces the relaunch of esomeprazole magnesium delayed-release capsules, usp"" .",30-Dec-2015 12:03:00,2015-12-30 12:03:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease30122015_30122015120341.zip,30-12-2015,3111.0,3172.0,3111.0,3121.14990234375,2921.17236328125,633284,0.0,0.0,06-01-2016,0
511,DRREDDY,Dr. Reddy's Laboratories Limited,updates, that the company has formulated a policy on determination of materiality. the said policy can be viewed at our website www.drreddys.com. further the contact details of the persons authorised for determining the materiality of any event or information.,23-Dec-2015 18:04:00,2015-12-23 18:04:00,-,-,https://nsearchives.nseindia.com/corporate/23122015_23122015180434.zip,23-12-2015,3015.0,3031.25,3010.14990234375,3024.60009765625,2830.808837890625,172714,0.0,0.0,31-12-2015,0
512,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 18, 2015, titled ""dr. reddy's promotes access to community health in vizianagaram district"".",18-Dec-2015 19:03:00,2015-12-18 19:03:00,-,-,"https://nsearchives.nseindia.com/corporate/Press_Release_Dec_18,_2015_18122015190307.zip",18-12-2015,3005.0,3008.25,2969.800048828125,2974.199951171875,2783.637939453125,438497,0.0,0.0,28-12-2015,0
513,DRREDDY,Dr. Reddy's Laboratories Limited,updates," that the company has submitted response to the usfda on december 7, 2015.",08-Dec-2015 18:35:00,2015-12-08 18:35:00,-,-,https://nsearchives.nseindia.com/corporate/Update08122015_08122015183550.zip,08-12-2015,3148.800048828125,3152.89990234375,3043.0,3063.199951171875,2866.93603515625,878625,0.0,0.0,15-12-2015,0
514,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 07, 2015, titled ""dr. reddy s signs mou with life sciences sector skill development council and vishnu institute of pharmaceutical education and research to strengthen the skilled labour pool in the life science industry"".",07-Dec-2015 11:27:00,2015-12-07 11:27:00,-,-,https://nsearchives.nseindia.com/corporate/DREDDY_07122015112705.zip,07-12-2015,3202.949951171875,3205.300048828125,3152.35009765625,3179.89990234375,2976.158203125,346625,0.0,0.0,14-12-2015,-1
515,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," that the nomination, governance & compensation committee of the board of directors of the company has allotted 19,138 equity shares of rs. 5/ - each of the company, fully paid up, on december 4, 2015, to employees on exercise of their stock options as per the following details.a) 18,958 equity shares of rs. 5/- each pursuant to dr. reddy's employees stock option scheme, 2002.b) 180 equity shares of rs. 5/- each underlying 180 adrs pursuant to dr. reddy's employees adr stock option scheme, 2007.",04-Dec-2015 13:25:00,2015-12-04 13:25:00,-,-,"https://nsearchives.nseindia.com/corporate/Stock_Exch_letter_Dec_4,_2015_04122015132558.zip",04-12-2015,3194.199951171875,3216.300048828125,3180.0,3195.5,2990.7587890625,325868,0.0,0.0,11-12-2015,-1
516,DRREDDY,Dr. Reddy's Laboratories Limited,news verification,"the exchange has sought clarification from dr. reddy's laboratories limited with respect to recent news item captioned ""usfda note: dr reddy's did not have data protection system"". the exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. dr. reddy's laboratories limited has submitted their response.",26-Nov-2015 16:04:00,2015-11-26 16:04:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_149_News_Verification_26112015_105602_reply_26112015160425.zip,26-11-2015,3150.0,3199.89990234375,3081.0,3100.75,2902.07958984375,2741563,0.0,0.0,03-12-2015,0
517,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 26, 2015, titled ""update on usfda warning letter"".",26-Nov-2015 14:31:00,2015-11-26 14:31:00,-,-,https://nsearchives.nseindia.com/corporate/Drreedy_PR_26112015143123.zip,26-11-2015,3150.0,3199.89990234375,3081.0,3100.75,2902.07958984375,2741563,0.0,0.0,03-12-2015,0
518,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 18, 2015 titled ""dr. reddy's announces the completion of fondaparinux intellectual property purchase"".",18-Nov-2015 08:53:00,2015-11-18 08:53:00,-,-,"https://nsearchives.nseindia.com/corporate/Press_Release_November_18,_2015_18112015085353.zip",18-11-2015,3423.0,3434.0,3360.0,3366.949951171875,3151.22412109375,743528,0.0,0.0,26-11-2015,-1
519,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 10, 2015 titled ""statement from dr. reddy's regarding the receipt of temporary restraining order (tro) for esomeprazole capsules""",10-Nov-2015 15:20:00,2015-11-10 15:20:00,-,-,https://nsearchives.nseindia.com/corporate/Statement_from_Dr_10112015152040.zip,10-11-2015,3498.0,3498.0,3300.0,3330.699951171875,3117.296630859375,1893661,0.0,0.0,19-11-2015,0
520,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 06, 2015 titled ""dr. reddy s statement on the receipt of warning letter from us fda"".",06-Nov-2015 10:12:00,2015-11-06 10:12:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease06112015_06112015101250.zip,06-11-2015,4258.0,4292.0,3615.0,3630.64990234375,3398.028076171875,4015493,0.0,0.0,17-11-2015,-1
521,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 04, 2015 titled ""biocodex inks distribution pact with dr. reddy's to market its flagship products in romania'' .",04-Nov-2015 11:36:00,2015-11-04 11:36:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease04112015_04112015113619.zip,04-11-2015,4340.10009765625,4379.2001953125,4310.0,4322.89990234375,4045.92431640625,286491,0.0,0.0,13-11-2015,-1
522,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 02, 2015 titled ""dr. reddy's strengthens otc portfolio-launches nise d spray"".",02-Nov-2015 11:15:00,2015-11-02 11:15:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease02112015_02112015111553.zip,02-11-2015,4253.0,4315.14990234375,4233.2001953125,4296.2998046875,4021.028076171875,447520,0.0,0.0,09-11-2015,-1
523,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 29, 2015 titled ""dr. reddy's q2 and h1 fy16 financial results"".",29-Oct-2015 16:17:00,2015-10-29 16:17:00,-,-,https://nsearchives.nseindia.com/corporate/DREDDY_Pressrelease_29102015161754.zip,29-10-2015,4114.9501953125,4240.0,4083.199951171875,4221.35009765625,3950.880859375,1215125,0.0,0.0,05-11-2015,0
524,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates, the standalone financial results along with the limited review report for the period ended 30-sep-2015.,29-Oct-2015 16:11:07,2015-10-29 16:11:07,-,-,https://nsearchives.nseindia.com/corporate/DREDDY_29102015161107.zip,29-10-2015,4114.9501953125,4240.0,4083.199951171875,4221.35009765625,3950.880859375,1215125,0.0,0.0,05-11-2015,0
525,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation," a copy of disclosure pursuant to regulation 7(2) read with regulation 6(2) of the sebi (prohibition of insider trading) regulations, 2015.",30-Sep-2015 19:41:00,2015-09-30 19:41:00,-,-,https://nsearchives.nseindia.com/corporate/FormC30092015_30092015194103_471.zip,30-09-2015,4088.0,4195.0,4080.0,4162.35009765625,3895.6611328125,549384,0.0,0.0,08-10-2015,0
526,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 28, 2015 titled ""dr. reddy's announces the launch of esomeprazole magnesium delayed-release capsules usp, 20 mg and 40 mg"".",28-Sep-2015 10:02:00,2015-09-28 10:02:00,-,-,https://nsearchives.nseindia.com/corporate/Press_Release_28092015_28092015100237.zip,28-09-2015,3992.0,4226.89990234375,3970.0,4191.25,3922.709716796875,914204,0.0,0.0,06-10-2015,0
527,DRREDDY,Dr. Reddy's Laboratories Limited,postal ballot updates, a copy of the scrutinizer's report along with the results (through e-voting and postal ballot) of the postal ballot process are enclosed herewith.,21-Sep-2015 08:11:00,2015-09-21 08:11:00,-,-,https://nsearchives.nseindia.com/corporate/Postalballotresults_21092015081131_125.zip,21-09-2015,3999.300048828125,3999.300048828125,3941.0,3957.300048828125,3703.74951171875,211844,0.0,0.0,29-09-2015,0
528,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 14, 2015, titled""dr. reddy s laboratories signs commercialization deal with hatchtech"".",14-Sep-2015 09:58:00,2015-09-14 09:58:00,-,-,https://nsearchives.nseindia.com/corporate/drreddy_14092015095853.zip,14-09-2015,4021.5,4050.0,3977.0,4042.699951171875,3783.677490234375,413912,0.0,0.0,22-09-2015,0
529,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 9, 2015 titled ""pantheryx and dr. reddy's announce an agreement to market pantheryx's proprietary nutritional intervention for pediatric infectious diarrhea"".",09-Sep-2015 20:08:00,2015-09-09 20:08:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_press_09092015200808.zip,09-09-2015,4060.0,4076.949951171875,3956.699951171875,4041.050048828125,3782.133544921875,733624,0.0,0.0,16-09-2015,0
530,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 04, 2015, titled ""dr. reddy s launches mintop pro tm procapiltm hair therapy""",04-Sep-2015 16:47:00,2015-09-04 16:47:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_press_01_04092015164735.zip,04-09-2015,4200.0,4200.0,4025.0,4052.85009765625,3793.17724609375,365814,0.0,0.0,11-09-2015,0
531,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," that the nomination, governance & compensation committee of the board of directors of the company has allotted 30,593 equity shares of rs.5/ - each of the company, fully paid up, on september 2, 2015, to employees on exercise of their stock options as per the following details .a) 24,409 equity shares of rs. 5/- each pursuant to dr. reddy's employees stock option scheme, 2002.b) 6,184 equity shares of rs. 5/- each underlying 6,184 adrs pursuant to dr. reddy's employees adr stock option scheme, 2007.",02-Sep-2015 13:33:00,2015-09-02 13:33:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_esop_02092015133333.zip,02-09-2015,4249.89990234375,4282.5,4177.2998046875,4200.14990234375,3931.039306640625,335510,0.0,0.0,09-09-2015,0
532,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 27, 2015 titled ""dr. reddy's announces management changes.""",27-Aug-2015 18:03:00,2015-08-27 18:03:00,-,-,https://nsearchives.nseindia.com/corporate/Dr_press_27082015180305.zip,27-08-2015,4122.0,4194.0,4085.39990234375,4130.10009765625,3865.477783203125,647940,0.0,0.0,03-09-2015,0
533,DRREDDY,Dr. Reddy's Laboratories Limited,news clarification," a clarification on media report captioned ""drl recalls dementia capsules in us"". the company has clarified that ""the company have recalled one batch of usp 1.5mg rivastigmine tartarate capsule from us market. this is a batch specific voluntary recall in conformance with our quality assurance norms practiced. the business impact from this will not be substantial"".",24-Aug-2015 11:16:00,2015-08-24 11:16:00,-,-,https://nsearchives.nseindia.com/corporate/DREDDY_newsclarification_24082015111607.zip,24-08-2015,4150.0,4198.5498046875,4024.199951171875,4043.25,3784.1923828125,401477,0.0,0.0,31-08-2015,1
534,DRREDDY,Dr. Reddy's Laboratories Limited,postal ballot updates," a copy of notice of postal ballot pursuant to section 110 of the companies act, 2013 along with postal ballot form.",18-Aug-2015 16:41:00,2015-08-18 16:41:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_cover.zip,18-08-2015,4204.5,4224.0,4159.14990234375,4191.35009765625,3922.802734375,420177,0.0,0.0,25-08-2015,0
535,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 12, 2015 titled ""dr. reddy s announces the launch of pramipexole dihydrochloride extended-release tablets.""",12-Aug-2015 17:49:00,2015-08-12 17:49:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease12082015_12082015174910_541.zip,12-08-2015,4228.2001953125,4285.85009765625,4204.0,4275.0,4001.093017578125,286074,0.0,0.0,19-08-2015,0
536,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 6, 2015 titled ""dr. reddy s announces strategic collaboration with amgen in india"".",06-Aug-2015 10:03:00,2015-08-06 10:03:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_press_06082015100324.zip,06-08-2015,4222.0,4326.5,4222.0,4266.60009765625,3993.232177734375,465617,0.0,0.0,13-08-2015,0
537,DRREDDY,Dr. Reddy's Laboratories Limited,press release (revised)," regarding a revised press release dated july 30, 2015 titled ""dr. reddy's q1 fy16 financial results"".",30-Jul-2015 19:38:00,2015-07-30 19:38:00,-,-,https://nsearchives.nseindia.com/corporate/drreddy__30072015193811.zip,30-07-2015,3739.0,3934.0,3721.0,3913.10009765625,3662.381591796875,1330017,0.0,0.0,06-08-2015,1
538,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 30, 2015 titled "" dr. reddy q1 fy 16 financial results "".",30-Jul-2015 13:55:00,2015-07-30 13:55:00,-,-,https://nsearchives.nseindia.com/corporate/drreddy_30072015135503.zip,30-07-2015,3739.0,3934.0,3721.0,3913.10009765625,3662.381591796875,1330017,0.0,0.0,06-08-2015,1
539,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates, the standalone & consolidated financial results along with the limited review report for the period ended 30-jun-2015.,30-Jul-2015 13:51:56,2015-07-30 13:51:56,-,-,https://nsearchives.nseindia.com/corporate/DR_30072015135156.zip,30-07-2015,3739.0,3934.0,3721.0,3913.10009765625,3662.381591796875,1330017,0.0,0.0,06-08-2015,1
540,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 13, 2015, titled ""dr. reddy's announces the launch of memantine hydrochloride tablets, usp"".",13-Jul-2015 15:39:00,2015-07-13 15:39:00,-,-,https://nsearchives.nseindia.com/corporate/drreddy_pr_13072015153934.zip,13-07-2015,3750.699951171875,3790.0,3701.0,3758.14990234375,3517.359130859375,193021,0.0,0.0,20-07-2015,0
541,DRREDDY,Dr. Reddy's Laboratories Limited,annual general meeting updates, a copy of the newspaper advertisement regarding notice of annual general meeting and e-voting information.,08-Jul-2015 19:10:00,2015-07-08 19:10:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_Agm_08072015191045.zip,08-07-2015,3728.60009765625,3770.35009765625,3705.0,3720.85009765625,3463.786376953125,338025,0.0,0.0,15-07-2015,0
542,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 01, 2015 titled ""dr. reddy's unveils new corporate brand identity"".",01-Jul-2015 17:11:00,2015-07-01 17:11:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease01072015_07012015171101_1.zip,01-07-2015,3548.0,3608.10009765625,3535.39990234375,3573.60009765625,3326.709716796875,262688,0.0,0.0,08-07-2015,0
543,DRREDDY,Dr. Reddy's Laboratories Limited,news clarification," vide letter dated june 30, 2015 regarding clarification on media report.",30-Jun-2015 18:28:00,2015-06-30 18:28:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_06302015182802_1.zip,30-06-2015,3497.0,3565.0,3453.199951171875,3559.449951171875,3313.537353515625,395298,0.0,0.0,07-07-2015,1
544,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," that the nomination, governance & compensation committee of the board of directors of the company has allotted 63,862 equity shares of rs.5/- each of the company, fully paid up, on june 23, 2015, to employees on exercise of their stock options.",24-Jun-2015 12:41:00,2015-06-24 12:41:00,-,-,https://nsearchives.nseindia.com/corporate/AllotmentIntimation_06242015124102_1.zip,24-06-2015,3443.35009765625,3475.0,3421.14990234375,3434.550048828125,3197.2666015625,273833,0.0,0.0,01-07-2015,0
545,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated june 19, 2015, titled ""dr. reddy s launches hairootz in india - its first otc hair growth supplement"".",22-Jun-2015 08:20:00,2015-06-22 08:20:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_06222015082002_1.zip,22-06-2015,3401.0,3430.0,3400.0,3425.89990234375,3189.213623046875,207202,0.0,0.0,29-06-2015,0
546,DRREDDY,Dr. Reddy's Laboratories Limited,updates," vide letter dated june 19, 2015 that this is in reference to company's earlier communication dated april 1, 2015 with regard to acquisition of select portfolio of the established products business of ucb in india. in this regard, the company has now inform that the company has concluded the transaction"".",19-Jun-2015 11:57:00,2015-06-19 11:57:00,-,-,https://nsearchives.nseindia.com/corporate/DREDDY_01_06192015115701_1.zip,19-06-2015,3391.050048828125,3426.699951171875,3374.39990234375,3384.75,3150.90673828125,353245,0.0,0.0,26-06-2015,0
547,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding the press released dated june 18, 2015, titled, ""dr. reddy's laboratories limited announces filing of annual report on form 20-f.""",18-Jun-2015 10:58:00,2015-06-18 10:58:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease18062015_06182015105801_1.zip,18-06-2015,3374.800048828125,3413.699951171875,3356.64990234375,3377.449951171875,3144.11083984375,431976,0.0,0.0,25-06-2015,0
548,DRREDDY,Dr. Reddy's Laboratories Limited,"code of conduct under sebi(pit) reg., 2015"," that the company has formulated the following codes under the securities and exchange board of india (prohibition of insider trading) regulations, 2015:  a) code of practices and procedures for fair disclosure of un-published price sensitive information. published on the company 's official website www.drreddys.com.  b) code of conduct to regulate, monitor and report insider trading. ",10-Jun-2015 12:45:00,2015-06-10 12:45:00,-,-,https://nsearchives.nseindia.com/corporate/dr_100620150001_06102015124502_1.zip,10-06-2015,3324.89990234375,3379.64990234375,3324.89990234375,3366.60009765625,3134.01025390625,177338,0.0,0.0,17-06-2015,0
549,DRREDDY,Dr. Reddy's Laboratories Limited,agm/book closure," that the register of members & share transfer books of the company will remain closed from july 14, 2015 to july 17, 2015 (both days inclusive) for the purpose of annual general meeting of the shareholders of the company and determining the shareholders who would be entitled for the payment of dividend, if declared at the forthcoming annual general meeting, scheduled to be held on july 31, 2015.",05-Jun-2015 19:56:00,2015-06-05 19:56:00,-,-,https://nsearchives.nseindia.com/corporate/drreeddyy_06052015195601_1.zip,05-06-2015,3430.0,3471.800048828125,3405.0,3415.60009765625,3179.62548828125,152444,0.0,0.0,12-06-2015,0
550,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," that the nomination, governance & compensation committee of the board of directors of the company has allotted 112,886 equity shares of rs.5/- each of the company, fully paid up, on june 04, 2015, to employees on exercise of their stock options.",05-Jun-2015 16:01:00,2015-06-05 16:01:00,-,-,https://nsearchives.nseindia.com/corporate/Allotmentintimation_06052015160101_1.zip,05-06-2015,3430.0,3471.800048828125,3405.0,3415.60009765625,3179.62548828125,152444,0.0,0.0,12-06-2015,0
551,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," that the nomination, governance & compensation committee of the board of directors of the company has allotted 112,886 equity shares of rs. 5/ - each of the company , fully paid up, on june 4, 2015, to employees on exercise of their stock options as per the following details .  a) 95,948 equity shares of rs. 5/- each pursuant to dr. reddy's employees stock option scheme, 2002 .  b) 16,938 equity shares of rs. 5/- each underlying 16,938 adrs pursuant to dr. reddy's employees adr stock option scheme, 2007. ",05-Jun-2015 15:54:00,2015-06-05 15:54:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_allot_06052015155401_2.zip,05-06-2015,3430.0,3471.800048828125,3405.0,3415.60009765625,3179.62548828125,152444,0.0,0.0,12-06-2015,0
552,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"dr. reddy's holdings ltd has submitted to the exchange vide letter dated june 01, 2015 a copy of disclosure under regulation 29(2) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",02-Jun-2015 13:08:00,2015-06-02 13:08:00,-,-,https://nsearchives.nseindia.com/corporate/drreddya_290001_06022015130801_1.zip,02-06-2015,3525.0,3531.10009765625,3465.0,3473.75,3233.75830078125,172239,0.0,0.0,09-06-2015,0
553,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 29, 2015 ""dr reddy's laboratories limited and astrazeneca pharma india limited entered into a distribution agreement for saxagliptin and its fixed dose combination with metformin, in type 2 diabetes"".",29-May-2015 18:52:00,2015-05-29 18:52:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease29052015_05292015185201_1.zip,29-05-2015,3565.0,3573.050048828125,3490.0,3535.25,3291.00927734375,758340,0.0,0.0,05-06-2015,0
554,DRREDDY,Dr. Reddy's Laboratories Limited,esops/esos/esps," that with reference to letter dated may 20, 2015 informing about grant of stock options by the company, that a grant of 1,600 option was erroneously included under ""dr. reddy's employees stock option scheme, 2002"" instead of being included under ""dr. reddy's employees adr stock option scheme, 2007"".  accordingly, the corrected grants to be read as-  102,224 stock options, exercisable at par value of rs. 5/- under ""dr. reddy's employees stock option scheme, 2002"" and 40,184 stock options, exercisable at par value of rs. 5/ under ""dr. reddy's employees adr stock option scheme, 2007"".  the total grant of 142,408 stock options and other terms and conditions of such grant remains the same.",22-May-2015 19:40:00,2015-05-22 19:40:00,-,-,https://nsearchives.nseindia.com/corporate/drreddy_05222015194001_1.zip,22-05-2015,3620.10009765625,3660.0,3595.0,3642.64990234375,3390.989013671875,205401,0.0,0.0,29-05-2015,0
555,DRREDDY,Dr. Reddy's Laboratories Limited,esops/esos/esps," that the nomination, governance and compensation committee of the board of directors of the company on may 11, 2015, has granted 103,824 stock options, exercisable at par value of rs. 5/- under ""dr. reddy's employees stock option scheme, 2002"" and 38,584 stock options, exercisable at par value of rs. 5/- under ""dr. reddy's employees adr stock option scheme, 2007"" to the employees of the company.",20-May-2015 19:23:00,2015-05-20 19:23:00,-,-,https://nsearchives.nseindia.com/corporate/Stockexchangeintimation_05202015192302_2.zip,20-05-2015,3636.0,3682.0,3596.0,3608.75,3359.430908203125,244898,0.0,0.0,27-05-2015,0
556,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 15, 2015 titled ""dr. reddy's launches somazina for stroke patients in india"".",15-May-2015 16:35:00,2015-05-15 16:35:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease15052015_05152015163502_1.zip,15-05-2015,3517.0,3517.0,3470.0,3496.449951171875,3254.889892578125,195407,0.0,0.0,22-05-2015,0
557,DRREDDY,Dr. Reddy's Laboratories Limited,updates," that the company is holding an investor day on may 18, 2015, monday at hyderabad (india) for institutional investors and analysts to discuss its r&d strategy, investments and road-map for future.    the presentation and transcript would be uploaded on our website, post event",15-May-2015 08:49:00,2015-05-15 08:49:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_update_05152015084902_1.zip,15-05-2015,3517.0,3517.0,3470.0,3496.449951171875,3254.889892578125,195407,0.0,0.0,22-05-2015,0
558,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 12, 2015 titled ""dr. reddy's q4 & fy15 financial results"".",12-May-2015 13:30:00,2015-05-12 13:30:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_press_05122015133002_1.zip,12-05-2015,3391.0,3496.699951171875,3362.85009765625,3468.89990234375,3229.24267578125,1270952,0.0,0.0,19-05-2015,0
559,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates,"dr. reddy's laboratories limited,  the standalone financial results along with the auditors report for the period ended 31-mar-2015.",12-May-2015 13:27:02,2015-05-12 13:27:02,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY-resuylts_05122015132701_.zip,12-05-2015,3391.0,3496.699951171875,3362.85009765625,3468.89990234375,3229.24267578125,1270952,0.0,0.0,19-05-2015,0
560,DRREDDY,Dr. Reddy's Laboratories Limited,disc. under reg.30 of sebi (sast) reg.2011,"satish reddy has submitted to the exchange vide letter dated april 08, 2015 a copy of disclosure under regulation 30(1) and 30(2) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",17-Apr-2015 17:48:00,2015-04-17 17:48:00,-,-,https://nsearchives.nseindia.com/corporate/drreddys_satish_04172015174802_1.zip,17-04-2015,3665.39990234375,3700.0,3620.0,3647.14990234375,3395.178466796875,258444,0.0,0.0,24-04-2015,0
561,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 07, 2015 titled ""dr. reddy's laboratories and its subsidiary promius pharmatm announce the filing of three ndas with the usfda"".",07-Apr-2015 20:13:00,2015-04-07 20:13:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease07042015_04072015201301_1.zip,07-04-2015,3668.0,3704.949951171875,3645.199951171875,3684.85009765625,3430.273681640625,232946,0.0,0.0,15-04-2015,0
562,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding the press release dated april 01, 2015, titled ""dr. reddy's laboratories to acquire select portfolio of the established products business of ucb in india"".",01-Apr-2015 12:30:00,2015-04-01 12:30:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease01042015_04012015123002_1.zip,01-04-2015,3541.0,3566.800048828125,3501.699951171875,3533.64990234375,3289.519287109375,282785,0.0,0.0,10-04-2015,1
563,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 23, 2015, titled ""dr. reddy s laboratories enters into partnership with hetero to accelerate access to treatment for hepatitis c in india""..   ",23-Mar-2015 16:14:00,2015-03-23 16:14:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_Pr_03232015161401_1.zip,23-03-2015,3430.0,3469.85009765625,3428.5,3458.64990234375,3219.700927734375,189693,0.0,0.0,30-03-2015,0
564,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," that pursuant to dr reddy's employees stock option scheme, 2002, the nomination, governance & compensation committee of the board of director of the company has allotted 1,445 equity shares of rs 5/- each of the company, fully paid up, on march 20, 2015, to employees on exercise of their stock options.",20-Mar-2015 16:35:00,2015-03-20 16:35:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_03202015163502_1.zip,20-03-2015,3438.199951171875,3465.0,3371.5,3426.60009765625,3189.865478515625,307930,0.0,0.0,27-03-2015,0
565,DRREDDY,Dr. Reddy's Laboratories Limited,news clarification,"the exchange had sought clarification from dr. reddy's laboratories limited with respect to a news item captioned ""drl may buy belgian co s india ops for $135m"". the company has clarified that ""we do not comment on market speculations. any m&a transaction or similar other event, if material in nature, we will be communicated to the stock exchanges by the company, at an appropriate time whenever it becomes certain"". ",11-Mar-2015 16:03:00,2015-03-11 16:03:00,-,-,https://nsearchives.nseindia.com/corporate/NEWSCLARIFICATION_DRREADY_03112015160301_1.zip,11-03-2015,3458.85009765625,3531.949951171875,3368.050048828125,3468.0,3228.405029296875,309701,0.0,0.0,18-03-2015,0
566,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 29, 2015, titled ""dr. reddy's q3 and 9 months fy15 financial results"".",29-Jan-2015 13:20:00,2015-01-29 13:20:00,-,-,https://nsearchives.nseindia.com/corporate/dr_01292015132001_1.zip,29-01-2015,3234.0,3380.0,3210.35009765625,3363.300048828125,3130.938720703125,1401638,0.0,0.0,05-02-2015,-1
567,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates, the standalone financial results along with the limited review report for the period ended 31-dec-2014.,29-Jan-2015 13:11:02,2015-01-29 13:11:02,-,-,https://nsearchives.nseindia.com/corporate/DREDDYS_31Dec14_S_01292015131102_.zip,29-01-2015,3234.0,3380.0,3210.35009765625,3363.300048828125,3130.938720703125,1401638,0.0,0.0,05-02-2015,-1
568,DRREDDY,Dr. Reddy's Laboratories Limited,press release," vide letter dated january 22, 2015 regarding a press release dated january 21, 2015 titled ""curis and aurigene announce collaboration, license and option agreement to discover, develop and commercialize small molecule antagonists for immuno-oncology and precision oncology targets"".",22-Jan-2015 15:39:00,2015-01-22 15:39:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease22012015_01222015153902_1.zip,22-01-2015,3330.10009765625,3365.0,3330.10009765625,3361.25,3129.030029296875,245798,0.0,0.0,30-01-2015,0
569,DRREDDY,Dr. Reddy's Laboratories Limited,news clarification,"the exchange had sought clarification from dr. reddy's laboratories limited with respect to a news item captioned ""maharashtra suspends dr reddy's licenses"". in this regard, the company has clarified that :   ""the order relates only to the wholesale licence of the clearing and forwarding agent. in our opinion there has been no violation of any statute or regulation by the company and it has been in compliance. the product being investigated is not a drug and is neither manufactured nor marketed by us. an interim stay has been granted today by the high court for two weeks. dr. reddy's shall approach the state (minister) on january 12, 2015 as directed by the court.  this is not expected to be material to the company's operations or consolidated results and hence we did not see a stock exchange notification necessary"".",09-Jan-2015 17:27:00,2015-01-09 17:27:00,-,-,https://nsearchives.nseindia.com/corporate/1303_001_01092015172702_1.zip,09-01-2015,3095.0,3170.0,3091.199951171875,3163.800048828125,2945.221435546875,593638,0.0,0.0,16-01-2015,0
570,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," that the nomination, governance & compensation committee of the board of directors of the company has allotted 13,890 equity shares of rs.5/- each of the company, fully paid up, on january 1, 2015, to employees on exercise of their stock options as per the following details: a) 13,800 equity shares of rs. 5/- each pursuant to dr. reddy's employees stock option scheme, 2002. b) 90 equity shares of rs. 5/- each underlying 90 adrs pursuant to dr. reddy's employees adr stock option scheme, 2007.",02-Jan-2015 13:56:00,2015-01-02 13:56:00,-,-,https://nsearchives.nseindia.com/corporate/DREDDY_01_01022015135601_1.zip,02-01-2015,3220.0,3242.64990234375,3215.0,3221.39990234375,2998.842041015625,86014,0.0,0.0,09-01-2015,0
571,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 19, 2014, titled ""dr. reddy s laboratories closes the acquisition of habitrol brand from novartis"".",19-Dec-2014 10:46:00,2014-12-19 10:46:00,-,-,https://nsearchives.nseindia.com/corporate/DREDDY_PR_12192014104601_1.zip,19-12-2014,3180.0,3220.0,3165.10009765625,3199.449951171875,2978.40869140625,476395,0.0,0.0,29-12-2014,0
572,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 16, 2014  titled ""dr. reddy s announces the launch of valganciclovir tablets, usp"".",16-Dec-2014 11:46:00,2014-12-16 11:46:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_12162014114601_1.zip,16-12-2014,3311.64990234375,3327.85009765625,3119.89990234375,3142.35009765625,2925.25341796875,1037122,0.0,0.0,23-12-2014,0
573,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation," vide letter dated december 11, 2014 a copy of disclosures under regulations 13(4), 13(4a) & 13(6) of sebi (prohibition of insider trading) regulations, 1992.",12-Dec-2014 08:51:00,2014-12-12 08:51:00,-,-,https://nsearchives.nseindia.com/corporate/FormD11122014_12122014085101_1.zip,12-12-2014,3411.0,3428.949951171875,3360.5,3377.75,3144.390625,187779,0.0,0.0,19-12-2014,-1
574,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation,", vide letter dated december 5, 2014, a copy of the disclosure pursuant to regulation 13(4), 13(4a) and 13(6) of sebi (prohibition of insider trading) regulations, 1992.",05-Dec-2014 21:00:00,2014-12-05 21:00:00,-,-,https://nsearchives.nseindia.com/corporate/FormD05122014_12052014210003_1.zip,05-12-2014,3477.949951171875,3477.949951171875,3386.10009765625,3395.5,3160.913818359375,319587,0.0,0.0,12-12-2014,0
575,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation," vide letter dated december 1, 2014 a copy of disclosure under regulation 13(4), 13(4a) and 13(6) of sebi (prohibition of insider trading) regulation, 1992.",01-Dec-2014 17:09:00,2014-12-01 17:09:00,-,-,https://nsearchives.nseindia.com/corporate/FormD01122014_12012014170901_1.zip,01-12-2014,3602.0,3666.25,3602.0,3628.449951171875,3377.76953125,214232,0.0,0.0,08-12-2014,-1
576,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation," vide letter dated november 28, 2014 a copy of disclosure under regulation 13(4), 13(4a) and 13(6) of sebi (prohibition of insider trading) regulation, 1992.",28-Nov-2014 17:51:00,2014-11-28 17:51:00,-,-,https://nsearchives.nseindia.com/corporate/PrabhkaranNair_11282014175103_3.zip,28-11-2014,3619.89990234375,3638.800048828125,3594.300048828125,3606.25,3357.103759765625,235293,0.0,0.0,05-12-2014,-1
577,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation," vide letter dated november 27, 2014 a copy of disclosure under regulation 13(4), 13(4a) and 13(6) of sebi (prohibition of insider trading) regulation, 1992.",27-Nov-2014 20:26:00,2014-11-27 20:26:00,-,-,https://nsearchives.nseindia.com/corporate/FormD27112014_11272014202601_1.zip,27-11-2014,3565.0,3639.0,3532.10009765625,3610.89990234375,3361.432373046875,275314,0.0,0.0,04-12-2014,0
578,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation," vide letter dated november 24, 2014 a copy of disclosure under regulation 13(4), 13(4a) and 13(6) of sebi (prohibition of insider trading) regulation, 1992.",24-Nov-2014 17:54:00,2014-11-24 17:54:00,-,-,https://nsearchives.nseindia.com/corporate/FormD24112014_11242014175401_1.zip,24-11-2014,3520.0,3554.25,3505.050048828125,3522.0,3278.674560546875,183095,0.0,0.0,01-12-2014,0
579,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 24, 2014 titled ""dr. reddy's announces the launch of docetaxel injection usp"".",24-Nov-2014 11:26:00,2014-11-24 11:26:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease24112014_11242014112601_1.zip,24-11-2014,3520.0,3554.25,3505.050048828125,3522.0,3278.674560546875,183095,0.0,0.0,01-12-2014,0
580,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 20, 2014 titled ""dr. reddy's announces the launch of over-the-counter fexofenadine hydrochloride 60 mg and pseudoephedrine hydrochloride 120 mg extended - release tablets"".",20-Nov-2014 15:24:00,2014-11-20 15:24:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_Pr_11202014152402_2.zip,20-11-2014,3568.0,3569.60009765625,3513.300048828125,3528.64990234375,3284.864990234375,234826,0.0,0.0,27-11-2014,0
581,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation," vide letter dated november 14, 2014 a copy of disclosure under regulation 13(4), 13(4a) and 13(6) of sebi (prohibition of insider trading) regulation, 1992.",14-Nov-2014 18:28:00,2014-11-14 18:28:00,-,-,https://nsearchives.nseindia.com/corporate/FormD14112014_11142014182801_1.zip,14-11-2014,3478.0,3478.0,3405.5,3435.050048828125,3197.731689453125,192601,0.0,0.0,21-11-2014,0
582,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation,", vide letter dated november 11, 2014 copies of disclosures under regulation 13(4), 13(4a) and 13(6) of sebi (prohibition of insider trading) regulation, 1992.",11-Nov-2014 18:20:00,2014-11-11 18:20:00,-,-,https://nsearchives.nseindia.com/corporate/FormD11112014_11112014182002_2.zip,11-11-2014,3449.89990234375,3449.89990234375,3401.0,3418.35009765625,3182.185302734375,303678,0.0,0.0,18-11-2014,0
583,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates, the standalone financial results along with the limited review report for the period ended 30-sep-2014.,29-Oct-2014 12:19:02,2014-10-29 12:19:02,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_30Sep14_B_10292014121901_.zip,29-10-2014,3076.5,3120.0,2997.199951171875,3045.60009765625,2835.188232421875,692735,0.0,0.0,07-11-2014,1
584,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 29, 2014 , titled ""dr. reddy's q2 and h1 fy15 financial results""",29-Oct-2014 12:18:00,2014-10-29 12:18:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_10292014121801_1.zip,29-10-2014,3076.5,3120.0,2997.199951171875,3045.60009765625,2835.188232421875,692735,0.0,0.0,07-11-2014,1
585,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 28, 2014 , titled ""dr. reddy's announces the launch of sirolimus tablets, 1 mg and 2 mg""",28-Oct-2014 18:08:00,2014-10-28 18:08:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease28102014_10282014180802_1.zip,28-10-2014,3115.050048828125,3123.39990234375,3057.10009765625,3081.10009765625,2868.23486328125,200669,0.0,0.0,05-11-2014,1
586,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 28, 2014, titled "" dr. reddy's announces the launch of sirolimus tablets, 1 mg and 2 mg"".",28-Oct-2014 18:05:00,2014-10-28 18:05:00,-,-,https://nsearchives.nseindia.com/corporate/drReddi_10282014180501_1.zip,28-10-2014,3115.050048828125,3123.39990234375,3057.10009765625,3081.10009765625,2868.23486328125,200669,0.0,0.0,05-11-2014,1
587,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation,"dr. reddy's laboratories limited  has submitted to the exchange, vide letter dated october 8, 2014 a copy of disclosure pursuant to regulation 13(4), 13(4a) and 13(6) of sebi (prohibition of insider trading) regulations, 1992.",08-Oct-2014 18:56:00,2014-10-08 18:56:00,-,-,https://nsearchives.nseindia.com/corporate/FormD08102014_08102014185640.zip,08-10-2014,3115.0,3118.0,2950.0,2966.199951171875,2761.273193359375,439272,0.0,0.0,15-10-2014,0
588,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation,", vide letter dated october 1, 2014 a copy of disclosure pursuant to regulation 13(4), 13(4a) and 13(6) of sebi (prohibition of insider trading) regulations, 1992.",01-Oct-2014 14:52:00,2014-10-01 14:52:00,-,-,https://nsearchives.nseindia.com/corporate/FormD01102014_01102014145218.zip,01-10-2014,3254.0,3277.0,3194.0,3200.39990234375,2979.292724609375,319889,0.0,0.0,13-10-2014,-1
589,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation,", vide letter dated september 29, 2014 a copy of disclosure pursuant to regulation 13(4), 13(4a) and 13(6) of sebi (prohibition of insider trading) regulations, 1992.",29-Sep-2014 19:50:00,2014-09-29 19:50:00,-,-,https://nsearchives.nseindia.com/corporate/FormD29092014_29092014195046.zip,29-09-2014,3247.0,3277.89990234375,3199.0,3208.199951171875,2986.5537109375,322436,0.0,0.0,09-10-2014,-1
590,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation,", vide letter dated september 17, 2014 a copy of disclosure pursuant to regulation 13(4), 13(4a) and 13(6) of sebi (prohibition of insider trading) regulations, 1992.",17-Sep-2014 18:12:00,2014-09-17 18:12:00,-,-,https://nsearchives.nseindia.com/corporate/FormD_09172014181201_1.zip,17-09-2014,3020.14990234375,3096.0,3011.699951171875,3081.949951171875,2869.026123046875,403959,0.0,0.0,24-09-2014,0
591,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," that the nomination, governance & compensation committee of the board of directors of the company has allotted 30,800 equity shares of rs.5/- each of the company, fully paid up, on september 4, 2014, to employees on exercise of their stock options as per the following details. (a) 20,153 equity shares of rs. 5/- each pursuant to dr. reddy's employees stock option scheme, 2002. (b) 10,647 equity shares of rs. 5/- each underlying 10,647 adrs pursuant to dr. reddy's employees adr stock option scheme, 2007.",04-Sep-2014 17:52:00,2014-09-04 17:52:00,-,-,https://nsearchives.nseindia.com/corporate/ESOPAllotmentSep42014_09042014175202_1.zip,04-09-2014,2995.0,3009.699951171875,2974.449951171875,3001.300048828125,2793.947998046875,147927,0.0,0.0,11-09-2014,0
592,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure of voting pattern - clause 35a, outcome of annual general meeting & clause 35a of the listing agreement-voting results,01-Aug-2014 18:16:00,2014-08-01 18:16:00,-,-,https://nsearchives.nseindia.com/corporate/Outcomeof30thAGMandClause35AoftheListingAgreementVotingResults_08012014181601_1.zip,01-08-2014,2775.0,2799.0,2744.0,2758.800048828125,2568.201904296875,387616,0.0,0.0,08-08-2014,0
593,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 30, 2014 titled ""dr. reddy's q1 fy15 financial results"".",30-Jul-2014 14:04:00,2014-07-30 14:04:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_PR_07302014140401_1.zip,30-07-2014,2771.89990234375,2849.949951171875,2765.0,2823.14990234375,2628.10595703125,699705,0.0,0.0,06-08-2014,0
594,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates, the standalone financial results along with the limited review report for the period ended 30-jun-2014.,30-Jul-2014 14:03:02,2014-07-30 14:03:02,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_30June14_S.zip,30-07-2014,2771.89990234375,2849.949951171875,2765.0,2823.14990234375,2628.10595703125,699705,0.0,0.0,06-08-2014,0
595,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation,", vide letter dated july 22, 2014 a copy of disclosure pursuant to regulation 13(4), 13(4a) and 13(6) of the sebi (prohibition of insider trading) regulations, 1992.",25-Jul-2014 15:00:00,2014-07-25 15:00:00,-,-,https://nsearchives.nseindia.com/corporate/drreddys_25072014_25072014145807.zip,25-07-2014,2692.0,2771.75,2692.0,2744.0,2554.4248046875,430540,0.0,0.0,04-08-2014,0
596,DRREDDY,Dr. Reddy's Laboratories Limited,esops/esos/esps," that the nomination, governance & compensation committee of the board of directors of the company on july 14, 2014, has granted 500 stock options, exercisable at par value of rs.5/- under ""dr. reddy's employees stock option scheme, 2002"" and 1,000 stock options, exercisable at par value of rs.5/- under ""dr. reddy's employees adr stock option scheme, 2007"" to the employees of the company.",15-Jul-2014 12:04:00,2014-07-15 12:04:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_150720143_07152014120401_1.zip,15-07-2014,2697.800048828125,2700.0,2606.0,2638.85009765625,2456.538818359375,270072,0.0,0.0,22-07-2014,0
597,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated june 27, 2014 titled ""dr. reddy's announces the launch of duloxetine delayed-release capsules usp"".",27-Jun-2014 10:08:00,2014-06-27 10:08:00,-,-,https://nsearchives.nseindia.com/corporate/DREDDY_27062014_06272014100801_1.zip,27-06-2014,2510.0,2575.64990234375,2510.0,2552.949951171875,2360.4345703125,397883,0.0,0.0,04-07-2014,0
598,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated june 27, 2014, titled""dr. reddy's laboratories limited announces filing of annual report on form 20-f"".",27-Jun-2014 09:16:00,2014-06-27 09:16:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_06272014091602_1.zip,27-06-2014,2510.0,2575.64990234375,2510.0,2552.949951171875,2360.4345703125,397883,0.0,0.0,04-07-2014,0
599,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated june 25, 2014, titled ""dr. reddy's announces the launch of paricalcitol capsules"".",25-Jun-2014 11:28:00,2014-06-25 11:28:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_06252014112802_1.zip,25-06-2014,2465.0,2484.89990234375,2452.699951171875,2478.25,2291.36767578125,302167,0.0,0.0,02-07-2014,1
600,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," that the nomination, governance & compensation committee of the board of directors of the company has allotted 56,031 equity shares of rs.5/- each of the company, fully paid up, on june 23, 2014, to employees on exercise of their stock options as per the following details. (a) 50,803 equity shares of rs. 5/- each pursuant to dr. reddy's employees stock option scheme, 2002. (b) 5,228 equity shares of rs. 5/- each underlying 5,228 adrs pursuant to dr. reddy's employees adr stock option scheme, 2007.",24-Jun-2014 11:40:00,2014-06-24 11:40:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_06242014114002_1.zip,24-06-2014,2455.0,2470.0,2454.050048828125,2462.550048828125,2276.8515625,336058,0.0,0.0,01-07-2014,1
601,DRREDDY,Dr. Reddy's Laboratories Limited,esops/esos/esps," that the nomination, governance & compensation committee of the board of directors of the company vide a circular resolution passed on june 15, 2014 has granted 95,428 stock options, exercisable at par value of rs.5/- under ""dr. reddy's employees stock option scheme, 2002"" and 4,700 stock options, exercisable at par value of rs.5/- under ""dr. reddy's employees adr stock option scheme, 2007"" to the employees of the company.  the grant of above stock options is in line with sebi (employee stock option scheme and employee stock purchase scheme) guidelines, 1999, as amended and as per the terms of the stock option schemes.",16-Jun-2014 11:36:00,2014-06-16 11:36:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_06162014113602_2.zip,16-06-2014,2444.5,2466.0,2405.14990234375,2424.449951171875,2241.624755859375,438571,0.0,0.0,23-06-2014,0
602,DRREDDY,Dr. Reddy's Laboratories Limited,agm/book closure," that the register of members & share transfer books of the company will remain close from july 15, 2014 to july 18, 2014 (both days inclusive) for the purpose of payment of dividend & annual general meeting scheduled to be held on july 31, 2014.",03-Jun-2014 19:52:00,2014-06-03 19:52:00,-,-,https://nsearchives.nseindia.com/corporate/BookclosurenoticetoBSENSE_06032014195201_1.zip,03-06-2014,2402.199951171875,2415.0,2333.0,2337.449951171875,2161.185302734375,409282,0.0,0.0,10-06-2014,0
603,DRREDDY,Dr. Reddy's Laboratories Limited,esops/esos/esps," vide its letter dated may 26, 2014 regarding grant of stock options.",26-May-2014 13:08:00,2014-05-26 13:08:00,-,-,https://nsearchives.nseindia.com/corporate/GrantofStockOptions_05262014130801_1.zip,26-05-2014,2325.0,2329.85009765625,2286.199951171875,2300.10009765625,2126.65185546875,523950,0.0,0.0,02-06-2014,0
604,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 13, 2014 titled ""senior level changes at dr. reddy's"".",13-May-2014 14:04:00,2014-05-13 14:04:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_PR_13052014_05132014140402_1.zip,13-05-2014,2740.0,2740.550048828125,2600.75,2610.75,2413.876220703125,995503,0.0,0.0,20-05-2014,-1
605,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 13, 2014 titled ""dr. reddy's q4 & fy14 financial results"".",13-May-2014 13:56:00,2014-05-13 13:56:00,-,-,https://nsearchives.nseindia.com/corporate/DREDDY_Pr_05132014135602_1.zip,13-05-2014,2740.0,2740.550048828125,2600.75,2610.75,2413.876220703125,995503,0.0,0.0,20-05-2014,-1
606,DRREDDY,Dr. Reddy's Laboratories Limited,consolidated result updates - ifrs," a copy of audited consolidated financial results of the company and its subsidiaries for the quarter and year ended march 31, 2014 prepared in compliance with ifrs as issued by international accounting standards board (iasb).",13-May-2014 13:44:00,2014-05-13 13:44:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_13052014_05132014134401_1.zip,13-05-2014,2740.0,2740.550048828125,2600.75,2610.75,2413.876220703125,995503,0.0,0.0,20-05-2014,-1
607,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 23, 2014, titled, ""dr. reddy's announces the launch of fenofibrate capsules, usp 43 mg and 130 mg"".",23-Apr-2014 10:44:00,2014-04-23 10:44:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_23042014_04232014104403_2.zip,23-04-2014,2560.0,2584.14990234375,2555.10009765625,2565.89990234375,2372.408203125,650619,0.0,0.0,30-04-2014,1
608,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release april 16, 2014, titled, ""dr. reddy's announces the launch of eszopiclone tablets c-iv.""",16-Apr-2014 10:24:00,2014-04-16 10:24:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_16042014_04162014102401_1.zip,16-04-2014,2595.0,2599.0,2531.10009765625,2536.75,2345.456298828125,210345,0.0,0.0,24-04-2014,0
609,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 27, 2014, titled ""dr. reddy's announces the launch of amlodipine besylate and atorvastatin calcium tablets"".",27-Mar-2014 10:16:00,2014-03-27 10:16:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_27032014_03272014101602_1.zip,27-03-2014,2646.949951171875,2650.949951171875,2575.39990234375,2588.60009765625,2393.396240234375,687284,0.0,0.0,03-04-2014,0
610,DRREDDY,Dr. Reddy's Laboratories Limited,news clarification,"the exchange had sought clarification from dr. reddy's laboratories limited with respect to a news item captioned ""lawsuit filed against drl in us"". the company has clarified that ""dr. reddy's laboratories ltd. is one of a number of companies that have filed applications with the usfda requesting permission to sell generic versions of cephalon's treanda(r) (bendamustine hci) injection for treatment of leukemia. the company's anda includes paragraph iv certifications reflecting the fact that it seeks approval to market the products prior to expiration of certain patents owned by cephalon. on december 20, 2013, cephalon filed suit in the us district court for the district of delaware, alleging that the company's actions infringe its patents. this is in the ordinary course of business of the pharmaceutical industry"".",20-Mar-2014 15:08:00,2014-03-20 15:08:00,-,-,https://nsearchives.nseindia.com/corporate/Clarification_DrReddy_03202014150802_2.zip,20-03-2014,2801.14990234375,2811.0,2764.300048828125,2778.85009765625,2569.2998046875,580118,0.0,0.0,27-03-2014,-1
611,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding press release dated march 05, 2014 titled,""dr. reddy's announces the launch of moxifloxacin hydrochloride tablets.""",05-Mar-2014 10:48:00,2014-03-05 10:48:00,-,-,https://nsearchives.nseindia.com/corporate/launchofmoxifloaxcin_03052014104802_1.zip,05-03-2014,2825.0,2853.0,2779.550048828125,2786.89990234375,2576.74267578125,374714,0.0,0.0,12-03-2014,0
612,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding press release dated february 25, 2014 titled ""dr. reddy's announces the launch of sumatriptan injection usp, autoinjector system"".",25-Feb-2014 19:32:00,2014-02-25 19:32:00,-,-,https://nsearchives.nseindia.com/corporate/launchofsumatriptan_02252014193201_1.zip,25-02-2014,2795.64990234375,2800.64990234375,2762.0,2769.14990234375,2560.3310546875,245678,0.0,0.0,05-03-2014,0
613,DRREDDY,Dr. Reddy's Laboratories Limited,record date," that the company has fixed record date as february 21, 2014 for the purpose of ascertaining the debenture holder's entitlement to receive the third and final year's interest, at the rate of 9.25% per annum, on non-convertible debentures (ncds) of the company due for payment on march 24, 2014. the said interest on ncds will be credited/paid on march 24, 2014.",11-Feb-2014 17:16:00,2014-02-11 17:16:00,-,-,https://nsearchives.nseindia.com/corporate/RecordDateforRedemptionInterest_02112014171602_1.zip,11-02-2014,2699.0,2699.0,2625.60009765625,2660.449951171875,2459.828125,502138,0.0,0.0,18-02-2014,0
614,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 11, 2014, titled, ""dr. reddy's q3 & 9 months fy14 financial results"".",11-Feb-2014 13:52:00,2014-02-11 13:52:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_11022014_02112014135202_1.zip,11-02-2014,2699.0,2699.0,2625.60009765625,2660.449951171875,2459.828125,502138,0.0,0.0,18-02-2014,0
615,DRREDDY,Dr. Reddy's Laboratories Limited,news clarification," the clarification on media release in financial express titled ""dr reddy's inks deal with us co for cancer vaccine""",20-Jan-2014 12:20:00,2014-01-20 12:20:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_01202014122002_1.zip,20-01-2014,2630.0,2682.5,2629.25,2653.39990234375,2453.3095703125,295063,0.0,0.0,27-01-2014,0
616,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 31, 2013 titled ""dr. reddy's q2 & h1 fy14 financial results"".",31-Oct-2013 14:12:00,2013-10-31 14:12:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_31102013_10312013141201_1.zip,31-10-2013,2529.0,2545.14990234375,2431.0,2456.39990234375,2271.1650390625,1432818,0.0,0.0,08-11-2013,0
617,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding press release dated september 17, 2013 titled ""dr. reddy's announces the approval of azacitidine for injection"".",17-Sep-2013 11:56:00,2013-09-17 11:56:00,-,-,https://nsearchives.nseindia.com/corporate/130917112148_0001_09172013115601_1.zip,17-09-2013,2232.0,2325.89990234375,2232.0,2304.449951171875,2130.673828125,297319,0.0,0.0,24-09-2013,0
618,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 22, 2013, titled ""dr. reddy's announces the launch of divalproex sodium extended - release tablets, usp""",22-Aug-2013 19:04:00,2013-08-22 19:04:00,-,-,https://nsearchives.nseindia.com/corporate/DRReddy_PR_22082013_08222013185202_2.zip,22-08-2013,2046.5999755859373,2120.0,2046.5999755859373,2108.550048828125,1949.54638671875,248498,0.0,0.0,29-08-2013,1
619,DRREDDY,Dr. Reddy's Laboratories Limited,press release," a copy of press release dated august 12, 2013 titled ""dr. reddy's appoints dr. sripada chandrasekhar as president and global head of human resources"".",12-Aug-2013 14:08:00,2013-08-12 14:08:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_08122013140802_4.zip,12-08-2013,2235.0,2235.050048828125,2157.550048828125,2181.14990234375,2016.6719970703125,553674,0.0,0.0,20-08-2013,0
620,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure of voting pattern - clause 35a," the disclosure of voting pattern for annual general meeting held on july 31, 2013 as per clause 35a of listing agreement along with outcome of the annual general meeting.",31-Jul-2013 18:08:00,2013-07-31 18:08:00,-,-,https://nsearchives.nseindia.com/corporate/Clause35AOutcomeofAGM_07312013180802_1.zip,31-07-2013,2150.050048828125,2294.35009765625,2135.800048828125,2281.199951171875,2109.1767578125,605278,0.0,0.0,07-08-2013,0
621,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 30, 2013 titled ""dr. reddy's q1 fy14 financial results"".",30-Jul-2013 15:40:00,2013-07-30 15:40:00,-,-,https://nsearchives.nseindia.com/corporate/drreddys2591_001_07302013154001_1.zip,30-07-2013,2225.0,2260.0,2145.60009765625,2177.25,2013.0655517578125,1015472,0.0,0.0,06-08-2013,0
622,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates," the standalone financial results along with the limited review report for the period ended june 30,2013.",30-Jul-2013 14:44:25,2013-07-30 14:44:25,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_30JUN2013_S_Q1.zip,30-07-2013,2225.0,2260.0,2145.60009765625,2177.25,2013.0655517578125,1015472,0.0,0.0,06-08-2013,0
623,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 27, 2013 titled ""dr. reddy s announces the launch of donepezil hydrochloride tablets, 23 mg"".",29-Jul-2013 10:00:00,2013-07-29 10:00:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_27072013_07292013100003_4.zip,29-07-2013,2283.0,2294.14990234375,2205.10009765625,2217.699951171875,2050.4658203125,260041,0.0,0.0,05-08-2013,0
624,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 12, 2013 titled ""dr. reddy's announces the launch of decitabine for injection"".",12-Jul-2013 10:12:00,2013-07-12 10:12:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_12072013_07122013101201_1.zip,12-07-2013,2300.75,2358.699951171875,2254.0,2349.449951171875,2172.280029296875,397780,15.0,0.0,19-07-2013,0
625,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 10, 2013, titled ""dr. reddy's laboratories limited announces filing of annual report on form 20-f"".",10-Jul-2013 10:00:00,2013-07-10 10:00:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_10072013_07102013100001_1.zip,10-07-2013,2294.199951171875,2297.0,2246.10009765625,2261.5,2077.301513671875,229049,0.0,0.0,17-07-2013,0
626,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"first state investments management (uk) limited has submitted to the exchange, vide letter dated june 07, 2013 a copy of disclosure under regulation 29(1) & 29(2) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",02-Jul-2013 13:56:00,2013-07-02 13:56:00,-,-,https://nsearchives.nseindia.com/corporate/drreddyslaboratories_firststateinvestments_29062013.zip,02-07-2013,2263.0,2288.550048828125,2240.60009765625,2263.39990234375,2079.046142578125,272890,0.0,0.0,09-07-2013,0
627,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding press release dated june 26, 2013 titled ""dr. reddy's announces the launch of lamotrigine extended-release tablets"".",26-Jun-2013 11:44:00,2013-06-26 11:44:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease26062013_06262013114402_1.zip,26-06-2013,2107.0,2120.0,2081.199951171875,2095.85009765625,1925.143310546875,344654,0.0,0.0,03-07-2013,1
628,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," vide letter dated june 22, 2013 regarding allotment of equity shares on exercise of esop.",24-Jun-2013 08:52:00,2013-06-24 08:52:00,-,-,https://nsearchives.nseindia.com/corporate/dreddy_allotment_24062013_06242013085202_3.zip,24-06-2013,2111.10009765625,2136.5,2080.14990234375,2103.050048828125,1931.757080078125,190741,0.0,0.0,01-07-2013,1
629,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation," vide letter dated june 10, 2013 a copy of disclosure pursuant to regulation 13(4), 13(4a) and 13(6) of the sebi (prohibition of) insider trading regulations, 1992. ",18-Jun-2013 18:12:00,2013-06-18 18:12:00,-,-,https://nsearchives.nseindia.com/corporate/drreddyslaboratoriesltd_18062013.zip,18-06-2013,2147.0,2150.0,2120.0,2130.949951171875,1957.384521484375,189805,0.0,0.0,25-06-2013,0
630,DRREDDY,Dr. Reddy's Laboratories Limited,esops/esos/esps," vide letter date june 4, 2013 regarding allotment of equity shares on excercise of esop.",04-Jun-2013 14:12:00,2013-06-04 14:12:00,-,-,https://nsearchives.nseindia.com/corporate/AllotmentOfSharesOnExerciseOfStockOptions03062013_06042013141202_1.zip,04-06-2013,2128.5,2165.10009765625,2120.699951171875,2157.10009765625,1981.4046630859373,362324,0.0,0.0,11-06-2013,0
631,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated june 03, 2013, titled ""fujifilm and dr. reddy's call off joint venture for generic drugs in japan"".",03-Jun-2013 11:40:00,2013-06-03 11:40:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_03062013_06032013114002_2.zip,03-06-2013,2093.10009765625,2129.0,2080.75,2111.85009765625,1939.8406982421875,272325,0.0,0.0,10-06-2013,0
632,DRREDDY,Dr. Reddy's Laboratories Limited,discl. under sebi insider trading and takeover regulation,"life insurance corporation of india has submitted to the exchange a copy of disclosure under sebi (substantial acquisition of shares & takeovers) regulations, 2011 and under sebi (prohibition of insider trading) regulations, 1992.",16-May-2013 15:44:00,2013-05-16 15:44:00,-,-,https://nsearchives.nseindia.com/corporate/Drrreddy.zip,16-05-2013,2085.25,2144.60009765625,2082.64990234375,2118.949951171875,1946.3621826171875,546032,0.0,0.0,23-05-2013,0
633,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 14, 2013 titled ""dr. reddy's q4 & fy13 financial results "".",14-May-2013 14:36:00,2013-05-14 14:36:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_14052013_05142013143602_1.zip,14-05-2013,2094.0,2120.0,2017.9000244140625,2027.9000244140625,1862.72802734375,1101119,0.0,0.0,21-05-2013,0
634,DRREDDY,Dr. Reddy's Laboratories Limited,consolidated result updates - ifrs,"dr. reddy's laboratories limited  has submitted to the exchange a copy of audited consolidated financial results of the company  for the quarter and year ended march 31, 2013 prepared in compliance with ifrs as issued by international accounting standards board (iasb).",14-May-2013 14:08:00,2013-05-14 14:08:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_CONSOLIDATEDIFRS_14052013_05142013140801_1.zip,14-05-2013,2094.0,2120.0,2017.9000244140625,2027.9000244140625,1862.72802734375,1101119,0.0,0.0,21-05-2013,0
635,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 09, 2013 titled ""dr. reddy s announces the relocation of their north america headquarters and establishment of a r&d center in princeton, nj, usa"".",09-Apr-2013 18:16:00,2013-04-09 18:16:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease09042013_04092013181601_1.zip,09-04-2013,1935.0,1935.949951171875,1903.050048828125,1916.5,1760.401611328125,570212,0.0,0.0,16-04-2013,0
636,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 04, 2013, titled ""dr. reddy's announces the launch of zoledronic acid injection"".",04-Apr-2013 10:36:00,2013-04-04 10:36:00,-,-,https://nsearchives.nseindia.com/corporate/DREREDDY_pr_04042013_04042013103602_1.zip,04-04-2013,1834.75,1904.75,1831.25,1889.75,1735.830322265625,479378,0.0,0.0,11-04-2013,0
637,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 01, 2013 titled ""dr. reddy's appoints gv prasad as chairman and satish reddy as vice-chairman of the company"".",01-Apr-2013 16:28:00,2013-04-01 16:28:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease01042013_04012013162801_1.zip,01-04-2013,1779.0,1838.300048828125,1768.25,1825.9000244140625,1677.1806640625,379436,0.0,0.0,08-04-2013,1
638,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 29, 2013 titled ""dr. reddy's announces the launch of zenatane (isotretinoin capsules usp)"".",01-Apr-2013 08:20:00,2013-04-01 08:20:00,-,-,https://nsearchives.nseindia.com/corporate/DREDDY_PR_30032013_04012013082001_1.zip,01-04-2013,1779.0,1838.300048828125,1768.25,1825.9000244140625,1677.1806640625,379436,0.0,0.0,08-04-2013,1
639,DRREDDY,Dr. Reddy's Laboratories Limited,press release," vide ite letter dated march 22, 2013 regarding a press release titled, ""dr. reddy's and nordion inc. (formerly mds inc.) settle claims"".",22-Mar-2013 20:08:00,2013-03-22 20:08:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease22032013_03222013200802_2.zip,22-03-2013,1760.25,1794.1500244140625,1748.050048828125,1752.0999755859375,1609.391845703125,207853,0.0,0.0,02-04-2013,0
640,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 15, 2013, titled ""dr. k. anji reddy is no more"".",18-Mar-2013 08:32:00,2013-03-18 08:32:00,-,-,https://nsearchives.nseindia.com/corporate/Pressrelease15032013_03182013083201_1.zip,18-03-2013,1791.0,1822.75,1785.6500244140625,1802.9000244140625,1656.054443359375,310064,0.0,0.0,25-03-2013,0
641,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 05, 2013 titled ""dr. reddy's announces the launch of zoledronic acid injection"".",05-Mar-2013 10:32:00,2013-03-05 10:32:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease05032013_03052013102802_1.zip,05-03-2013,1765.0,1804.5,1751.300048828125,1793.949951171875,1647.8331298828125,226517,0.0,0.0,12-03-2013,0
642,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 28, 2013 titled ""dr. reddy's holds 98.6% of the shares in octoplus after the post closing acceptance period"" .",28-Feb-2013 10:04:00,2013-02-28 10:04:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease28022013_02282013100401_1.zip,28-02-2013,1768.0,1779.9000244140625,1725.0999755859375,1755.449951171875,1612.4691162109375,451853,0.0,0.0,07-03-2013,0
643,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"first state investment management (uk) limited has submitted to the exchange vide letter dated february 19, 2013 a copy of disclosure under regulation 29(1) and 29(2) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",21-Feb-2013 13:00:00,2013-02-21 13:00:00,-,-,https://nsearchives.nseindia.com/corporate/DRRDY_First_Reg29.zip,21-02-2013,1823.800048828125,1831.9000244140625,1800.0,1821.199951171875,1672.86376953125,220512,0.0,0.0,28-02-2013,0
644,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 14, 2013, titled ""dr. reddy's q3 & 9 months fy13 financial results"".",14-Feb-2013 14:04:00,2013-02-14 14:04:00,-,-,https://nsearchives.nseindia.com/corporate/DRRDDY_PR_14022013_02142013140401_1.zip,14-02-2013,1906.0,1908.0,1852.449951171875,1874.3499755859373,1721.6844482421875,1046407,0.0,0.0,21-02-2013,0
645,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 12, 2013, titled ""dr. reddy's declares offer for octoplus unconditional"".",12-Feb-2013 09:20:00,2013-02-12 09:20:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_12022013_02122013092001_1.zip,12-02-2013,1921.0999755859373,1921.199951171875,1903.199951171875,1915.050048828125,1759.0697021484375,468367,0.0,0.0,19-02-2013,0
646,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"first state investment management (uk) limited has submitted to the exchange vide its letter dated january 29, 2013 a copy of disclosure under regulation 29(1) and 29(2) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",06-Feb-2013 17:36:00,2013-02-06 17:36:00,-,-,https://nsearchives.nseindia.com/corporate/Firststatementinvestment_dr_02062013173602_1.zip,06-02-2013,1908.0,1919.5,1888.0999755859373,1899.25,1744.556396484375,203423,0.0,0.0,13-02-2013,0
647,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 25, 2013 about the launch of desloratadine odt (orally disintegrating tablets)",25-Jan-2013 10:40:00,2013-01-25 10:40:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_01252013104002_3.zip,25-01-2013,1936.0,1970.0,1935.4000244140625,1945.1500244140625,1786.7177734375,432202,0.0,0.0,01-02-2013,0
648,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"life insurance corporation of india has submitted to the exchange vide letter dated january 12, 2013 a copy of disclosure under regulation 29(2) of sebi (substantial acquisition of shares and takeovers) regulations, 2011 along with a copy of disclosure under regulation 13(3) and 13(6) of sebi (prohibition of insider trading) regulations, 1992.",14-Jan-2013 11:55:00,2013-01-14 11:55:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_LICDISC_14012013.zip,14-01-2013,1900.0999755859373,1918.9000244140625,1900.0,1913.050048828125,1757.232421875,451885,0.0,0.0,21-01-2013,0
649,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 03, 2013, titled ""dr. reddy's announces the launch of finasteride tablets"".",03-Jan-2013 10:10:00,2013-01-03 10:10:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_PR_03012013.zip,03-01-2013,1849.0,1891.5,1841.0999755859373,1882.300048828125,1728.987060546875,584794,0.0,0.0,10-01-2013,0
650,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation," vide its letter dated december 24, 2012 a copy of disclosure pursuant to regulation 13(4), 13(4a) and 13(6) of the sebi (prohibition of insider trading) regulations, 1992.",26-Dec-2012 16:55:00,2012-12-26 16:55:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_REG13_26122012.zip,26-12-2012,1822.0,1838.0,1812.0,1818.8499755859373,1670.704833984375,217946,0.0,0.0,02-01-2013,0
651,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 14, 2012, titled ""dr. reddy's launches the recommended public cash offer for all the issued and outstanding ordinary shares of octoplus n.v."".",14-Dec-2012 08:50:00,2012-12-14 08:50:00,-,-,https://nsearchives.nseindia.com/corporate/drreddy_pr_14122012.zip,14-12-2012,1856.25,1863.699951171875,1825.0,1830.050048828125,1680.99267578125,266915,0.0,0.0,21-12-2012,0
652,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 27, 2012, titled ""dr. reddy's announces the appointment of new chief financial officer (cfo) and head for north america business"".",27-Nov-2012 15:55:00,2012-11-27 15:55:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_27112012.zip,27-11-2012,1765.25,1795.0,1765.25,1787.550048828125,1641.95458984375,167359,0.0,0.0,05-12-2012,0
653,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 19, 2012, titled ""dr. reddy's announces the launch of sildenafil tablets"".",19-Nov-2012 09:31:00,2012-11-19 09:31:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddys_pr_19112012.zip,19-11-2012,1751.300048828125,1774.800048828125,1725.0999755859375,1738.0,1596.4403076171875,283544,0.0,0.0,26-11-2012,0
654,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated november 16, 2012, titled ""dr. reddy's laboratories to request afm approval for offer memorandum in connection with its offer for octoplus n.v."".",16-Nov-2012 09:23:00,2012-11-16 09:23:00,-,-,https://nsearchives.nseindia.com/corporate/drreddy_pr_16112012.zip,16-11-2012,1711.050048828125,1784.949951171875,1711.050048828125,1756.9000244140625,1613.80078125,430225,0.0,0.0,23-11-2012,0
655,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 30, 2012, titled ""dr. reddy's q2 & h1 fy13 financial results"".",30-Oct-2012 13:45:00,2012-10-30 13:45:00,-,-,https://nsearchives.nseindia.com/corporate/dreaddy_pr_30102012.zip,30-10-2012,1705.199951171875,1739.0,1700.550048828125,1724.300048828125,1583.856201171875,652618,0.0,0.0,06-11-2012,0
656,DRREDDY,Dr. Reddy's Laboratories Limited,consolidated result updates - ifrs," a copy of unaudited consolidated financial results of the company and its subsidiaries for the quarter and half year ended september 30, 2012 prepared in compliance with ifrs as issued by international accounting standards board (iasb).",30-Oct-2012 13:42:00,2012-10-30 13:42:00,-,-,https://nsearchives.nseindia.com/corporate/drready_irfs_30102012.zip,30-10-2012,1705.199951171875,1739.0,1700.550048828125,1724.300048828125,1583.856201171875,652618,0.0,0.0,06-11-2012,0
657,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates," the standalone financial results along with the limited review report for the period ended september 30,2012.",30-Oct-2012 13:33:54,2012-10-30 13:33:54,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_30SEP2012_S_Q2.zip,30-10-2012,1705.199951171875,1739.0,1700.550048828125,1724.300048828125,1583.856201171875,652618,0.0,0.0,06-11-2012,0
658,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding the press release dated october 22, 2012, titled ""dr. reddy's laboratories limited intends to make a recommended public offer for octoplus n.v."".",22-Oct-2012 08:51:00,2012-10-22 08:51:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_22102012.zip,22-10-2012,1704.699951171875,1731.949951171875,1704.699951171875,1728.75,1587.9437255859375,243677,0.0,0.0,31-10-2012,0
659,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation," vide letter dated october 11, 2012 a copy of disclosure pursuant to regulation 13(4), 13(4a) and 13(6) of the sebi (prohibition of insider trading) regulations, 1992.",12-Oct-2012 16:48:00,2012-10-12 16:48:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddy_reg_12102012.zip,12-10-2012,1710.9000244140625,1718.0,1676.0999755859375,1683.949951171875,1546.792724609375,163425,0.0,0.0,19-10-2012,0
660,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 08, 2012, titled ""dr. reddy's custom pharmaceutical services (cps) business expands its manufacturing operations in mirfield, uk"".",08-Oct-2012 16:37:00,2012-10-08 16:37:00,-,-,https://nsearchives.nseindia.com/corporate/DRReddys_pr_08102012.zip,08-10-2012,1695.0,1714.0,1676.0,1701.949951171875,1563.3265380859375,244573,0.0,0.0,15-10-2012,0
661,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 27, 2012, titled ""dr. reddy's announces the launch of montelukast sodium oral granules"".",27-Sep-2012 12:35:00,2012-09-27 12:35:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY01_pr_27092012.zip,27-09-2012,1618.25,1639.4000244140625,1616.300048828125,1622.800048828125,1490.6234130859375,678858,0.0,0.0,05-10-2012,0
662,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 20, 2012, titled ""dr.reddy's announces the launch of amoxicillin tablets, capsules, and oral suspension"".",20-Sep-2012 13:09:00,2012-09-20 13:09:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddy_PR_20092012.zip,20-09-2012,1674.0,1682.199951171875,1658.0,1665.050048828125,1529.4320068359375,774304,0.0,0.0,27-09-2012,0
663,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation," vide its letter dated september 13, 2012 a copy of disclosure pursuant to regulation 13(4), 13(4a) and 13(6) of the sebi (prohibition of insider trading) regulations, 1992.",17-Sep-2012 09:13:00,2012-09-17 09:13:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_REG13_14092012.zip,17-09-2012,1756.300048828125,1759.0,1662.0,1670.5,1534.438232421875,909462,0.0,0.0,25-09-2012,0
664,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 11, 2012, titled ""dr.reddy's announces the launch of metoprolol succinate er (extended-release) tablets"".",12-Sep-2012 07:56:00,2012-09-12 07:56:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_Pr_12092012.zip,12-09-2012,1735.0,1785.75,1731.0,1769.4000244140625,1625.28271484375,469604,0.0,0.0,20-09-2012,-1
665,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 07, 2012, titled ""dr. reddy's announces the launch of montelukast sodium tablets and montelukast sodium chewable tablets"".",07-Aug-2012 18:05:00,2012-08-07 18:05:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddy_pr_07082012.zip,07-08-2012,1666.0,1674.75,1630.75,1659.300048828125,1524.1505126953125,161944,0.0,0.0,14-08-2012,0
666,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 27, 2012, titled ""usfda lifts import alert from dr. reddy's chemical manufacturing facility at cuernavaca, mexico"".",30-Jul-2012 08:57:00,2012-07-30 08:57:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_30072012.zip,30-07-2012,1630.0,1639.0,1610.25,1625.1500244140625,1492.78173828125,512333,0.0,0.0,06-08-2012,0
667,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"g. v. sanjana reddy has submitted to the exchange vide letter dated july 25, 2012 a copy of disclosure in terms of regulation 29(2) of the sebi (substantial acquisition of shares and takeovers) regulations, 2011 (the""sebi takeover regulations"").",26-Jul-2012 10:21:00,2012-07-26 10:21:00,-,-,https://nsearchives.nseindia.com/corporate/drreddy_sanjana_26072012.zip,26-07-2012,1615.0,1648.5,1609.949951171875,1623.0,1490.806884765625,645095,0.0,0.0,02-08-2012,0
668,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"k satish reddy has submitted to the exchange vide letter dated july 25, 2012 a copy of disclosure in terms of regulation 29(2) of the sebi (substantial acquisition of shares and takeovers) regulations, 2011 (the""sebi takeover regulations"").",26-Jul-2012 10:18:00,2012-07-26 10:18:00,-,-,https://nsearchives.nseindia.com/corporate/drreddy_ksatish_26072012.zip,26-07-2012,1615.0,1648.5,1609.949951171875,1623.0,1490.806884765625,645095,0.0,0.0,02-08-2012,0
669,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"dr. k. anji reddy has submitted to the exchange vide letter dated july 25, 2012 a copy of disclosure in terms of regulation 29(2) of the sebi (substantial acquisition of shares and takeovers) regulations, 2011 (the""sebi takeover regulations"").",26-Jul-2012 10:16:00,2012-07-26 10:16:00,-,-,https://nsearchives.nseindia.com/corporate/ddreddy_anji_26072012.zip,26-07-2012,1615.0,1648.5,1609.949951171875,1623.0,1490.806884765625,645095,0.0,0.0,02-08-2012,0
670,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"g. v. prasad has submitted to the exchange vide letter dated july 25, 2012 a copy of disclosure in terms of regulation 29(2) of the sebi (substantial acquisition of shares and takeovers) regulations, 2011 (the""sebi takeover regulations"").",26-Jul-2012 10:13:00,2012-07-26 10:13:00,-,-,https://nsearchives.nseindia.com/corporate/drreddy_prasad_26072012.zip,26-07-2012,1615.0,1648.5,1609.949951171875,1623.0,1490.806884765625,645095,0.0,0.0,02-08-2012,0
671,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"g. anuradha has submitted to the exchange vide letter dated july 25, 2012 a copy of disclosure in terms of regulation 29(2) of the sebi (substantial acquisition of shares and takeovers) regulations, 2011 (the""sebi takeover regulations"").",26-Jul-2012 10:07:00,2012-07-26 10:07:00,-,-,https://nsearchives.nseindia.com/corporate/drreddy_anuradha_26072012.zip,26-07-2012,1615.0,1648.5,1609.949951171875,1623.0,1490.806884765625,645095,0.0,0.0,02-08-2012,0
672,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations,"aps trust has submitted to the exchange vide letter dated july 25, 2012 a copy of disclosure in terms of regulation 29(2) of the sebi (substantial acquisition of shares and takeovers) regulations, 2011.",26-Jul-2012 09:59:00,2012-07-26 09:59:00,-,-,https://nsearchives.nseindia.com/corporate/drreddy_aps_26072012.zip,26-07-2012,1615.0,1648.5,1609.949951171875,1623.0,1490.806884765625,645095,0.0,0.0,02-08-2012,0
673,DRREDDY,Dr. Reddy's Laboratories Limited,outcome of annual general meeting," regarding the outcome of annual general meeting held on july 20, 2012.",20-Jul-2012 20:01:00,2012-07-20 20:01:00,-,-,https://nsearchives.nseindia.com/corporate/Drreddy_AGM_20072012.zip,20-07-2012,1640.0,1640.0,1597.800048828125,1611.199951171875,1479.96826171875,1133680,0.0,0.0,27-07-2012,0
674,DRREDDY,Dr. Reddy's Laboratories Limited,consolidated result updates - ifrs," a copy of unaudited consolidated financial results of the company for the quarter ended june 30, 2012 prepared in compliance with international financial reporting standards (ifrs) as issued by international accounting standards board (iasb).",19-Jul-2012 15:03:00,2012-07-19 15:03:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddy_consolidated_19072012.zip,19-07-2012,1686.0,1697.5,1642.550048828125,1654.550048828125,1519.7874755859375,878174,0.0,0.0,26-07-2012,0
675,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 19, 2012, titled ""dr. reddy's q1 fy13 financial results"".",19-Jul-2012 14:59:00,2012-07-19 14:59:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddy_pr_19072012.zip,19-07-2012,1686.0,1697.5,1642.550048828125,1654.550048828125,1519.7874755859375,878174,0.0,0.0,26-07-2012,0
676,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates," the standalone financial results for the period ended june 30,2012 with limited review report.",19-Jul-2012 14:52:04,2012-07-19 14:52:04,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_30JUN2012_S_Q1.zip,19-07-2012,1686.0,1697.5,1642.550048828125,1654.550048828125,1519.7874755859375,878174,0.0,0.0,26-07-2012,0
677,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 18, 2012, titled ""dr. reddy's announces the launch of atorvastatin calcium tablets"".",18-Jul-2012 14:13:00,2012-07-18 14:13:00,-,-,https://nsearchives.nseindia.com/corporate/drreddy02_pr_18072012.zip,18-07-2012,1711.0,1714.800048828125,1661.800048828125,1672.449951171875,1536.229248046875,265897,0.0,0.0,25-07-2012,0
678,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 18, 2012, titled ""dr. reddy's laboratories limited announces filing of annual report on form 20-f"".",18-Jul-2012 11:03:00,2012-07-18 11:03:00,-,-,https://nsearchives.nseindia.com/corporate/drreddy_PR_18072012.zip,18-07-2012,1711.0,1714.800048828125,1661.800048828125,1672.449951171875,1536.229248046875,265897,0.0,0.0,25-07-2012,0
679,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 02, 2012, titled ""dr. reddy's announces the launch of ibandronate sodium tablets"".",02-Jul-2012 11:10:00,2012-07-02 11:10:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddys01_pr_02072012.zip,02-07-2012,1636.0,1649.9000244140625,1629.0,1644.0,1510.0966796875,267695,0.0,0.0,09-07-2012,0
680,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation," vide its letter dated june 07, 2012 a copy of disclosure pursuant to regulation 13(4), 13(4a) and 13(6) of the sebi (prohibition of insider trading) regulations, 1992.",08-Jun-2012 13:26:00,2012-06-08 13:26:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddy_Reg13_08062012.zip,08-06-2012,1597.199951171875,1629.0,1597.199951171875,1621.25,1476.4766845703125,428534,0.0,0.0,15-06-2012,0
681,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated june 07, 2012, titled ""dr. reddy's announces the launch of ropinirole hydrochloride xr (extended-release) tablets.""",07-Jun-2012 09:56:00,2012-06-07 09:56:00,-,-,https://nsearchives.nseindia.com/corporate/drrreddy_pr_07062012.zip,07-06-2012,1624.0,1624.0,1607.0,1617.1500244140625,1472.742919921875,569719,0.0,0.0,14-06-2012,0
682,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated june 06, 2012, titled ""dr. reddy's laboratories ltd. and merck serono announce collaboration to develop and commercialize biosimilars"".",06-Jun-2012 11:10:00,2012-06-06 11:10:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddy_pr_06062012.zip,06-06-2012,1611.0,1639.0,1601.300048828125,1615.5,1471.240234375,676133,0.0,0.0,13-06-2012,0
683,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 21, 2012 titled ""dr. reddy's announces the launch of over-the-counter lansoprazole delayed-release capsules"".",21-May-2012 08:39:00,2012-05-21 08:39:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_21052012.zip,21-05-2012,1665.0,1672.300048828125,1650.0,1652.9000244140625,1505.3006591796875,240070,0.0,0.0,28-05-2012,0
684,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 18, 2012, titled ""dr. reddy's announces the launch of clopidogrel tablets, usp"".",18-May-2012 10:04:00,2012-05-18 10:04:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_18052012.zip,18-05-2012,1638.3499755859375,1667.0999755859375,1638.3499755859375,1660.300048828125,1512.0399169921875,370342,0.0,0.0,25-05-2012,0
685,DRREDDY,Dr. Reddy's Laboratories Limited,consolidated result updates - ifrs," a copy of audited consolidated financial results of the company  for the quarter and year ended march 31, 2012 prepared in compliance with ifrs as issued by international accounting standards board (iasb).",11-May-2012 14:50:00,2012-05-11 14:50:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_ConsolidatedIfrs_11052012.zip,11-05-2012,1700.0,1715.0,1644.6500244140625,1660.300048828125,1512.0399169921875,588980,0.0,0.0,18-05-2012,0
686,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 11, 2012, titled ""dr. reddy's revenues cross $2 billion milestone in fy12"".",11-May-2012 14:33:00,2012-05-11 14:33:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_11052012.zip,11-05-2012,1700.0,1715.0,1644.6500244140625,1660.300048828125,1512.0399169921875,588980,0.0,0.0,18-05-2012,0
687,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 24, 2012, titled ""dr. reddy's announces the launch of olanzapine tablets"".",24-Apr-2012 21:17:00,2012-04-24 21:17:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddy_pr_24042012.zip,24-04-2012,1782.0,1795.949951171875,1756.050048828125,1763.449951171875,1605.978759765625,190036,0.0,0.0,02-05-2012,0
688,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 28, 2012, titled ""dr. reddy's announces the launch of quetiapine fumarate tablets.""",28-Mar-2012 10:03:00,2012-03-28 10:03:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_28032012.zip,28-03-2012,1685.0,1719.0,1683.050048828125,1699.0,1547.2840576171875,430505,0.0,0.0,04-04-2012,0
689,DRREDDY,Dr. Reddy's Laboratories Limited,updates," a copy of the abstract of the terms of re-appointment mr. satish reddy, as whole time director designated as managing director and chief operating officer (coo) of the company for a period of 5 (five) years effective from october 01, 2012 to september 30, 2017 and the relevant memorandum of interest.",15-Feb-2012 18:07:00,2012-02-15 18:07:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddy_updts_15022012.zip,15-02-2012,1612.0,1625.0,1610.0,1620.25,1475.566162109375,429803,0.0,0.0,23-02-2012,0
690,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated february 03, 2012 titled ""dr. reddy's q3 fy12 financial results highest ever quarterly sales and profit"".",03-Feb-2012 14:37:00,2012-02-03 14:37:00,-,-,https://nsearchives.nseindia.com/corporate/DREDDY_pr_03022012.zip,03-02-2012,1653.0,1682.0,1635.3499755859375,1670.75,1521.5565185546875,1562635,0.0,0.0,10-02-2012,0
691,DRREDDY,Dr. Reddy's Laboratories Limited,consolidated result updates - ifrs," a copy of un audited consolidated financial results of the company and its subsidiaries for the quarter and nine months ended december 31, 2011 prepared in compliance with ifrs as issued by international accounting standards board (iasb).",03-Feb-2012 14:14:00,2012-02-03 14:14:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_consolidated_03022012.zip,03-02-2012,1653.0,1682.0,1635.3499755859375,1670.75,1521.5565185546875,1562635,0.0,0.0,10-02-2012,0
692,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates," the standalone and consolidated financial results along with limited review report for the period ended december 31,2011.",03-Feb-2012 14:08:03,2012-02-03 14:08:03,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_31DEC2011_B_Q3.zip,03-02-2012,1653.0,1682.0,1635.3499755859375,1670.75,1521.5565185546875,1562635,0.0,0.0,10-02-2012,0
693,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 27, 2012, titled ""dr. reddy's clarifies media reports.""",27-Jan-2012 13:55:00,2012-01-27 13:55:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_27012012.zip,27-01-2012,1655.0,1667.0,1534.75,1645.6500244140625,1498.6981201171875,805478,0.0,0.0,03-02-2012,0
694,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation," a copy of disclosure under regulation 13(4), 13(4a) and 13(6) of sebi (prohibition of insider trading) regulations, 1992.",23-Jan-2012 20:12:00,2012-01-23 20:12:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_DISCL_23012012.zip,23-01-2012,1639.949951171875,1657.949951171875,1631.1500244140625,1647.800048828125,1500.6558837890625,177042,0.0,0.0,31-01-2012,0
695,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation," a copy of disclosure under regulation 13(4), 13(4a) and 13(6) of sebi (prohibition of insider trading) regulations, 1992.",23-Jan-2012 19:47:00,2012-01-23 19:47:00,-,-,https://nsearchives.nseindia.com/corporate/REDDY_DISC_23012012.zip,23-01-2012,1639.949951171875,1657.949951171875,1631.1500244140625,1647.800048828125,1500.6558837890625,177042,0.0,0.0,31-01-2012,0
696,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under insider trading regulation," a copy of disclosure under regulation 13(4), 13(4a) and 13(6) of sebi (prohibition of insider trading) regulations, 1992.",22-Nov-2011 14:45:00,2011-11-22 14:45:00,-,-,https://nsearchives.nseindia.com/corporate/DREDDY_reg_22112011.zip,22-11-2011,1538.9000244140625,1564.75,1509.0999755859375,1539.050048828125,1401.6171875,355611,0.0,0.0,29-11-2011,0
697,DRREDDY,Dr. Reddy's Laboratories Limited,disclosure under sebi takeover regulations," a copy of disclosure under regulation 29(2) of sebi (substantial acquisition of shares and takeovers) regulations, 2011 along with regulation 13(4) of sebi (prohibition of insider trading) regulations, 1992.",18-Nov-2011 15:05:00,2011-11-18 15:05:00,-,-,https://nsearchives.nseindia.com/corporate/DRREADY_REG_18112011.zip,18-11-2011,1546.0,1579.9000244140625,1545.0,1556.0999755859375,1417.14453125,536794,0.0,0.0,25-11-2011,0
698,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 25, 2011, titled, ""teva and dr. reddy's announce launch of generic zyprexa in the united states"".",25-Oct-2011 18:18:00,2011-10-25 18:18:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddy02_pr_25102011.zip,25-10-2011,1554.75,1589.800048828125,1546.300048828125,1579.550048828125,1438.500732421875,814241,0.0,0.0,03-11-2011,0
699,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 25, 2011 titled, ""dr.reddy's q2 fy12 financial results"".",25-Oct-2011 14:19:00,2011-10-25 14:19:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddy_pr_25102011.zip,25-10-2011,1554.75,1589.800048828125,1546.300048828125,1579.550048828125,1438.500732421875,814241,0.0,0.0,03-11-2011,0
700,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 26, 2011, titled "" dr. reddy's and jb chemicals & pharmaceuticals (jbcpl) terminate rx business deal in russia and other cis "".",26-Sep-2011 15:27:00,2011-09-26 15:27:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_PR_26092011.zip,26-09-2011,1493.8499755859375,1498.0,1472.050048828125,1484.800048828125,1352.2113037109375,213862,0.0,0.0,03-10-2011,0
701,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 22, 2011 titled, "" dr. reddy's announces the launch of rivastigmine tartrate capsules "".",22-Sep-2011 18:10:00,2011-09-22 18:10:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddys_PR_22092011.zip,22-09-2011,1522.0,1526.6500244140625,1490.5,1503.949951171875,1369.6513671875,264178,0.0,0.0,29-09-2011,0
702,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated september 02, 2011, titled ""dr. reddy's announces start of phase ii study with the cetp inhibitor, drl-17822 in dyslipidemia patients "".",02-Sep-2011 11:49:00,2011-09-02 11:49:00,-,-,https://nsearchives.nseindia.com/corporate/Drreddy_PR01_02092011.zip,02-09-2011,1540.8499755859375,1556.699951171875,1497.050048828125,1507.8499755859375,1373.2032470703125,530896,0.0,0.0,09-09-2011,0
703,DRREDDY,Dr. Reddy's Laboratories Limited,press release," vide its letter dated august 31, 2011, regarding a press release dated august 30, 2011, titled "" dr. reddy's announces settlement of lipitor (atorvastatin) anda litigation with pfizer "".",02-Sep-2011 11:27:00,2011-09-02 11:27:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_PR_02092011.zip,02-09-2011,1540.8499755859375,1556.699951171875,1497.050048828125,1507.8499755859375,1373.2032470703125,530896,0.0,0.0,09-09-2011,0
704,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 30, 2011, titled ""dr. reddy's announces the launch of over-the-counter fexofenadine hci and pseudoephedrine hci extended release tablets"".",30-Aug-2011 18:31:00,2011-08-30 18:31:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddy_pr_30082011.zip,30-08-2011,1482.0,1502.0,1451.1500244140625,1496.0,1362.4112548828125,357328,0.0,0.0,08-09-2011,0
705,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 28, 2011, titled ""fujifilm and dr. reddy's to establish an exclusive joint venture for developing, manufacturing and promoting generic drugs in japan"".",28-Jul-2011 11:32:00,2011-07-28 11:32:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDYLTD_pr_28072011.zip,28-07-2011,1578.0,1618.800048828125,1561.550048828125,1603.800048828125,1460.5850830078125,1000351,0.0,0.0,04-08-2011,0
706,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 27, 2011, titled ""dr. reddy's announces the launch of gemcitabine for injection"".",28-Jul-2011 08:14:00,2011-07-28 08:14:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_28072011.zip,28-07-2011,1578.0,1618.800048828125,1561.550048828125,1603.800048828125,1460.5850830078125,1000351,0.0,0.0,04-08-2011,0
707,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 22, 2011, titled ""dr reddy's acquires prescription business of jb chemicals & pharmaceuticals in russia & other cis markets"".",22-Jul-2011 19:05:00,2011-07-22 19:05:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_PR_22072011.zip,22-07-2011,1551.4000244140625,1577.75,1547.5,1569.8499755859375,1429.6668701171875,286839,0.0,0.0,29-07-2011,0
708,DRREDDY,Dr. Reddy's Laboratories Limited,outcome of annual general meeting," regarding the outcome of the annual general meeting of the members of the company held on july 21, 2011.",21-Jul-2011 16:12:00,2011-07-21 16:12:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddy_agmoutcome_21072011.zip,21-07-2011,1550.0,1564.0,1530.25,1539.8499755859375,1402.345703125,321204,0.0,0.0,28-07-2011,0
709,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 21, 2011, titled ""dr reddy's laboratories limited announces filing of annual report on form 20-f"".",21-Jul-2011 15:03:00,2011-07-21 15:03:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_21072011.zip,21-07-2011,1550.0,1564.0,1530.25,1539.8499755859375,1402.345703125,321204,0.0,0.0,28-07-2011,0
710,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 20, 2011, titled ""dr reddy's q1 fy12 financial results"".",20-Jul-2011 14:45:00,2011-07-20 14:45:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_20072011.zip,20-07-2011,1620.0,1620.9000244140625,1556.5,1566.550048828125,1426.661376953125,624301,0.0,0.0,27-07-2011,0
711,DRREDDY,Dr. Reddy's Laboratories Limited,consolidated result updates - ifrs," a copy of unaudited consolidated financial results of the company and its subsidiaries for the quarter ended june 30, 2011 prepared in compliance with ifrs as issued by international accounting standards board (iasb).",20-Jul-2011 14:43:00,2011-07-20 14:43:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_consolidated_20072011.zip,20-07-2011,1620.0,1620.9000244140625,1556.5,1566.550048828125,1426.661376953125,624301,0.0,0.0,27-07-2011,0
712,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 13, 2011, titled ""dr. reddy's announces the usfda approval of fondaparinux sodium injection.""",13-Jul-2011 10:03:00,2011-07-13 10:03:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDY_PR1_13072011.zip,13-07-2011,1575.0999755859375,1622.949951171875,1575.0999755859375,1595.800048828125,1453.2996826171875,1107852,0.0,0.0,20-07-2011,0
713,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 07, 2011, titled ""dr. reddy's announces the launch of amlodipine besylate and benazepril hydrochloride capsules."" ",07-Jul-2011 10:42:00,2011-07-07 10:42:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_07072011.zip,07-07-2011,1525.0,1574.9000244140625,1524.0,1565.300048828125,1425.5230712890625,572139,0.0,0.0,14-07-2011,0
714,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated june 22, 2011, titled ""dr. reddy's announces the launch of levofloxacin tablets"". ",22-Jun-2011 10:51:00,2011-06-22 10:51:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_22062011.zip,22-06-2011,1527.199951171875,1527.199951171875,1492.0,1514.5,1369.2615966796875,134684,0.0,0.0,29-06-2011,0
715,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated june 14, 2011, titled ""dr. reddy's chemical manufacturing facility at cuernavaca, mexico receives warning letter from usfda"".",15-Jun-2011 08:41:00,2011-06-15 08:41:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_15062011.zip,15-06-2011,1532.0,1575.0,1523.0999755859375,1555.5999755859375,1406.4200439453125,1176253,0.0,0.0,22-06-2011,0
716,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated june 06, 2011, titled ""dr. reddy's announces three generic product launches in the us market"".",06-Jun-2011 17:16:00,2011-06-06 17:16:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_PR_06062011.zip,06-06-2011,1565.0,1614.4000244140625,1560.050048828125,1607.4000244140625,1453.2523193359375,150904,0.0,0.0,13-06-2011,0
717,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a revised press release dated may 13, 2011, titled ""dr. reddy's q4 fy11 & fy11 financial results"".",13-May-2011 18:20:00,2011-05-13 18:20:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddy_revisedpr_13052011.zip,13-05-2011,1617.0,1678.199951171875,1603.1500244140625,1651.6500244140625,1493.2589111328125,725623,0.0,0.0,20-05-2011,0
718,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 13, 2011, titled ""dr. reddy's q4 fy11 & fy11 financial results"".",13-May-2011 14:36:00,2011-05-13 14:36:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddy_pr_13052011.zip,13-05-2011,1617.0,1678.199951171875,1603.1500244140625,1651.6500244140625,1493.2589111328125,725623,0.0,0.0,20-05-2011,0
719,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates," the standalone and consolidated financial results for the period ended march 31,2011.",13-May-2011 14:31:55,2011-05-13 14:31:55,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_31MAR2011_B_Q4A.zip,13-05-2011,1617.0,1678.199951171875,1603.1500244140625,1651.6500244140625,1493.2589111328125,725623,0.0,0.0,20-05-2011,0
720,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 10, 2011, titled ""dr reddy's launches pegfilgrastim in india under the brand name 'peg-grafeel (tm)"".",10-May-2011 16:15:00,2011-05-10 16:15:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_10052011.zip,10-05-2011,1599.699951171875,1615.0,1582.0999755859375,1593.3499755859375,1440.550048828125,95717,0.0,0.0,17-05-2011,0
721,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 14, 2011, titled ""dr reddy's announces the launch of over-the-counter fexofenadine hci tablets"".",15-Apr-2011 08:49:00,2011-04-15 08:49:00,-,-,https://nsearchives.nseindia.com/corporate/drready_pr_15042011.zip,15-04-2011,1645.0,1659.9000244140625,1636.050048828125,1654.25,1495.609619140625,329510,0.0,0.0,25-04-2011,0
722,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 11, 2011, titled ""dr reddy's expands its r&d centre in cambridge, united kingdom"".",11-Apr-2011 17:56:00,2011-04-11 17:56:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY123_PR_11042011.zip,11-04-2011,1631.0,1633.050048828125,1600.5,1614.1500244140625,1459.3553466796875,142636,0.0,0.0,20-04-2011,0
723,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated april 01, 2011, titled ""promius (tm) pharma and valeant form collaboration to market cloderm cream in the united states"".",01-Apr-2011 17:41:00,2011-04-01 17:41:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_PR_01042011.zip,01-04-2011,1644.0,1658.6500244140625,1601.199951171875,1617.9000244140625,1462.7457275390625,308861,0.0,0.0,08-04-2011,0
724,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 30, 2011, titled ""dr. reddy's announces completion of the acquisition of us penicillin facility and products from glaxosmithkline"".",30-Mar-2011 11:00:00,2011-03-30 11:00:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddy_pr_30032011.zip,30-03-2011,1617.9000244140625,1644.6500244140625,1616.0,1634.4000244140625,1477.663330078125,333283,0.0,0.0,06-04-2011,0
725,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated march 28, 2011, titled ""dr. reddy's launches levocetirizine tablets in us"".",28-Mar-2011 11:11:00,2011-03-28 11:11:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_PR_28032011.zip,28-03-2011,1548.0,1562.800048828125,1543.3499755859375,1549.8499755859375,1401.2215576171875,344224,0.0,0.0,04-04-2011,1
726,DRREDDY,Dr. Reddy's Laboratories Limited,allotment of securities," that the management committee of the board of directors of the company at its meeting held on march 24, 2011, has approved the allotment of 1,015,516,392 unsecured redeemable non-convertible debentures of rs. 5/- each carrying a coupon of 9.25% per annum, (""bonus debentures"") amounting to an aggregate value of rs. 5,077,581,960/- from the general reserve by way of distribution as bonus, to the members, based on their equity holding on the record date i.e. march 18, 2011, in the ratio of 6 (six) bonus debentures of rs. 5/- each for every equity share of rs. 5/- each held.",24-Mar-2011 10:56:00,2011-03-24 10:56:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_Allot_24032011.zip,24-03-2011,1561.0,1569.0,1539.300048828125,1542.0999755859375,1394.2147216796875,189651,0.0,0.0,31-03-2011,1
727,DRREDDY,Dr. Reddy's Laboratories Limited,updates," a copy of the abstract of the terms of re-appointment of dr.k.anji reddy, whole time director designated as chairman of the company for a further period of 5(five) years effective from july 13, 2011 to july 12, 2016 and of mr. g. v. prasad, whole time director designated as vice-chairman and chief executive officer (ceo) of the company for a further period of 5 (five) years effective from january 30, 2011 to january 29, 2016.",15-Feb-2011 15:08:00,2011-02-15 15:08:00,-,-,https://nsearchives.nseindia.com/corporate/DRRed_Updates_15022011.zip,15-02-2011,1544.0,1548.3499755859375,1511.050048828125,1538.5999755859375,1391.0504150390625,229014,0.0,0.0,22-02-2011,0
728,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 31, 2011, titled ""dr. reddy's provides update on the fexofenadine-pseudoephedrine 24 hour litigation"".",31-Jan-2011 10:24:00,2011-01-31 10:24:00,-,-,https://nsearchives.nseindia.com/corporate/drready_pr_31012011.zip,31-01-2011,1591.0,1632.0,1589.25,1624.25,1468.4866943359375,580773,0.0,0.0,07-02-2011,0
729,DRREDDY,Dr. Reddy's Laboratories Limited,consolidated result updates - ifrs," a copy of unaudited consolidated financial results of the company and its subsidiaries for the quarter ended december 31, 2010 prepared in compliance with ifrs as issued by international accounting standards board.",25-Jan-2011 14:32:00,2011-01-25 14:32:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddy_ifrsRESULT_25012011.zip,25-01-2011,1647.0,1668.800048828125,1569.0,1578.8499755859375,1427.4404296875,928542,0.0,0.0,02-02-2011,0
730,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 25, 2011, titled ""dr. reddy's q3 fy11 financial results"".",25-Jan-2011 14:13:00,2011-01-25 14:13:00,-,-,https://nsearchives.nseindia.com/corporate/DrReddy_pr_25012011.zip,25-01-2011,1647.0,1668.800048828125,1569.0,1578.8499755859375,1427.4404296875,928542,0.0,0.0,02-02-2011,0
731,DRREDDY,Dr. Reddy's Laboratories Limited,financial result updates," the standalone and consolidated financial results for the period ended december 31,2010.",25-Jan-2011 14:05:23,2011-01-25 14:05:23,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_31DEC2010_B_Q3.zip,25-01-2011,1647.0,1668.800048828125,1569.0,1578.8499755859375,1427.4404296875,928542,0.0,0.0,02-02-2011,0
732,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated january 20, 2011, titled ""dr. reddy's announces the launch of pantoprazole sodium delayed-released tablets"".",20-Jan-2011 16:52:00,2011-01-20 16:52:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_PR_20012011.zip,20-01-2011,1635.5,1678.0,1635.5,1666.25,1506.4588623046875,312008,0.0,0.0,28-01-2011,-1
733,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated december 21, 2010, titled ""dr. reddy's enters into an agreement with r-pharm of russia collaboration in the areas of high-technology and knowledge sharing"".",22-Dec-2010 08:52:00,2010-12-22 08:52:00,-,-,https://nsearchives.nseindia.com/corporate/DrREDDYS_PR_22122010.zip,22-12-2010,1633.949951171875,1711.0,1616.0999755859375,1676.8499755859375,1516.042236328125,1542182,0.0,0.0,29-12-2010,0
734,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding the press release dated november 23, 2010, titled ""glaxosmithkline and dr. reddy's agree to the sale of us penicillin facility and products"".",24-Nov-2010 08:40:00,2010-11-24 08:40:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_24112010.zip,24-11-2010,1761.1500244140625,1813.449951171875,1761.1500244140625,1781.25,1610.4302978515625,430480,0.0,0.0,01-12-2010,0
735,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding the press release dated november 20, 2010, titled ""dr. reddy's announces the launch of zafirlukast tablets"".",22-Nov-2010 08:48:00,2010-11-22 08:48:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_22112010.zip,22-11-2010,1770.0,1781.6500244140625,1740.050048828125,1762.699951171875,1593.659423828125,508147,0.0,0.0,29-11-2010,0
736,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding the press release dated october 25, 2010, titled ""dr. reddy's expands portfolio in russia & cis through in-licensing deals"".",25-Oct-2010 15:52:00,2010-10-25 15:52:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_PR_25102010.zip,25-10-2010,1630.0999755859375,1649.699951171875,1620.5,1638.5999755859375,1481.4603271484375,368872,0.0,0.0,01-11-2010,0
737,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated october 16, 2010 titled ""dr. reddy's announces the approval of lansoprazole delayed-release capsules"".",18-Oct-2010 09:15:00,2010-10-18 09:15:00,-,-,https://nsearchives.nseindia.com/corporate/drreddy_pr_18102010.zip,18-10-2010,1585.25,1620.0,1585.25,1614.800048828125,1459.9429931640625,537380,0.0,0.0,25-10-2010,0
738,DRREDDY,Dr. Reddy's Laboratories Limited,press release," vide its letter dated september 23, 2010 regarding a press release dated september 22, 2010 titled ""dr. reddy's laboratories limited announces filing of annual report on form 20-f"".",27-Sep-2010 11:29:00,2010-09-27 11:29:00,-,-,https://nsearchives.nseindia.com/corporate/drrreddy_pr_27092010.zip,27-09-2010,1511.699951171875,1511.699951171875,1485.0999755859375,1493.0,1349.8231201171875,258508,0.0,0.0,04-10-2010,0
739,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated august 09, 2010 titled ""dr. reddy's launches darbepoetin alfa in india under the brand name 'cresp'"".",09-Aug-2010 17:02:00,2010-08-09 17:02:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_PR_09082010.zip,09-08-2010,1349.0,1357.9000244140625,1333.199951171875,1338.050048828125,1209.7330322265625,346945,0.0,0.0,16-08-2010,0
740,DRREDDY,Dr. Reddy's Laboratories Limited,outcome of annual general meeting," regarding the outcome of annual general meeting held on july 23, 2010.",23-Jul-2010 17:26:00,2010-07-23 17:26:00,-,-,https://nsearchives.nseindia.com/corporate/drreddy_outcome_23072010.zip,23-07-2010,1368.0,1386.9000244140625,1277.1500244140625,1365.300048828125,1234.3697509765625,1396959,0.0,0.0,30-07-2010,0
741,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated july 22, 2010 titled ""dr. reddy's q1 fy11 financial results revenue at rs.16.8 billion ($363 million) ebitda at rs.3.4 billion ($74 million) profit after tax at rs.2.1 billion($45 million)"".",22-Jul-2010 14:27:00,2010-07-22 14:27:00,-,-,https://nsearchives.nseindia.com/corporate/DRredy_PR_22072010.zip,22-07-2010,1404.0,1405.0,1362.25,1380.699951171875,1248.2926025390625,753076,0.0,0.0,29-07-2010,0
742,DRREDDY,Dr. Reddy's Laboratories Limited,consolidated result updates - ifrs," a copy of unaudited consolidated financial results of the company and its subsidiaries for the quarter ended june 30, 2010 prepared in compliance with ifrs as issued by international accounting standards board. a copy of the same shall be available on the nse website   (http://www.nseindia.com) under: corporates > latest announcements and on the extranet server (/common/corporate announcements).",22-Jul-2010 14:25:00,2010-07-22 14:25:00,-,-,https://nsearchives.nseindia.com/corporate/drreddy_res_22072010.zip,22-07-2010,1404.0,1405.0,1362.25,1380.699951171875,1248.2926025390625,753076,0.0,0.0,29-07-2010,0
743,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated june 29, 2010 titled ""dr. reddy's announces the launch of anastrozole 1mg tablets"".",29-Jun-2010 18:02:00,2010-06-29 18:02:00,-,-,https://nsearchives.nseindia.com/corporate/drreddy_pr_29062010.zip,29-06-2010,1479.6500244140625,1490.0,1442.4000244140625,1455.0999755859375,1305.2833251953125,246184,0.0,0.0,06-07-2010,0
744,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated june 12, 2010, titled ""dr. reddy's provides update on the fexofenadine-pseudoephedrine 24 hour preliminary injunction hearing"".",14-Jun-2010 08:42:00,2010-06-14 08:42:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY_pr_14062010.ZIP,14-06-2010,1439.0,1439.0,1379.5999755859375,1411.550048828125,1266.21728515625,1162246,0.0,0.0,21-06-2010,0
745,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 21, 2010, titled ""dr. reddy's announces the launch of tacrolimus capsules, the generic version of prograf"".",21-May-2010 16:25:00,2010-05-21 16:25:00,-,-,https://nsearchives.nseindia.com/corporate/Drreddy_PR_21052010.ZIP,21-05-2010,1310.0,1334.75,1280.050048828125,1310.0,1175.122802734375,503382,0.0,0.0,28-05-2010,0
746,DRREDDY,Dr. Reddy's Laboratories Limited,scheme of arrangement," that pursuant to an order dated april 21, 2010, passed by the hon'ble high court of andhra pradesh in the company application (dr. reddy's laboratories limited), a meeting of the members of dr. reddy's laboratories limited, the applicant abovenamed, is being convened for the purpose of considering and, if thought fit, approving, with or without modification, the proposed scheme of arrangement between dr. reddy's laboratories limited and its members for the issue of unsecured, redeemable, non-convertible, fully paid up bonus debentures of dr. reddy's laboratories limited from its general reserve, under sections 391 to 394 of the companies act, 1956 (hereinafter referred to as the ""scheme"").",17-May-2010 18:57:00,2010-05-17 18:57:00,-,-,https://nsearchives.nseindia.com/corporate/DRReady_Notice_17052010.zip,17-05-2010,1285.0,1315.0,1273.550048828125,1307.800048828125,1173.1492919921875,537747,0.0,0.0,24-05-2010,0
747,DRREDDY,Dr. Reddy's Laboratories Limited,press release," regarding a press release dated may 06, 2010 titled ""dr. reddy's fy10 financial results, revenues at rs. 70.3 billion ($1.56 billion) ebitda adjusted at rs. 15.8 billion ($352 million) profits after tax adjusted at rs. 9.2 billion ($205 million)"", alongwith consolidated unaudited financial results as per ifrs for the year ended march 31, 2010.",06-May-2010 14:37:00,2010-05-06 14:37:00,-,-,https://nsearchives.nseindia.com/corporate/DRREDDY01_PR_06052010.ZIP,06-05-2010,1250.0,1269.9000244140625,1227.050048828125,1242.550048828125,1114.617431640625,988916,0.0,0.0,13-05-2010,0
